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Abstract 
Receptor tyrosine-kinase like orphan receptor (ROR1) is a member of the 
tyrosine kinase family. Importantly, ROR1 is absent in healthy, critical tissue 
but overexpressed in various solid and haematological malignancies, including 
Chronic Lymphocytic Leukaemia (CLL). Moreover, recent studies suggest 
ROR1 is expressed on cancer stem cell-like cells (CSCs). The overriding aim 
of this study was therefore to combine the unique features of ROR1 with the 
exquisite specificity/therapeutic potential of monoclonal antibodies (MAbs) 
and/or their derivatives.  
To this end, our group generated a rat hybridoma library and screened >150 
anti-ROR1+ clones. I then cloned 16 of our novel antibodies to human IgG1, 
kappa constant regions, of which 12 recognised ROR1 on different cell types. 
Based on functional/characterisation data, it was identified that clone SA1 
exhibited significant CDC activity on primary CLL cells, whilst clone F was the 
only MAb able to bind the Frizzled domain of ROR1. Further investigation, 
however, revealed clone SA1 bound non-specifically to ROR1- cells. 
Therefore, my investigation focused instead on clone F, which was developed 
in parallel as a bispecific T-cell engager (BiTE) within our group.  
Having shown F BiTE elicited potent and specific cytotoxicity of ROR1+ cells 
on various solid cancer cell lines, including pancreatic cancer (PaCa), ROR1 
BiTE was tested on PaCa cell line-derived CSCs using an in vitro 
tumoursphere model. Immunocytochemistry data confirmed specific 
elimination of cells expressing both CSC biomarkers and ROR1.  
As a whole, ROR1 MAb-based immunotherapy, particularly using BiTEs, 
seems to not only target ROR1+ cells present in the bulk of the tumour but, 
crucially, it also eliminates ROR1+ CSC subsets in PaCa. This approach 
represents a relevant and much needed addition to the current options for 
cancer treatment. Further preclinical and clinical studies will ultimately reveal 
the true therapeutic potential of ROR1 BiTEs alone and in combination.   
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PI  Propidium iodide 
PI3K  Phosphatidylinositol 3-kinase,  
PSC  Pancreatic stellate cells 
qPCR  Quantitative polymerase chain reaction 
qPSC  Quiescent pancreatic stellate cells 
R  Reducing conditions 
ROR1  Receptor tyrosine kinase-like orphan receptor 1 
ROR2  Receptor tyrosine kinase-like orphan receptor 2 
RTKs  Receptor tyrosine kinases  
Rtx  Rituximab 
scFv  Single chain variable fragment 
sCRS  Severe cytokine release syndrome 
SD  Standard deviation 
SEM  Standard error of the mean 
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SDS  Sodium dodecyl sulphate 
SHH  Sonic hedgehog 
SPR  Surface plasmon resonance 
TAA  Tumour-associated antigen 
TB  Trypan blue 
TCR  T-cell receptor 
TIL  Tumour infiltrating lymphocytes 
TME  Tumour microenvironment 
TNF  Tumour necrosis factor 
TRUCK T-cells redirected universal cytokine killing 
TTF-1  Thyroid transcription factor 
VCAM1 Vascular cell adhesion protein 1 
VEGF  Vascular endothelial growth factor 
VH  Variable heavy antibody region 
Vim  Vimentin 
VL  Variable light antibody region 
αSMA  α-smooth muscle actin 
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Chapter 1 Introduction 
1.1 Cancer immunosurveillance, immunoediting and immunotherapy  
As defined by Hanahan and Weinberg almost two decades ago, cancer is not 
one but more than a hundred diseases bearing unanticipated high levels of 
complexity (Hanahan and Weinberg, 2000). It has now become evident that 
malignant tumours, rather than insular masses of proliferating cancer cells, are 
complex tissues composed of multiple distinct cell types that interact with one 
another. These various cell types actively contribute to tumourigenesis and 
disease progression, and constitute the tumour microenvironment (TME) 
(Hanahan and Weinberg, 2011). Consequently, in order to grow and expand, 
cancer tumours exploit several strategies, including immune escape; a feature 
that has become a hallmark of cancer.  
Extensive investigation of the relationship between immunity and cancer has 
been carried out for over a century, since (Coley, 1893) reported successful 
treatment of inoperable sarcoma by mixed bacterial toxins (S. erysipelas and 
B. prodigiosus). A few years later, Paul Ehrlich postulated for the first time in 
1909 the concept of ‘tumour surveillance’, whereby tumour cells can be 
distinguished from healthy cells and could therefore be eliminated by the 
immune system before clinical detection (Ehrlich, 1909). Unfortunately, no 
convincing experimental evidence supported this notion. It was only on the 
second half of the last century where homograft rejection studies led Lewis 
Thomas (Thomas, 1959) but mostly Frank MacFarlane Burnet to champion the 
‘cancer immunosurveillance’ hypothesis (Burnet, 1967).  
On the following years, contradicting experimental data began to emerge and 
most immunologists were still sceptical. This changed since the 1990s as 
evidence in favour of effective tumour-specific immunity became increasingly 
compelling, amongst them: i) identification of various tumour-associated 
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antigens (TAA) (Urban and Schreiber, 1992, Rosenberg, 1999), ii) 
presentation of TAAs by dendritic cells (DCs) to the adaptive immune system 
(Flamand et al., 1994, Steinman and Dhodapkar, 2001, Parmiani et al., 2002), 
and iii) immunodeficient murine models (e.g. RAG-/-, STAT1-/-, perforin-/- mice) 
with much higher incidences of tumour than their wild-type counterparts (van 
den Broek et al., 1996, Dighe et al., 1994), etc.  
A greater understanding of cellular immunity and the availability of better 
animal models not only supported the immunosurveillance concept, but led to 
the realisation that it only represented one dimension of the complex 
relationship between the immune system and cancer (Dunn et al., 2002, Dunn 
et al., 2004). Evidence showing that the immune system promoted the 
formation of primary tumours with reduced immunogenicy, able to escape 
immune recognition and destruction (Shankaran et al., 2001) prompted the 
development of the ‘cancer immunoediting’ hypothesis. The latter 
encompasses potential host-protective and tumour-sculpting functions; it is a 
dynamic process composed of three phases: elimination, equilibrium and 
escape (Fig. 1. 1). 
The Elimination phase refers to what was originally described as ‘cancer 
immunosurveillance’; whereby natural killer (NK) cells and NKT cells produce 
IFN- in response to local tumour inflammation. These interactions have direct 
anti-proliferative and apoptotic effects on malignant cells, whilst indirectly 
preventing angiogenesis. In turn, DCs acquire tumour antigens and migrate to 
the lymph node in order to present antigens to T-cells. These TAA-specific T-
cells migrate from the lymph node to the tumour and mediate tumour 
regression. In parallel, to induce tumour cell death, the escalating immune 
response recruits NK cells and macrophages (Dunn et al., 2002). Despite its 
effectiveness, this immune response is not aways successful in preventing 
tumour development. 
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Equilibrium takes place when the immune system controls tumour growth but 
cannot eliminate the tumour. In line with this, a study by (Koebel et al., 2007) 
revealed that the immune system of a naive mouse can also restrain cancer 
growth for extended time periods. In their experiments, these researchers 
injected mice with a chemical carcinogen, methylcholanthrene (MCA), to 
induce tumourigenesis. There was a group of mice, however, that did not 
develop tumours. This group was then treated with antibodies that depleted 
CD8 or CD4 T-cells or neutralised IFN-, resulting in the development of 
sarcomas. These observations suggested that microscopic tumours were 
controlled by the immune system and were able to grow only when this control 
was disrupted. 
Escape occurs when tumours accumulate new and several mutations that 
prevent their recognition and subsequent elimination by the immune system. 
An important escape mechanism is the reduced expression of the tumour 
antigen, or of the proteins involved in antigen presentation such as the 
downregulation of human leukocyte antigen (HLA) directly (Algarra et al., 
2000) or of the components of the antigen processing pathways (Seliger et al., 
2001). Alternatively, the tumour and/or the TME can promote immune 
dysfunction by overexpression of immunosuppressive cytokines (Khong and 
Restifo, 2002) or the recruitment of immunosuppressive cells like regulatory T-
cells (Tregs), NKT cells (Terabe and Berzofsky, 2004), dysfunctional DCs 
(Pinzon-Charry et al., 2005) and tumour-resident myeloid derived suppressor 
cells (MDSC) (Gabrilovich, 2004). 
The knowledge that: i) expression of the inhibitory receptor cytotoxic T 
lymphocyte associated antigen 4 (CTLA-4) on Tregs is an important regulator 
of T-cell activation (Schwartz, 1992); and ii) overexpression of the immuno-
modulatory receptor programmed death-ligand 1 (PD-L1) promotes 
dysfunction of tumour-infiltrating T-cells (Chen and Flies, 2013), has led to the 
targeting of these molecules using monoclonal antibodies. Certainly, cancer 
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patients treated with checkpoint blockade antibodies against CTLA-4, PD-L1 
or, its receptor on T-cells, PD-1, have achieved great clinical outcomes 
(Pardoll, 2012). Certainly, this type of therapy represents an illustrative 
example of what can be achieved when the escape phase of immunoediting 
is disrupted. This is discussed in more detail in section 1.1.3.1. 
 
    
The great amount of evidence supporting the ‘cancer immunoediting’ theory 
has led both clinicians and immunologists to utilise the potential of the immune 
system to control and ultimately eliminate tumours in cancer patients. 
Recently, this has resulted in significant advances in the use of monoclonal 
antibodies (MAbs), therapeutic vaccines and adoptive cellular therapy 
(Lowdell and Thomas, 2017). The unprecedented clinical benefit that 
checkpoint blockade antibodies and other strategies have attained in patients 
with advanced-stage tumours strongly support the concept that 
immunotherapy represents a promising treatment for cancer (Chen and 
Mellman, 2013, Voena and Chiarle, 2016).  
Fig. 1. 1. Cancer immunoediting. Elimination phase; where the immune response is able to 
kill tumour cells and reject the tumour. Equilibrium; tumour cells are still present due to 
incomplete elimination but still controlled by the immune system. Escape; genomic instability 
within the tumour and/or an immunosuppressive TME prevent malignant cells from being 
recognized by the immune system. TME= Tumour microenvironment. Modified from (Hotblack, 
2016). 
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Cancer immunotherapy can be defined as the approach to treating cancer by 
generating or augmenting an immune response against malignant tumours 
(Khalil et al., 2016), whereby both the innate and adaptive arms of immunity 
can target tumour cells. Importantly, this approach has broad potential and 
offers the possibility of achieving durable and robust responses across a 
diverse spectrum of malignancies. In the next paragraphs, the main strategies 
in cancer immunotherapy, including oncological vaccines, oncolytic viruses, 
monoclonal antibodies and adoptive cell therapy will be summarised. 
Additionally, in Fig. 1. 2, an overview of the current immunotherapeutic agents 
in cancer, categorised by their ability to directly target tumour cells or activate 
immune cells is presented. 
Fig. 1. 2. Conceptual palette of cancer immunotherapy agents. Different approaches for 
cancer immunotherapy are presented and classified based on their tumour targeting and 
immune cell activation effects. MAbs= Monoclonal antibodies, CDC= Complement-dependent 
cytotoxicity, ADCC= Ab-dependent cellular cytotoxicity, ADCP= Ab-dependent cellular 
phagocytosis, BiTE= Bispecific T-cell engager, ADC= Ab-drug conjugate, TILs= Tumour 
infiltrating lymphocytes, CAR= Chimeric antigen receptor, NK= Natural killer cells. 
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1.1.1 Cancer vaccines 
The knowledge that cancer patients could harbour CD8+ and CD4+ T-cells 
capable of recognising tumour antigens (Rosenberg et al., 1988), prompted 
the possibility of developing cancer vaccines (Boon et al., 2006). This was 
supported by clinic-pathological studies that demonstrated a strong 
association between the presence of intratumoural T-cells, an IFN-γ signature 
and prolonged patient survival (Galon et al., 2006, Zhang et al., 2003).  
The main goal of therapeutic cancer vaccines is to induce T-cell cytotoxicity by 
immunising patients against tumour-associated antigens (TAA). Unfortunately, 
their long history of failure has tainted this strategy. Many of the initial attempts 
were compromised by a lack of understanding of immunisation mechanisms, 
particularly the role of DCs (Mellman et al., 2011). DCs are known as the most 
effective antigen presenting cells (APCs) and are pivotal in coordinating innate 
and adaptive immune responses.  
Another key consideration in vaccine therapy is the identification of suitable 
antigens. In the past, the use of short peptides derived from TAA (usually 
without effective DC-activating adjuvants) resulted in minimal clinical success 
(Sathyanarayanan and Neelapu, 2015). It is likely that vaccination with this 
type of antigens induced low to moderate affinity T-cells because of self-
tolerance mechanisms. In contrast, the use of tumour-specific antigens could 
be recognised as foreign and lead to induction of high affinity T-cells and 
robust anti-tumour immunity (Cohen et al., 2015). Also, another major 
deficiency seen in clinical trials was the lack of suitable co-treatment during 
vaccination in order to overcome the highly immuno-suppressive tumour 
microenvironment (van der Burg et al., 2016).  
To date, Sipuleucel-T is the only FDA-approved DC-based therapeutic cancer 
vaccine. It has been indicated for the treatment of asymptomatic or minimally 
symptomatic castrate resistant prostate cancer. Sipuleucel-T consists of 
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autologous CD54+ APCs co-cultured and activated with a fusion protein of 
prostatic acid phosphatase conjugated with the DC growth and differentiation 
factor granulocyte macrophage colony-stimulating factor (GM-CSF). Although 
this therapy achieved an approximately 4-month improvement in median 
survival, randomised clinical trials failed to show effects on the time to disease 
progression (Kantoff et al., 2010).  
In this context, the ideal cancer vaccine would be one able to trigger the 
maturation of DCs, which would in turn promote the production of tumour-
reactive CD8+ cytotoxic T-cells by using immunogenic tumour specific 
antigens. Since many of the standard-of-care chemotherapies can shape the 
immuno-suppressive cancer microenvironment, combinations of vaccines and 
chemotherapy would probably be the first step for improving clinical effects of 
therapeutic vaccines. For instance, treatment with an antimicrotubule agent, 
Paclitaxel (Taxol), in advanced ovarian cancer was shown to upregulate 
cytotoxic T-cell function (Emens and Jaffee, 2005). Similarly, (Shurin et al., 
2012) has shown that many chemotherapeutic agents can directly stimulate 
functional activity of DCs. Furthermore, the inclusion of checkpoint therapy is 
likely to boost the tumour-specific immune response of vaccines (van der Burg 
et al., 2016). 
With regards to ROR1 vaccines, (Imani Fooladi et al., 2015) designed in silico 
a ROR1 endotoxin B chimeric protein capable of stimulating ROR1-specific T- 
and B-cell mediated immune responses. Evaluation of this approach in in vitro 
and in vivo models remains to be performed. 
1.1.2 Oncolytic virus therapy 
Oncolytical viruses (OVs) are natural or genetically modified viruses that 
selectively infect and replicate in tumour cells, leading to immunogenic tumour 
cell death (Kaufman et al., 2015). Oncolysis is followed by activation of 
adaptive anti-tumour immunity through the release of anti-tumour antigens and 
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danger signals (e.g. damage-associated molecular pattern [DAMPs] and 
pathogen-associated molecular pattern [PAMPs] molecules) (Bartlett et al., 
2013).  
Hence, anti-tumour responses are promoted mainly through two mechanisms 
of action: i) non-immunogenic cell death; acute tumour debulking due to 
tumour cell infection followed by lysis, and ii) immunogenic cell death; 
presentation of danger signals and TAAs by dendritic cells to T-cells in order 
to induce/initiate systemic anti-tumour immunity. Additionally, OVs can be 
engineered to express specific cytokines able to stimulate immune cell 
recruitment/activation or to facilitate stimulation of intra-tumoural T-cells by the 
production of T-cell costimulatory molecules on infected tumour cells (Farkona 
et al., 2016, Hu et al., 2006, van Rikxoort et al., 2012). 
Up to date, several types of viruses have been evaluated as vectors for OV 
immunotherapy. Viruses such as Newcastle disease virus, reovirus or Seneca 
valley virus are naturally non-pathogenic to humans. Others (like vaccinia 
virus, herpes simplex virus or measles virus) need to be genetically 
manipulated to become non-pathogenic (Chiocca and Rabkin, 2014). 
Accordingly, Talimogene laherparepvec (T-VEC), a modified oncolytic herpes 
simplex virus type I, is the most advanced OV agent in clinical development 
and it is now the first oncolytic immunotherapy to be FDA-approved for the 
treatment of advanced melanoma.  
T-VEC has been modified in order to prevent neuronal involvement and to 
allow the secretion of GM-CSF. Enhanced production of this cytokine favours 
APC recruitment to the tumour microenvironment and induces anti-tumour 
immunity. Thus, T-VEC promotes viral replication, antigen presentation and 
increases oncolytic therapeutic activity overall (Johnson et al., 2015). 
Nevertheless, some limitations in terms of its application have been associated 
to this type of therapy. For example, OVs could not be used in 
immunocompromised patients as antitumour immunity could be compromised 
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(Senzer et al., 2009). Also, low levels of efficiency have been reported in 
patients with advanced disease. Furthermore, since OVs are injected locally, 
organs that are difficult to reach could not be treated (Ledford, 2015). 
All in all, OV therapy possess a favourable risk-benefit ratio and its FDA-
approval in 2015 (Ledford, 2015) is already a milestone in the field. It is 
anticipated that the targeting of immune-modulatory circuits involved in 
promoting tumour tolerance, such as CTLA-4 and PD-1/PD-L1 in combination 
with OVs would considerably augment anti-tumour immunity (Bartlett et al., 
2013). 
1.1.3 Monoclonal antibodies (MAbs) 
As reviewed by (Strebhardt and Ullrich, 2008), Paul Ehrich first proposed the 
“magic bullet” hypothesis over a century ago; yet, it was the development of 
the hybridoma technology by (Kohler and Milstein, 1975) that the generation 
of monoclonal antibodies (MAbs) became feasible. 
In the past two decades, the use of monoclonal antibodies has become an 
established strategy for the treatment of both haematological and solid 
malignancies (Scott et al., 2012), either as monotherapy or in combination with 
chemotherapy, small-molecule inhibitors and other antibodies (Loisel et al., 
2011). Certainly, naked antibodies have improved overall response rate, 
complete remission rates, and progression-free as well as overall survival in 
multiple cancers including breast cancer, colon cancer, lymphomas, amongst 
others (Sathyanarayanan and Neelapu, 2015). 
One of the first MAbs that showed encouraging results on clinical trials was 
Rituximab, an anti-CD20 chimeric mouse-human antibody used on non-
Hodgkin lymphoma patients (Maloney et al., 1997, O'Brien et al., 2001). It is 
now evident that, in combination with chemotherapy, Rituximab has 
revolutionised the treatment of B-cell malignancies (Keating et al., 2005, Rai 
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and Jain, 2015). Recently, advances in antibody engineering and the discovery 
of better tumour-associated targets have contributed to the expansion of the 
field of antibody-based therapeutics. As of July 2017, more than 24 MAbs, 
most of them human IgG-based, have been FDA-approved for cancer therapy 
and ≥150 mAbs and/or antibody fragments are in clinical development 
(Pandey and Mahadevan, 2014).  
Based on their target, antibodies used in cancer treatment can be classified 
into two categories: i) direct targeting MAbs; comprised of conventional 
antibodies that target tumour cells by direct binding to either lineage-specific 
antigens (such as CD20 or CD52), tumour neoantigens (e.g. glycans) or 
oncogenic biomarkers (e.g. epidermal growth factor receptor [EGFR]); which 
upon antibody engagement, eliminate tumour cells via Fc-signalling (Yu et al., 
2017). ii) immunomodulatory MAbs; do not directly engage tumour cells but 
target receptors on immune cells in an attempt to stimulate the immune 
system, particularly CD8+ T-cells (Lee et al., 2013, Berman et al., 2015). 
Accordingly, researchers in the field of cancer immunotherapy are now 
focussing not only on the induction/activation of the immune system but also 
on overcoming immunosuppression from the tumour microenvironment 
(Nicholas et al., 2016b). This type of therapy will be discussed in the next 
paragraphs.  
1.1.3.1 Immune checkpoint blockade 
One of the main reasons why cancer immunotherapy has come under the 
spotlight is the remarkable clinical benefits observed after cancer patients were 
treated with immune checkpoint therapy. This approach is based on the notion 
that anti-tumour T-cells are generated by the organism in response to tumour 
antigens (mutated neo-antigens); moreover, these are likely to be high affinity 
T-cells (Cohen et al., 2015, Gros et al., 2014). These cells however could be 
rendered ineffective due to several immune resistance mechanisms, 
collectively called immune checkpoints (Sledzinska et al., 2015). Crucially, 
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blocking the immune checkpoints enhances the function of anti-tumour T-cells 
and tilts the balance in the tumour microenvironment from immunosuppressive 
and immune resistance to immune destruction of the tumour. 
It is now accepted that activated T-cells upregulate various co-inhibitory 
receptors on their cell surface in order to regulate their function and prevent 
unwanted immune responses against normal tissues. Many such receptors 
have been identified over the last years, including CTLA-4, PD-1, TIM-3, BTLA, 
LAG-3, among others (Tsiatas et al., 2016). In acute infections, for instance, 
once the antigen has been eliminated, T-cells downregulate their inhibitory 
receptors and a subset of T-cells persist as memory T-cells. In chronic 
infections and cancer, however, chronic antigenic stimulation leads to 
overexpression of inhibitory receptors on T-cells, which results in impaired 
function or even T-cell exhaustion (Wherry, 2011, Blackburn et al., 2009).  
Not surprisingly, several tumour escape mechanisms use immune checkpoint 
pathways to evade the immune response. The most relevant examples are the 
interactions between CTLA-4 on activated T-cells and CD80/86 on DCs, which 
results in T-cell inhibition. Similarly, binding of PD-1 on activated T-cells to PD-
L1 on tumour cells results in T-cell signalling attenuation and inhibition of T-
cell proliferation and function (Fig. 1. 3). 
The use of Ipilimumab and Nivolumab -monoclonal antibodies against CTLA-
4 and PD-1, respectively- has become paradigm-shifting in the treatment of 
solid tumours. Several reports indicate these blocking MAbs promoted 
prolongation of overall survival (Hodi et al., 2010) and durable clinical 
responses, with some patients remaining free from disease progression for 
many years (Topalian et al., 2014).  
For instance, according to (Phan et al., 2003, Hodi et al., 2010) anti-CTLA-4 
MAbs unleash pre-existing anticancer T-cell responses, trigger potent 
antitumour properties and prolong overall survival. Similarly, antibodies 
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against PD-1 and PD-L1 have attained long-lasting clinical responses within a 
broad range of human cancers (Brahmer et al., 2012, Mahoney et al., 2015).  
Despite these unprecedented results, concomitant immune-related toxicities 
have also been observed, particularly with CTLA-4, where severe adverse 
events have been observed in up to 35% patients (Phan et al., 2003, Hodi et 
al., 2010). Futhermore, a major disadvantage of checkpoint blockade MAbs is 
that only a relatively small fraction of patients obtains clinical benefit. Current 
efforts are on-going to identify novel immune modulators with similar efficiency 
but less toxicity (Farkona et al., 2016). 
 
Fig. 1. 3. Immune checkpoints and blocking antibodies. (A) In the lymph node. Both 
immunological signals 1 (TCR recognition of antigens through MHC) and 2 (CD28-B7 
costimulation) are required for T-cell activation in the lymph node. Interaction between B7 and 
CTLA-4 suppresses T-cells by blocking immunologic signal 2. Anti-CTLA-4 antibodies 
(Ipilimumab) allow T-cell activation. (B) In the tumour microenvironment; PD-1 is an inhibitory 
receptor expressed on antigen-activated T-cells and its interaction with PD-L1 blocks anti-tumour 
response. MAbs targeting PD-1 impede activation of the PD-1 pathway, thereby allowing T-cell 
activation. TCR= T-cell receptor, MHC= Major histocompatibility complex. Modified from Farkona 
et al., 2016. 
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1.1.4 Adoptive cell transfer (ACT) 
Another form of immunotherapy is the adoptive transfer of lymphocytes – that 
have firstly been isolated from patients’ peripheral blood, tumour draining 
lymph nodes or tumour tissue, expanded ex vivo, and reinfused back into the 
patient (Hinrichs and Rosenberg, 2014).  
An example of this approach is the ACT of NK cells, which are phenotypically 
defined as CD3-CD56+ lymphocytes. This type of therapy has been more 
successful in haematological malignancies than solid tumours. In 2011, Curti 
et al. reported that out of 13 acute myeloid leukaemia (AML) patients, 6 
achieved transient complete remission (CR) responses (Curti et al., 2011); 
thereby suggesting this infusion of NK cells was feasible in elderly patients. 
For solid tumours, (Parkhurst et al., 2011) reported results of a clinical trial 
where 8 patients with metastatic melanoma or renal carcinoma were treated 
with autologous NK cells. Although no clinical responses were observed, 
adoptively transferred NK cells persisted for at least one week and, in some 
patients, for several months after transfer. Taken together, NK cell-based 
therapies have achieved modest clinical success in cancer patients and more 
developments are necessary to improve clinical efficacy.    
Tumour-infiltrating lymphocytes (TILs) represent a more successful example 
of ACT. TILs are mixtures of CD8+ and CD4+ T-cells from resected tumours, 
and are expanded in presence of a cocktail of various cytokines. This is done 
in an attempt to reverse the functional impairment of these T-cells caused by 
the immunosuppressive tumour microenvironment (Gilham et al., 2015). TIL 
infusion after a lympho-depleting conditioning regimen resulted in an objective 
response rate (ORR) of more than 50%, as well as durable, complete 
regression of metastatic melanoma (Geukes Foppen et al., 2015). Importantly, 
host lymphodepletion is thought to improve TIL functionality by eliminating 
immunosuppressive cells such as Tregs and myeloid-derived suppressor cells 
(MDSCs) in the TME. Plus, it promotes overexpression of homeostatic 
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cytokines IL-7 and IL-15 (Gattinoni et al., 2005). Nevertheless, one of the major 
limitations of this approach is the cost and time required to develop these cell 
populations. Plus, TIL therapy is largely restricted to melanoma, as it is the 
only malignancy where clear clinical benefit has been achieved (Hinrichs and 
Rosenberg, 2014).  
Another form of ACT is the transfer of T-cells expressing a chimeric antigen 
receptor (CAR). This CAR technology combines the antigen recognition 
domain of an antibody with T-cell intracellular signalling domains into a single 
chimeric protein (Fig. 1. 4). Patients’ own T-cells are first activated, genetically 
modified to express a CAR, then expanded ex vivo and transferred-back into 
the patient. CAR T-cells will then be specifically redirected against cells 
expressing a tumour-associated antigen in a major histocompatibility complex 
(MHC)-independent manner (Riches and Gribben, 2014, Suryadevara et al., 
2015). 
Most clinical trials have used second generation CAR T-cells (i.e. engineered 
T-cells bearing two intracellular domains) against CD19, a cell membrane 
protein uniformly expressed on normal and malignant B-cells. In a hallmark 
study, (Porter et al., 2011) showed that these CD19 CARs have potent anti-
tumour activity, even in high-risk patients. Notably, the introduction of the 4-
1BB signalling domain resulted in increased persistence of CAR T-cells partly 
explained by the generation of memory CAR T-cells, which retained anti CD19-
effector functionality (Kalos et al., 2011). An important aspect to consider when 
interpreting the results of this and other trials is that patients received 
lymphocyte-depleting chemotherapy that might have contributed to the 
reported remissions (Kochenderfer and Rosenberg, 2013). In line with this, 
inferior rate responses were observed in trials that did not include conditioning 
chemotherapy, such as those carried out at MD Anderson (Kebriaei, 2014).  
One of the most successful CAR programs is the one designed at University 
of Pennsylvania and the Children’s Hospital of Philadelphia (Maude et al., 
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2014, Porter et al., 2015). Data from 48 evaluable pediatric patients treated 
with conditioning chemotherapy followed by CD19 CAR have shown 94% CR, 
whilst 6-month disease-free survival (DFS) was 76%. In terms of toxicity, 
severe cytokine-release syndrome (sCRS) reached 29% cases, plus there 
were 67% of patients that presented CD19-negative relapses. Certainly, some 
of the most toxic adverse events related to this type of immunotherapy are 
sCRS, macrophage activation syndrome (MAS; or haemophagocytic 
lymphohistiocytosis, HLH) and neurological toxicities. Selection of patients 
with low tumour burdens might minimise the occurrence of CRS and related 
toxicities in the future (Khalil et al., 2016). 
With regards to solid tumours, CAR therapy faces three unique challenges not 
seen in B-cell malignancies. First, the microenvironment in malignancies such 
as B-cell acute lymphoblastic leukaemia (B-ALL), where CAR therapy has 
achieved impressive clinical outcomes, is not as immunosuppressive as in 
solid cancers. Second, antigen selection tends to be more challenging since 
antigen heterogeneity in the tumour and the TME is higher in solid 
malignancies (Fidler and Hart, 1982, Marusyk and Polyak, 2010). Third, the 
‘on-target, off-tumour’ toxicity is usually more problematic as potential antigens 
in solid tumours are more likely to be expressed in other critical organs. 
Nevertheless, CARs targeting mesothelin for the treatment of mesothelioma 
(Adusumilli et al., 2014), pancreatic and ovarian cancer are now entering 
clinical trials.  
Due to the immunosuppressive nature of the TME in cancer, a fourth 
generation CAR has been proposed recently, when (Chmielewski et al., 2011) 
demonstrated that production of CAR T-cells bearing a CAR-inducible IL-12 
cassette secreted this cytokine upon CAR engagement. Therefore, CAR T-
cells that release a transgenic product (usually a pro-inflammatory cytokine) 
and accumulate in the targeted tissue are called ‘T-cells redirected for 
universal cytokine killing’ (TRUCKs) (Chmielewski et al., 2014). Although 
systemic administration of IL-12 was shown to be toxic in early phase clinical 
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trials (Leonard et al., 1997), local administration could be achieved by IL-12 
TRUCKs. The first clinical trial using armoured CAR T-cells targeting mucin-
16 and secreting IL-12 in patients with ovarian cancer has opened 
(NCT02498912) (Koneru et al., 2015a) and is currently recruiting patients as 
final data will be collected in August 2018. Results are now awaited as IL-12 
secretion in preclinical studies has been shown to enhance CAR T-cell 
persistence, resistance to Tregs and MDSC inhibition which provide enhanced 
antitumour efficacy in vivo (Kerkar et al., 2011, Chinnasamy et al., 2012, 
Koneru et al., 2015b). 
 
In this thesis, the ROR1-based immunotherapies generated were tested in 
both haematological and solid malignancies, namely: Chronic lymphocytic 
leukaemia and Pancreatic cancer. In the following sections, the disease 
biology, TME and current status of clinical applications will be discussed for 
both cancer types. 
Fig. 1. 4. CARs are produced by combining the scFv specificity of an antibody, a 
transmembrane stalk and the intracellular signalling domains of a T-cell receptor (TCR). A 
schematic of an anti-EGFRvIII CAR is shown. For 1st generation CARs, CD3z was the intracellular 
domain of choice. More recently, additional costimulatory moieties (CD28 and/or 4-1BB) are being 
included to improve T-cell persistence, proliferation and anti-tumour activity, where 2nd and 3rd 
generation CARs are defined by their number of intracellular moieties. Reproduced from 
Suryadevara et al., 2015. 
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1.2 Focus on: Chronic lymphocytic leukaemia (CLL) and pancreatic 
cancer (PaCa) 
1.2.1 Chronic lymphocytic leukaemia (CLL)  
CLL is a chronic haematological malignancy characterised by the progressive 
accumulation of CD5+ CD19+ B-cells (Van Bockstaele et al., 2009) in blood, 
bone marrow, lymph nodes or other lymphoid tissues (Chiorazzi et al., 2005). 
It is the most common leukaemia diagnosed in the Western world among the 
elderly. Despite the current availability of novel small molecule inhibitors, 
including B-cell receptor antagonist such as Ibrutinib, and new monoclonal 
antibodies including  Obinutuzumab, CLL remains incurable (Park and 
Brentjens, 2013). To date, allogeneic stem cell transplantation represents the 
only curative option due to the graft-versus-leukaemia effect mediated by the 
allogeneic T-cells. Nevertheless, the age-related excess in morbidity and 
mortality of this treatment –due to concomitant graft-versus-host disease 
(GvHD)– restricts its application. 
1.2.1.1 CLL biology 
More than a decade ago, chronic lymphocytic leukaemia was considered as a 
homogenous disease, where high counts of mature B-cells were mainly due 
to a fault in the mechanisms that lead to apoptosis. Nonetheless, research 
advances in the past few years have revealed that the accumulation of 
lymphocytes is not only characterised by prolonged B-cell survival but also by 
high cell proliferation (Chiorazzi, 2007).   
CLL has now been demonstrated to be a heterogeneous disease with survival 
ranging from months to decades depending on age, gender, diversity of cell 
morphology, bone marrow histology, cytogenetics (mutation status of 
immunoglobulin heavy chain variable region (IGHV) genes, TP53, etc.), 
epigenetic alterations and immunophenotype, amongst others (Rodriguez-
Vicente et al., 2013). Remarkably, high levels of Lactate dehydrogenase 
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enzyme (LDH), deletion of the short arm of chromosome 17 (del17p), high 
CD38 expression and increased ZAP70 (Zeta-associated protein of 70kDa) 
are associated with a reduced survival time (Van Bockstaele et al., 2009).  
Genetic alterations in CLL can include chromosomal alterations, somatic 
mutations, changes in the expression of microRNAs (miRNAs) and epigenetic 
modifications. A study by (Dohner et al., 2000) revealed that ~80% of CLL 
patients carry at least one of four common chromosomal alterations: a deletion 
in chromosome 13q14.3 (del(13q)), del(11q), del(17p) and trisomy 12. Of 
these, del(13q) is the most common one (>50% of patients) and is associated 
with good prognosis. Trisomy 12 is associated with an intermediate prognosis 
and is found in 16% of patients, whilst del(11q), del(17p) are less common but 
are associated with adverse clinical outcome. A report by (Van Dyke et al., 
2016) revisiting the Dohner classification in CLL, however, has shown that in 
general the overall survival has improved in recent years. 
A series of studies involving next generation and whole-exome sequencing 
have increased our understanding of the genetic heterogeneity of CLL (Landau 
et al., 2015, Puente et al., 2015). Recurrent somatic mutations have been 
observed in genes with a role in: DNA damage (e.g. TP53, ATM), mRNA 
processing (e.g. SF3B1, XPO1), chromatin modification (e.g. HIST1H1E, 
CHD2, ZMYM3), Wnt and Notch signalling pathways, as well as BRAF, which 
can affect B-cell related signalling and transcription (Damm et al., 2014). 
Interestingly, somatic mutations can be induced after chemotherapy or small 
molecule inhibitors. A recent study reported that CLL patients treated with 
Ibrutinib (a BTK inhibitor) showed mutations associated with drug resistance 
as they were different from those detected in CLL patients treated with 
standard chemotherapy (Burger et al., 2016). 
(Calin et al., 2002) reported for the first time the involvement of miRNAs in any 
human disease. The study described that the most common lesion in CLL is 
the downregulation/deletion of two closely linked miRNAs: mir-15-1 and mir-
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16a. Since both miRNAs target BCL2 and MCL1 (Cimmino et al., 2005), their 
loss enhances the expression of the target genes -which encode anti-apoptotic 
proteins of the BCL2 family- thereby prolonging CLL cell survival (Fabbri et al., 
2011). Reduced expression or loss of other miRNAs can promote CLL 
development, amongst them: miR-29a/b, miR-29c, miR-34b, miR-181b and 
miR-3676 (Balatti et al., 2015). In contrast, (Costinean et al., 2006, Cui et al., 
2014) has shown that overexpression of mir-155 is associated with enhanced 
B-cell receptor (BCR) signalling, B cell proliferation and lymphomagenesis.  
CLL heterogeneity also includes epigenetic changes. Recent studies (70, 71) 
have linked disordered methylation to genetic aberrations in CLL, thereby 
contributing to the accumulation of somatic mutations and adverse clinical 
outcome. Not surprisingly, methylation signatures can be used to classify 
distinct clinical CLL subgroups (Bhoi et al., 2016, Kulis et al., 2012). 
With regards to the BCR signalling in CLL, it has been shown in vivo that the 
surface immunoglobulin of CLL cells is engaged by autoantigen, which results 
in constitutive BCR signalling (Duhren-von Minden et al., 2012). Certainly, the 
importance of this interaction is supported by the success of kinase inhibitors 
in the clinic. These types of therapies will be further discussed in section 
1.2.1.4. 
1.2.1.2 Tumour microenvironment in CLL 
In CLL, the TME is mainly composed of neighbouring non-malignant stromal 
cells, nurse-like cells (lymphoma-associated macrophages), T-cells (CD4+, 
CD8+, Tregs), NK cells, DCs, endothelial cells and mesenchymal stromal/stem 
cells (Nicholas et al., 2016a). Importantly, CLL cells depend on the survival 
signals released by the TME. Therefore, CLL cells follow chemokine gradients 
into lymph nodes (usually mediated by CXCR4 in response to nurse-like cell-
secreted CXCL12), where ‘proliferation centres’ are formed (Herishanu et al., 
2011). Migration of CLL cells into lymph nodes can also occur via CCR7 in 
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response to CCL19 and CCL21 (produced by endothelial cells of high 
endothelial venules (HEVs)). 
Once in the proliferation centres, the TME promotes CLL cells proliferation and 
are exposed to chemokines, integrins, cytokines and survival factors, such as: 
BAFF (TNF ligand superfamily member 13B) and APRIL (TNF ligand 
superfamily member 13B), which activate NF-B (nuclear factor-B) before 
they go back to the bloodstream (Endo et al., 2007). Activation of the latter 
results in mir-155 expression which enhances BCR signalling, and in turn, CLL 
cell proliferation (Cui et al., 2014). CLL survival is also promoted through CD31 
and CD38 activation, as well as interaction of ROR1/2 and/or various Frizzled 
receptors with Wnt factors produced by stromal cells. Consistent with this, high 
expression of ROR1 has been associated with accelerated disease 
progression (Cui et al., 2016). In parallel, mesenchymal stromal cells 
expressing VCAM1 (vascular cell adhesion protein 1) interact with CLL cells 
via binding to α4β1 integrin, which contributes with CLL survival. 
CLL cells can also secrete chemokines to recruit T-cells and monocytes to the 
CLL TME. Activated T-cells send proliferative signals to CLL cells through 
CD40L (CD40 ligand) and CD40 interactions. Adding to the complexity of CLL 
cell-TME interactions, (Smallwood et al., 2016) showed that CD40/IL-4-
stimulated CLL cells released extracellular vesicles (EVs) enriched with 
specific miRNAs, including miR-363. Transfer of these EVs to autologous 
CD4+ T-cells exhibited enhanced migration and immune synapse formation 
interactions with tumour cells. This study revealed that CLL-EVs could modify 
T-cell function, highlighting the bidirectional effects of CD4+ T-cell:tumour 
interactions. In parallel, amongst the cytokines that are secreted by T-cells, 
namely IL-2, IL-10 and IL-4, the latter can upregulate IgM on CLL cells, thereby 
facilitating the interaction of CLL cells with their autoantigen (Aguilar-
Hernandez et al., 2016). Importantly, IL-10 (a known immunosuppressive 
cytokine) may also be secreted by CLL cells (DiLillo et al., 2013). Additionally, 
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(Ramsay et al., 2012) showed that CLL cells express high levels of both PD-
L1 and PD-L2. These findings underline the immunosuppressive interactions 
in CLL that lead to T-cell exhaustion and impaired cellular immune function. 
The high heterogeneity and complex CLL cell-TME interactions observed in 
this disease have to be therefore taken into account when designing the 
treatment strategy as it can have a direct impact on clinical course and 
response to treatment (Zenz et al., 2010). Current standard therapy and 
research on novel treatment options for CLL will be therefore discussed below.   
1.2.1.3 Standard therapy 
A meta-analysis study performed by the CLL Trialists’ Collaborative Group 
more than 15 years ago found that the single-agent chlorambucil was the most 
effective treatment in terms of survival and, that inclusion of anthracycline gave 
no evidence of added benefit. Monotherapy with alkylating agents –in this 
case– chlorambucil, was recommended as the first line of treatment and it was, 
for several years, the gold standard (CLL trialists’ collaborative group [(1999)]). 
It is noteworthy to mention that, based on that same report; asymptomatic 
patients with early-stage disease are usually not offered treatment as no 
advantage was ascertained when early treatment with chlorambucil was 
compared to observation and/or late treatment. Indeed, up to a third of CLL 
patients never require treatment and yet have a near-normal life expectancy, 
with death resulting from causes other than CLL. Importantly, no studies on 
asymptomatic patients using current therapies have been performed 
(Rozovski et al., 2014). However, according to (Zenz et al., 2010), new clinical 
trials are selecting high-risk subgroups of CLL patients at early stages based 
on biological and clinical criteria with the aim to reassess the effects of early 
treatment.  
Nevertheless, ever since that seminal publication in 1999, there has been a 
transition from single-agent therapy with alkylating compounds to nucleosides, 
    Chapter 1 
41 
 
multidrug combinations and chemo-immunotherapy (Zenz et al., 2010). 
Accordingly, results from a clinical phase III trial (Hallek et al., 2010) showed 
for the first time that addition of an anti-CD20 antibody (Rituximab) to a 
combinatorial chemotherapeutic approach (i.e. Cyclophosphamide, an 
alkylating agent, and Fludarabine, a purine analogue that inhibits DNA repair 
of interstrand crosslinks caused by the former) had better efficacy in overall 
survival despite the increased toxicity. As reviewed by (Nabhan et al., 2014), 
this chemo-immunotherapeutic approach (known as FCR) is currently 
recommended to be used in fit patients with normal renal function as the 
standard upfront treatment.  
Notably, a variety of drug combinations are currently available. Chemo-
immunotherapeutic regimens would have to be adjusted depending on 
patients’ performance status, renal function and comorbidities (Hallek, 2013). 
Nevertheless, due to the considerable toxicity of this sort of approach, 
alternative treatment options are being explored. 
1.2.1.4 New therapies 
Emerging research and evolving understanding of CLL biology have allowed 
the generation of new compounds that are currently in clinical development. In 
the next paragraphs, small-molecule inhibitors targeting the B-cell receptor 
and tyrosine kinases, along with immunotherapies encompassing the 
development of novel monoclonal antibodies, immunomodulatory drugs and 
chimeric antigen receptors will be discussed. 
1.2.1.4.1 Small-molecule inhibitors 
As reviewed by Tsubata, 2001, the B-cell receptor (BCR) signalling pathway 
is involved in cell proliferation, differentiation and antibody production in normal 
B-cells. Similarly, in CLL cells, this receptor plays a pivotal role in cell survival, 
proliferation and trafficking (Tsubata, 2001). Importantly, chronic lymphocytic 
leukaemia, along with other haematological malignancies, display aberrantly 
phosphorylated proteins involved in the BCR signalling pathway, mimicking 
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activated B-cells. This has led to the generation of kinase inhibitors targeting 
spleen tyrosine kinase (SYK) (Friedberg et al., 2010), mammalian target of 
rapamycin (mTOR) (Zent et al., 2010), Bruton’s tyrosine kinase (BTK) 
(Honigberg et al., 2010) and phosphoinositide 3’-kinase (PI3K) (Lannutti et al., 
2011).   
Possibly the most impressive responses have been achieved by inhibitors 
developed against BTK, PI3K and SYK; namely, Ibrutinib, Idelalisib and 
Fostamatinib (Davids and Brown, 2012, Kipps et al., 2017b). These molecules 
have been found, in preclinical models, to reduce CLL cell viability through 
modulation of the stromal microenvironment. More recently, these drugs have 
been evaluated in patients with CLL. A brief summary of the clinical findings is 
presented below.   
Ibrutinib is a highly potent BTK inhibitor. It is an orally bioavailable small 
molecule that have shown to be well tolerated in relapsed/refractory patients 
of all ages, including elderly patients. It has been reported that Ibrutinib works 
in part by disrupting the protective effect that stromal cells have on CLL cells 
(Herman et al., 2011). A randomised study of Ibrutinib versus Ofatumumab in 
patients with relapsed CLL revealed that Ibrutinib was highly effective even in 
high-risk patients bearing the del(17p) (Byrd et al., 2014). Results from this 
study led to the approval of Ibrutinib for the treatment of patients with relapsed 
CLL or as initial therapy of patients with del(17p). Similarly, a randomised study 
of Ibrutinib versus Chlorambucil as initial therapy showed that the BTK inhibitor 
was more effective than chemotherapy in patients ≥65 years of age without 
del(17p). This resulted in the approval of Ibrutinib for the initial treatment of 
CLL patients (Burger et al., 2015). Some adverse effects of this therapy, 
however, include fatigue, diarrhoea, bleeding, ecchymoses, rash, arthralgia, 
myalgia, increased blood pressure and atrial fibrillation. Second generation 
BTK inhibitors, such as Acalabrutinib (Byrd et al., 2016) or ONO/GS-4059 
(Walter et al., 2016), are now in clinical trials in order to determine whether any 
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of these drugs has a superior therapeutic effect and/or less toxicity (Wu et al., 
2016).  
Similarly, Idelalisib (CAL-101), a potent and highly specific inhibitor of the PI3K 
delta isoform, promotes apoptosis in CLL cells in a time- and dose-dependent 
manner without inducing apoptosis of normal T-cells or natural killer cells. 
CAL-101 has been shown to disturb the interaction of several 
microenvironmental factors, such as nurse-like cells, cytokines and 
chemokines with the cancer cells (Wiestner, 2012). Remarkably, in a large 
phase I study, clinical benefit was observed even in patients with poor 
prognostic factors, as reviewed by (Davids and Brown, 2012). Idelalisib was 
approved in the United Stated and Europe after data from a clinical trial 
revealed that patients treated with Rituximab and Idelalisib had significantly 
higher response rates and overall survival than patients treated with Rituximab 
and placebo (Furman et al., 2014). Adverse effects of Idelalisib include 
transaminitis, pneumonitis and colitis, which tends to be severe enough to 
require therapy discontinuation (Lampson et al., 2016). Recently, the FDA 
recommended the closure of clinical trials investigating the Idelalisib and 
Rituximab combination as first-line treatment for CLL patients due to a high 
number of infections and deaths associated to this treatment (Buensalido and 
Chandrasekar, 2014). Currently, other PI3K inhibitors, such as Duvelisib, 
TGR-1022 and ACP-319 are also being evaluated in clinical trials (Blunt and 
Steele, 2015). 
As reviewed by (Kipps et al., 2017a), treatment with Fostamatinib, an oral SYK 
inhibitor, caused reduction in lymphadenopathy with concomitant 
lymphocytosis in phase I/II clinical trials (Friedberg et al., 2010). Side effects 
of this treatment include neutropenia, thrombocytopenia and diarrhoea. 
Entospletinib, another SYK inhibitor, is currently being evaluated in preclinical 
and clinical studies. 
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Although small-molecule inhibitors have shown very promising results in pre-
clinical models and clinical trials, a limitation to bear in mind is the development 
of resistance to treatment often seen in patients treated with monotherapies 
(Mani et al., 2015). More recently, new clinical trials exploring the use of these 
inhibitors in combination with monoclonal antibodies and/or chemotherapy are 
being carried out (Hallek, 2013). Such is the case of Venetoclax (ABT-199), 
an orally administered agent that selectively inhibits BCL-2 and does not target 
other members of the BCL family –preventing growth of lymphocytes without 
interfering with platelet homeostasis. This BCL-2 inhibitor has been recently 
tested in combination with Rituximab in a phase 1b trial, attaining an ORR of 
88% (Roberts et al., 2014). The most common grade 3 to 4 adverse events 
however were neutropenia, thrombocytopenia and anaemia (Owen et al., 
2015). Studies examining the use of Venetoclax with or without an anti-CD20 
MAb, and with or without Ibrutinib are ongoing (Cervantes-Gomez et al., 2015, 
Thijssen et al., 2015). It is expected these combinations will provide higher 
response rates to therapy than with Venetoclax alone.  
1.2.1.4.2 Immunotherapies: Immuno-modulatory drugs, Monoclonal antibodies & 
CAR T-cells 
Despite the encouraging data obtained so far with both chemo-immunotherapy 
and small-molecule inhibitors, the former cannot be used in frail or elderly 
patients due to its toxicity. Small-molecule inhibitors, although better tolerated, 
produce relatively low rates of complete remission (CR, obtained in <10% of 
patients) and still do not seem to represent a cure for CLL (Riches and 
Gribben, 2014). Hence, new options of treatment need to be explored. 
Immune-based therapies seek to boost or redirect the patient’s own immune 
system in order to break tolerance to cancer cells and eliminate them 
(Makkouk and Weiner, 2015). As most malignancies, CLL presents defective 
immunological processes. As reviewed by (Emole et al., 2015), recent studies 
suggest that an immunotherapeutic approach can target and overcome these 
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aberrant processes without the toxicity of chemotherapy. In CLL, this could be 
achieved by: i) immunomodulatory therapy and ii) adoptive transfer of anti-
tumour/checkpoint blockade monoclonal antibodies or chimeric antigen 
receptor (CAR) T-cells. These strategies will be briefly discussed below. 
Lenalidomide, a derivative of thalidomide, is a chemically modified drug with 
enhanced immunomodulation and decreased neurologic toxicity (Carballido et 
al., 2012). It has been found that treatment with Lenalidomide indirectly affects 
the stromal microenvironment that would otherwise support CLL cells’ 
proliferation; it also promotes expression of CD154 on CLL cells and anti-
ROR1 antibody production (Lapalombella et al., 2010). Moreover, this drug 
reverses the defective immunological synapse formation reported in CLL 
(Ramsay et al., 2008). Lately, as commented by (Seiffert, 2014), Lenalidomide 
was found to have a direct anti-proliferative effect on CLL cells in vitro by 
targeting cereblon, a protein involved in cell-cycle arrest. 
Despite its relevant anti-proliferative activity, which resulted in encouraging 
results in the treatment of high-risk patients; the side effects of Lenalidomide 
are considerable. In 58% of patients, it caused tumour flare reactions (i.e. 
visible and painful increase in lymph nodes size, malaise and fever) and 
tumour lysis syndrome. Plus, the overall rate response when used as 
monotherapy ranged between 32-54% in different clinical trials (Hallek, 2013). 
The combination of Lenalidomide with Rituximab and other drugs have more 
recently been explored. Improved response (ORR of 66%) has been reported 
in relapsed/refractory CLL in a phase II study when Lenalidomide was used in 
combination with Rituximab (Badoux et al., 2013). Furthermore, therapy with 
an anti-CD20 MAb 9 days before initiation of Lenalidomide therapy seemed to 
mitigate the risk for tumour flare reaction (Vitale et al., 2016). 
Rituximab, a chimeric anti-human CD-20 monoclonal antibody, although vastly 
efficient when used in combination, it is less active as a single agent unless 
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very high doses are used (O'Brien et al., 2001). More recently, Ofatumumab –
a fully humanised anti-CD20 antibody targeting a different epitope than the 
one recognized by Rituximab– has shown increased binding affinity and 
prolonged dissociation rate. When compared to Rituximab, higher levels of cell 
killing through cell-dependent cytotoxicity (CDC) (Pawluczkowycz et al., 2009) 
and antibody-dependent cellular cytotoxicity (ADCC) activity have been found 
(Hallek, 2013). Nevertheless, there has not been a formal clinical trial 
comparing both antibodies.    
Obinutuzumab (GA 101) is the most recently developed anti-CD20 monoclonal 
antibody. It has been humanised and glyco-engineered in order to have a 
higher binding affinity and increased ADCC and direct cell death induction, 
although it does have a lower CDC activity when compared to Rituximab in 
vitro (Mossner et al., 2010). Updated results from a clinical trial (CLL11), where 
Obinutuzumab was used in combination with chemotherapy in elderly patients, 
showed significant reduction in disease progression or death. In combination 
with Chlorambucil (Goede et al., 2015), it has been approved for front-line 
treatment of frail or elderly patients (Emole et al., 2015). 
Alemtuzumab, an anti-CD52 monoclonal antibody has also been widely used 
for the treatment of CLL. This is a recombinant, fully humanised antibody that 
has proven to be an effective therapeutic option for patients bearing high-risk 
genetic markers (Lozanski et al., 2004). Since Alemtuzumab can lead to 
severe immunosuppression, it is no longer commercially available for CLL and 
is reserved mainly for fit patients with high-risk disease through the Campath 
Distribution Program (Emole et al., 2015). A very recent study, however, has 
shown that subcutaneous administration of Alemtuzumab at low dosage has 
good tolerability and long-term efficacy in heavily pretreated CLL patients. The 
authors claim that low-dose Alemtuzumab represent an effective yet safe 
alternative for relapsed/refractory CLL and even for frail and elderly patients 
(Sciume et al., 2015). Further studies are needed in order to confirm these 
observations. 
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An important aspect to consider about monoclonal antibody therapy is that 
some CLL patients seem to easily develop resistance, particularly against anti-
CD20 antibodies. Resistance mechanisms include downregulation of CD20 
during therapy as well as decreased complement activity by the loss of 
component C2. Furthermore, it has been suggested that indirect resistance 
may be triggered by Lenalidomide treatment as it downregulates CD20 
expression in vitro (Lapalombella et al., 2008). 
As described in section 1.1.4, another form of immunotherapy is the CAR T-
cell approach. The first trials investigating CAR T-cell therapy were performed 
on patients with CLL, where the first two out of three patients achieved a 
complete response (Porter et al., 2011). Updated results reported by 
researchers from University of Pennsylvania revealed that from 14 evaluable 
patients, 4 achieved a complete response and 4 other patients achieved a 
partial response (Porter et al., 2015). In contrast, studies carried out at the 
Memorial Sloan Kettering Cancer Centre (MSKCC), in which 9 patients were 
treated with or without conditioning therapy, resulted in no observable clinical 
benefit. Only one of the patients that received conditioning chemotherapy 
achieved a complete response (Park, 2012).  
It has been suggested that CD19 CAR T-cells in CLL are not as successful as 
they are in B-ALL (Park, 2014) due to the inherent effector T-cell dysfunction 
observed in CLL (Riches et al., 2013). Also, immune suppression via PD-L1/2 
(McClanahan et al., 2015), the presence of immunosuppressive cell types, 
such as Tregs, MDSCs or nurse-like cells, and the production of inhibitory 
cytokines (Boissard et al., 2015, Saulep-Easton et al., 2016, Burger et al., 
2000) might influence CAR T-cell efficacy in patients with CLL. Further 
engineering of CAR T-cell therapy is needed in order to counteract the 
immunosuppressive TME existing in CLL. 
Additionally, as reviewed by (Park and Brentjens, 2013), considerable toxicity 
of CAR-based cell therapies in the form of cytokine release syndrome, tumour 
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lysis syndrome and other adverse effects has been reported. Despite of this, 
adoptive cell transfer of CAR T-cells is currently amongst the most novel and 
promising type of treatments for CLL. Certainly, CD19 CARs can induce potent 
and sustained responses in some patients with advanced, refractory CLL and 
high-risk patients; the long-term efficacy and toxicity of this approach, 
however, needs to be further investigated. 
Due to the key role that the TME plays in the success of immunotherapies, it 
is not surprising that the use of immune checkpoint inhibitors has been 
explored in CLL. The use of anti-PD-L1 blocking antibodies in preclinical in 
vivo models was shown to reactivate immune effector cells (McClanahan et 
al., 2015). More recently, Pembrolizumab, an anti-PD-1 antibody was used for 
treating patients with relapsed and Richter transformed (RT) CLL. Objective 
responses were observed in 4 out of 9 RT patients, whilst the median overall 
survival in this cohort was 10.7 months (Ding et al., 2017). Further clinical 
studies are needed to confirm the benefit of PD-1 blockade in CLL patients 
with RT observed in this trial. 
In Table 1. 1, some of the most efficient and current therapies used for the 
treatment of chronic lymphocytic leukaemia are presented.   
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Table 1. 1. Efficient drugs in the treatment of Chronic Lymphocytic Leukaemia. Based 
on (Nabhan, 2014). 
Alkylating agents 
(Cause DNA 
damage) 
Purine 
analogues 
(Inhibit DNA 
repair) 
B-Cell Receptor 
pathway and 
Tyrosine Kinase 
inhibitors 
Immunotherapy 
Monoclonal 
antibodies 
Immuno-
modulatory 
agents 
CAR T-cells 
Chlorambucil Fludarabine 
Ibrutinib (targets 
Bruton’s tyrosine 
kinase) 
Rituximab 
(aCD20) 
Lenalidomide 
(multiple 
targets) 
CD19 
Chimeric 
Antigen 
Receptor 
(CAR) T-cells 
Bendamustine Pentostatin 
Idelalisib (targets 
phosphoinositide-
3’-kinase delta) 
Ofatumumab 
(aCD20) 
  
Cyclophosphamide Cladribine 
Venetoclax 
(targets BCL-2) 
Obinutuzumab 
(aCD20) 
  
  
Fostamatinib 
(targets SYK) 
Alemtuzumab 
(aCD52) 
  
 
Nevertheless, it is important to note that in the case of CD19 CAR therapy, the 
most successful CAR therapy so far, an additional form of cytotoxicity is 
introduced: on-target, off-tumour toxicity. As long-term persisting anti-CD19 
CAR T-cells are infused into the patients, continuing elimination of both normal 
and malignant CD19-expressing cells will occur leading to profound and 
prolonged B-cell aplasia and ultimately, hypogammaglobulinemia (Dotti et al., 
2014). Similarly, Rituximab, one of the first MAbs that revolutionised the 
treatment of B-cell malignancies, also causes on-target, off-tumour toxicity. 
Treatment with Rituximab and more advanced anti-CD20 antibodies also 
results in B-cell aplasia. Consequently, there is a pressing need to identify 
better tumour associated antigens (TAA) expressed, preferentially, by 
malignant cells. In this scenario, targeting of ROR1, a protein expressed on 
CLL cells but not healthy B cells, seems crucial if we are to improve the long-
term toxicity profile and availability of this and other immunotherapies.  
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1.2.2 Pancreatic Cancer (PaCa) 
According to (Ansari et al., 2016), the first known report on pancreatic cancer 
was authored by Giovanni Battista Morgagni in 1761. The lack of microscopic 
evaluation rendered the diagnosis of this disease uncertain. Almost 100 years 
later, Jacob Mendez Da Costa revisited Morgagni’s work and produced the 
first microscopic diagnosis, describing PaCa as a true malignancy (Costa, 
1858). 
Similarly, the first reported attempt of pancreatic surgery took place in the last 
decade of the 19th century, but it was Allen Oldfather Whipple in 1935 who 
sparked the interest in pancreaticoduodenectomies (partial resection of 
duodenum and the head of the pancreas) (Whipple et al., 1935). Two years 
later, Alexander Brunschwig performed the first successful surgery for 
pancreatic adenocarcinoma (Brunschwig, 1937). Today, pancreatic surgery is 
a safe procedure with an operative mortality below 3% (Yoshioka et al., 2014). 
Despite major advances in surgical management, long-term survival for PaCa 
patients is still extremely poor as only 10-15% of newly diagnosed patients are 
deemed eligible (Winter et al., 2012). The current understanding of this 
disease in terms of PaCa biology, TME and clinical management are briefly 
summarised below.  
1.2.2.1 PaCa biology 
According to  (Warshaw and Fernandez-del Castillo, 1992), pancreatic cancer 
can be classified into two major categories according to the type of cells it 
originates from: exocrine and endocrine tumours. Of these, pancreatic ductal 
adenocarcinoma (PDAC), an exocrine tumour, is the most frequent type of 
pancreatic cancer (Wolfgang et al., 2013). 
In PDAC, neoplastic cells of invasive ductal adenocarcinoma form glands and 
infiltrate into tissues (Hruban, 2007). In general, this type of tumour is solid and 
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firm probably because almost all invasive ductal adenocarcinoma cells invade 
nerves and spread along perineural spaces. Another feature of PDAC is its 
high invasiveness, which results in tumour spreading in lymph nodes and liver 
metastasis (Wolfgang et al., 2013). Not surprisingly, by the time most PDACs 
are diagnosed, the disease has spread beyond the gland and cannot be 
treated by surgical resection. Nevertheless, one of the major characteristics of 
PDAC is the intense desmoplastic reaction they elicit (Jacobetz et al., 2013). 
The latter consists of fibroblasts, inflammatory cells, endothelial cells and a 
complex extracellular matrix (ECM). The desmoplastic reaction reduces 
tumour tissue elasticity and increases tumour interstitial fluid pressure that 
represents a barrier for many therapeutic agents (Lohr et al., 1994, Heldin et 
al., 2004, Provenzano et al., 2012). 
As reviewed by (Distler et al., 2014), PDAC originates from mainly three 
lesions: i) precursor lesions identified as intraductal papillary mucinous 
neoplasm (IPMN), ii) mucinous cystic neoplasm (MCN) or iii) pancreatic 
intraepithelial neoplasia (PanIN). The latter represent the most frequent pre-
lesions in PDAC and are well characterised (Hruban et al., 2004). PanINs are 
classified into different grades based on their morphological characteristics 
and severity of the lesions: PanIN 1A (flat duct lesions) and PanIN 1B (papillary 
duct lesions), which are low-grade lesions with minimal atypia; PanIN 2 
(intermediate-grade PanIN), which show mild/moderate dysplasia; and PanIN 
3 (also known as carcinoma in situ), which present severe atypia. All PanIN 
lesions are non-invasive and are characterised by hypovascularity, immune 
cell infiltration and feature specific genetic alterations that increase in 
frequency and variety with the progression of PanIN stages. These biological 
alterations and somatic mutations are required for PanIN lesions to progress 
into invasive carcinoma and are also implicated in the rapid metastatic spread 
that characterises this malignant disease (Hezel et al., 2006). 
In terms of molecular pathways and genetics in PDAC, there are currently no 
molecular signatures for staging or prognostication, as this disease is highly 
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heterogeneous (Yabar and Winter, 2016). Whole-exome sequencing 
performed in 124 PDAC genomes revealed that more than 1300 genes were 
mutated (Jones et al., 2008); of which KRAS was the only oncogene 
genetically activated in more than 95% of PDACs. Since targeted therapy 
against this gene has proved disappointing (Van Cutsem et al., 2004), 
researchers have focused instead on identifying core signalling pathways 
involved in PDAC initiation/progression (Jones et al., 2008, Biankin et al., 
2012). Interestingly, (Waddell et al., 2015) found that approximately 25% of 
PDAC tumours harbour functional defects in DNA damage pathways; which 
suggests that these tumours might be sensitive to poly adenosine diphosphate 
ribose polymerase (PARP) inhibitors or platinum drugs. 
Apart from KRAS, high-frequency mutations appear also in tumour suppressor 
genes, such as CDKN2A, TP53 and SMAD4 (Jones et al., 2008, Biankin et al., 
2012). Inactivating alterations on these genes consist of mutations in one allele 
and genetic loss of the second allele due to chromosomal instability. Some of 
the most common gene mutations in PDAC are shown in Table 1. 2.  
  
    Chapter 1 
53 
 
Table 1. 2. Significantly mutated pathways in pancreatic ductal adenocarcinoma. Based 
on (Yabar and Winter, 2016). 
Core Pathway Gene Protein Function 
Mutation 
Rate (%)* 
KRAS signalling 
KRAS Oncogene; GTPase; activates MARK activity 
100 
MAP2K4 
Dual specificity mitogen-activated protein 
kinase 4; Toll-like receptor signalling pathway 
DNA damage 
control 
TP53 Tumour suppressor p53 83 
Control of G1/S 
phase transition 
CDKN2A 
Cyclin-dependent kinase inhibitor 2A; tumour 
suppressor 
83–96 
TGF-β signalling 
SMAD4 
Mothers against decapentaplegic homolog 4; 
BMP signalling pathway 
63–100 
TGFBR2 TGF-β receptor type II; regulation of growth 
* Depending on which gene expressed in sample of tumor studied. 
Abbreviations: BMP, bone morphogenetic protein; TGF, transforming growth factor. 
 
It is worth mentioning that during PanIN 1, KRAS activation and telomere 
shortening are the first oncogenic events to occur. During PanIN 2, p16 loss is 
observed; whilst TP53, SMAD4 and BRCA2 inactivation takes place in the 
PanIN 3 stage (Distler et al., 2014). Epithelial-to-mesenchymal transition 
(EMT) is promoted by loss of E-cadherin, resulting in a highly lethal phenotype 
in advanced stages (Winter et al., 2008). Notably, (Yachida et al., 2010) have 
shown that this PanIN to PDAC transformation is a 10 to 20-year process. 
1.2.2.2 Tumour microenvironment in PaCa  
Histology studies evaluating patients with chronic pancreatitis have shown that 
epithelial wound healing response is particularly robust in the pancreas 
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(Ceyhan and Friess, 2015). Notably, relevant features associated with a 
wound healing response include fibroblast activation, immune suppression, 
remodelling of the extracellular matrix as well as trophic signals to promote re-
epithelialisation (Dvorak, 1986).  
It has been therefore hypothesised that the stromal response is hijacked during 
PDAC, as the stroma provides paracrine signals that seem to select certain 
tumour cells (Makohon-Moore and Iacobuzio-Donahue, 2016). These 
paracrine signals originate mostly from α-smooth muscle actin (αSMA)+ 
myofibroblasts, which in turn are derived from quiescent pancreatic stellate 
cells (qPSCs). Importantly, the characteristic desmoplastic reaction seen in 
PDAC is mediated by activation of qPSCs (Neesse et al., 2011). Upon 
activation, these cells: i) lose their cytoplasmic lipid, ii) transdifferentiate into 
αSMA+ myofibroblasts with proliferative capacity, iii) secrete various growth 
factors and iv) promote ECM formation (Masamune and Shimosegawa, 2015).  
In the PDAC context, PSCs and other stromal mesenchymal cells are 
continuously activated by the epithelium, through secretion of platelet-derived 
growth factor (PDGF), TGFβ and sonic hedgehog (SHH) (Bailey et al., 2008, 
Taeger et al., 2011). This notion was supported by an in vivo study where 
pharmacological inhibition of PSC activation led to stromal collapse, smaller 
tumours and improved chemotherapeutic delivery (Sherman et al., 2014).  
The abundant extracellular matrix in PDAC is another part of its 
microenvironment and it effectively acts as a physical barrier to the neoplasm 
(Jacobetz et al., 2013). The hyaluronic acid contained in the ECM is a 
negatively charged glycosaminoglycan that binds to large amounts of water, 
resulting in high hydrostatic pressure and interstitial fluid pressure (IFP) 
(Stromnes et al., 2014). This is particularly problematic in terms of therapy 
delivery (Provenzano et al., 2012), and it has been shown it could also lead to 
hypoxia (Olive et al., 2009), a pervasive feature of cancer. 
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With regards to the immune system in PDAC, there is a large amount of data 
indicating that the pancreatic cancer microenvironment is immunosuppressed 
at multiple levels, as shown by (Clark et al., 2007) in a study where the immune 
response during tumour evolution was characterised using a mouse model of 
PaCa. More recently, (Ene-Obong et al., 2013) showed for the first time that 
activated PSCs appeared to reduce migration of CD8+ T-cells to tumour-
proximal stromal compartments, preventing therefore their access to cancer 
cells. As reviewed by (Makohon-Moore and Iacobuzio-Donahue, 2016), T-cell 
suppression in PDAC is promoted by several mechanisms: i) accumulation of 
Tregs, ii) M2 tumour-associated macrophages (TAMs), iii) MDSCs and 
iv)fibroblast activation protein (FAP)+ fibroblasts, a type of stromal cell different 
from PSC-derived myofibroblasts. Interestingly, unlike CLL, endogenous 
cytotoxic T-cells do not seem to be dysfunctional, as latent immune responses 
and intratumoural accumulation of T-cells were observed when (FAP)+ 
carcinoma-associated fibroblasts (CAFs) were removed and/or CXCR4 
inhibitors were added to an in vivo model of human PDAC (Feig et al., 2013).   
1.2.2.3 Standard therapy 
In terms of clinical management and according to the American Joint 
Committee of Cancer and the Union for International Cancer Control (Cascinu 
et al., 2010), PDAC is divided into three categories: i) localised resectable 
tumours (stage I and II), ii) unresectable locally advanced tumours (stage III); 
and iii) metastatic tumours (stage IV). In the following paragraphs, the standard 
therapy approach provided to PDAC patients according to their staging is 
summarised.  
Stages I and II, surgically resectable PDAC; if the tumour is restricted to the 
pancreas alone (stage I), then the treatment of choice is surgical removal of 
all recognisable tumour tissue. Unfortunately, relapse is observed in 60-70% 
of stage I patients due to micrometastases during or after surgery (Cid-Arregui 
and Juarez, 2015). To avoid this, systemic chemotherapy/chemoradiation 
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(also known as adjuvant therapy) is administered after surgery. As reviewed 
by (Goodman and Saif, 2014), treatment with Gemcitabine or 5-fluoruracil (5-
FU) increased the 5-year survival rate from 10% to 20% compared to 
observation. Although there was no significant difference between 
Gemcitabine and 5-FU, PDAC patients treated with the former experienced 
significantly less toxicity. More recently, in a phase III study carried out in 
Japan, Gemcitabine was compared with S-1, an oral fluoropyrimidine prodrug 
that is enzymatically converted into 5-FU. The quality of life and 2-year overall 
survival was significantly higher (70%) for S-1 than for Gemcitabine (53%) 
(Ueno et al., 2013)). Further studies in other countries are needed in order to 
determine that the effect seen on Asian patients can be replicated in other 
populations. 
The efficacy of chemoradiation after surgery is less clear due to mixed results 
from different clinical trials showing no added benefit (Klinkenbijl et al., 1999) 
or even detrimental effects (Neoptolemos et al., 2004). A recent retrospective 
study reviewing 955 patients however showed that 5-year overall survival for 
patients treated with chemoradiation was 41.2% compared to patients treated 
with adjuvant chemotherapy alone (25.7%) (Morganti et al., 2014).  
Another approach to prevent micrometastases and relapse is the 
administration of neoadjuvant therapy (chemotherapy, chemoradiation or a 
combination of treatments) before surgery. Importantly, this type of therapy 
does not seem to be beneficial for patients with resectable tumour but for those 
diagnosed with borderline resectability or with locally advanced non-resectable 
tumours (Heinemann et al., 2013). This is consistent with a previous study by 
(Katz et al., 2008), who reported that out of 125 PDAC patients with borderline 
resectable tumours receiving neoadjuvant therapy and subsequent restaging, 
66 (41%) underwent surgery. The median survival for the 66 patients who 
completed all therapy was 40 months compared to only 13 months for the 94 
patients who did not undergo surgery.  
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Currently, no optimal protocol for neoadjuvant therapy has been reported, 
although multidrug therapy, such as Gemcitabine after Nab-paclitaxel (albumin 
bound paclitaxel) or the multiagent regimen FOLFIRINOX (Leucovorin, 5-FU, 
Irinotecan, Oxaliplatin) have shown promise. In a retrospective study, it has 
been shown that FOLFIRINOX was able to induce conversion to resectability 
in >20% of locally advanced PDAC patients (Faris et al., 2013). Moreover, 
there are at least two ongoing phase II trials using radiation therapy and 
FOLFIRINOX in borderline resectable PDAC patients (NCT01560949 and 
NCT01591733). 
Stage III, locally advanced, unresectable PDAC; due to the poor response 
rates after different therapeutic strategies, the clinical management of these 
patients remains controversial. Chemotherapy with 2-3 cycles of Gemcitabine 
followed by restaging and, where possible, chemoradiation is the frequent 
treatment of choice (Cid-Arregui and Juarez, 2015).  
Other options such as FOLFIRINOX or Gemcitabine/Nab-paclitaxel are being 
investigated (Faris et al., 2013). The efficacy and toxicity of these approaches 
remain to be determined. 
Stage IV, metastatic PDAC; it can be classified as stage IVa, when metastasis 
is found adjacently, and in stage IVb, when the disease has spread to distant 
organs (usually, liver, stomach, spleen or lungs) (Cid-Arregui and Juarez, 
2015). Gemcitabine is the first-line therapy for these patients since it was 
shown in 1997 that patients treated with this drug had a 12-month survival rate 
of 18% vs 2% achieved by 5-FU-treated PaCa patients (Burris et al., 1997). 
To date, different Gemcitabine-based combinations has been tested in 
randomised trials in comparison with Gemcitabine alone, of which three 
combinations have shown beneficial effects: Gemcitabine plus Erlotinib (an 
EGFR inhibitor) (Moore et al., 2007), Gemcitabine plus S-1 (Ueno et al., 2013), 
and Gemcitabine plus Nab-paclitaxel (Von Hoff et al., 2011).  
    Chapter 1 
58 
 
Additionally, treatment with FOLFIRINOX has achieved a clear clinical benefit 
in metastatic PDAC (Conroy et al., 2011). In this clinical trial, 342 stage IV 
PDAC patients not previously treated with chemotherapy were assessed. The 
median overall survival in the FOLFIRINOX arm was 11.1 months compared 
to 6.8 months seen in the Gemcitabine group. Definitive deterioration in the 
quality of life at 6 months was 31% in FOLFIRINOX-treated patients and 66% 
in the Gemcitabine arm. One of the limitations of this approach however is the 
substantial toxicities. In an effort to counteract this, modified regimens of this 
drug (no bolus 5-FU and addition of haematopoietic growth factor) are being 
tested. In line with this, (Mahaseth et al., 2013) reported that modified 
FOLFIRINOX maintained efficacy whilst causing significantly less grade 3-4 
toxicities. Further studies including additional refinement of these regimens will 
shed light on how to improve safety whilst maintaining/enhancing efficacy. 
The relatively modest clinical benefit reached by the approaches mentioned 
above coupled with a better (although still limited) understanding of PDAC 
biology and its microenvironment has led scientists and clinicians to explore 
novel targeted therapies. 
1.2.2.4 New therapies 
In the past decade, several agents targeting the tumour or stroma have been 
developed. Although promising results were shown in preclinical studies, most 
of them have not achieved a significant improvement in overall survival in 
clinical trials when compared to Gemcitabine or other strategies. 
1.2.2.4.1 Small molecule inhibitors 
As indicated by (Cid-Arregui and Juarez, 2015) and (Adamska et al., 2017), 
inhibitors targeting various molecules have been developed, including PARP 
(DNA damage pathway), Matrix metalloproteinases (MMP; extracellular 
matrix), Vascular endothelial growth factor (VEGF; angiogenesis), Hedgehog, 
PI3K and KRAS pathways, amongst others. Of these, Everolimus and 
Sunitinib (mTOR inhibitors – PI3K signalling) have shown great promise as 
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progression-free survival time was increased from 5 to 11 months (Liu et al., 
2013, Wiedmann and Mossner, 2012). In contrast, when Everolimus or 
Temsirolimus were used to inhibit PI3k/Akt/mTOR pathways in previous phase 
II studies, disappointing results were obtained (Javle et al., 2010). 
Nevertheless, differences in the study’s design and patients’ population make 
it difficult to draw further conclusions from these trials. Although no superiority 
over standard therapy has been shown with most of these inhibitors, clinical 
trials using different protocols are ongoing. For instance, PBI-05204, another 
mTOR inhibitor, is currently being tested in stage IV patients (NCT02329717). 
1.2.2.4.2 Immunotherapies 
Therapeutic vaccines; these are designed to stimulate the immune system to 
react against TSAs by induction of specific cytotoxic T-cells. In the PDAC 
context, several types of vaccines have been generated. A very good review 
on this can be found in (Amedei et al., 2014). Briefly, peptide-based vaccines, 
such as PANVAC-V (Bernhardt et al., 2006) and GV1001 (Middleton et al., 
2014) failed to show significant clinical benefit over standard therapies in 
clinical trials. In contrast, whole-cell vaccines, such as Algenpentucel-L 
(NCT01072981, NCT01836432) and GVAX (NCT01896869) are now in phase 
II/III trials, where combinations with checkpoint blockade antibodies are being 
tested (Le et al., 2013).  
MAbs; in PDAC, MAbs targeting EGFR or VEGF have shown disappointing 
results. In a phase III study, Cetuximab (an anti-EGFR MAb) was administered 
in combination with Gemcitabine to patients with advanced PDAC, yet no 
significant difference in median overall survival was observed when compared 
to Gemcitabine alone (6.3 vs 5.9 months, respectively) (Philip et al., 2010). A 
similar outcome was observed when Bevacizumab, an anti-VEGF MAb, was 
tested in phase II (Kindler et al., 2005) and phase III trials (Kindler et al., 2010). 
Due to the immunosuppressive nature of the TME in PDAC, checkpoint 
blockade antibodies such as Nivolumab, an anti-PD-1 MAb, are being tested 
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alone (NCT02423954), or in combination with: i) Ipilimumab, an anti-CTL-4 
MAb (NCT01928394) or ii) Gemcitabine (NCT01473940). Unfortunately, 
preliminary data was not encouraging, as there were no indications of 
significant improvement; nevertheless, official results are awaited. 
Interestingly, CD40 targeting has emerged as a novel strategy to block TME 
immunosuppression and increase anti-tumour activity (Loskog and Eliopoulos, 
2009). Accordingly, a combination of Gemcitabine and an anti-CD40 antibody 
is being evaluated in clinical trials (Vonderheide et al., 2013). It is expected 
that this combination would enhance the accumulation of tumour-suppressive 
macrophages, thereby prompting tumour regression. 
T-cell therapy; since the general number of tumour-specific T-cells in the 
PDAC population is too small, T-cells are taken from the patient, engineered 
and expanded ex vivo to then be transferred back to the patient. This can be 
done using the T-cell receptor (TCR) strategy, whereby T-cells from the patient 
are transduced to express a tumour-targeting TCR. This technology is 
currently being tested using the anti-MAGE-A3 protein (NCT02111850) and 
anti-NY-ESO-1 antigen (NCT01967823). 
Another strategy is to use CAR T-cells. At the moment, CAR T-cells targeting 
mesothelin are in clinical trials for solid malignancies, including PDAC 
(NCT01583686) (Adamska et al., 2017). 
1.2.2.4.3 Cancer stem-like cell therapy  
Cancer stem cell-like cells (CSCs) in PDAC represent a small population of 
cells with the ability to prompt tumour initiation, disease progression and 
metastasis. It has been increasingly shown that these cells are highly resistant 
to conventional chemotherapy; furthermore, its presence may account for the 
rapid and virtually universal relapse seen in PDAC (Wolfgang et al., 2013, Qiu 
et al., 2015).   
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To date, no distinctive PDAC CSC biomarkers have been identified, yet 
markers, such as CD24, CD133 and ALDH1 are deemed as the most 
characteristic. Nevertheless, it is considered that various CSCs subtypes may 
express only one or two surface markers, which complicates the development 
of therapeutic strategies (Ansari et al., 2016). Furthermore, most of these 
markers are also expressed in healthy tissue. Recently, CSC targeting has 
been proposed to be carried out by disruption of signalling pathways involving 
Sonic hedgehog, Notch or PI3K (Raj et al., 2015), but none of these 
approaches are currently in clinical trials for PDAC.  
Taken together, the complex genetic heterogeneity, desmoplastic nature of 
PDAC and immunosuppressive microenvironment make it a challenging 
disease to treat. Combinations of different targeted and immunotherapeutic 
strategies are now being actively evaluated in the clinic. It is envisaged that 
strategies that combine bypassing the immunosuppressive TME with CSC 
targeting will prove instrumental to PDAC therapy. Identification of druggable 
targets expressed on malignant cells, amongst them CSCs, but not healthy, 
critical organs is therefore required. 
 
1.3 Need of a new therapeutic target: Receptor tyrosine kinase-like 
orphan receptor 1 (ROR1)  
An example of better tumour-associated targets recently discovered is 
Receptor tyrosine kinase-like Orphan Receptor-1 (ROR-1). Considerable 
ROR1 expression has been found in a range of solid (Zhang et al., 2012b) and 
haematological malignancies (Daneshmanesh et al., 2013), including CLL 
(Baskar et al., 2008). Importantly, ROR1 is implicated in tumour cell survival 
and metastasis through the non-canonical Wnt signalling pathway (Fukuda et 
al., 2008).  
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Accordingly, ROR1 targeting with monoclonal antibodies induced apoptosis of 
CLL cells in vitro (Daneshmanesh et al., 2012), and inhibited cancer 
progression and reversed epithelial-mesenchymal transition (EMT) in breast 
cancer both in vivo and in vitro (Cui et al., 2013). More recently, ROR1 
expression on cancer stem cell-like cells (CSC) has been reported in a 
glioblastoma cell line (Jung et al., 2016) and in ovarian cancer primary cells 
(Zhang et al., 2014). Remarkably, successful targeting of these CSCs following 
treatment with Cirmtuzumab, an anti-ROR1 antibody (UC-961 clone), was 
observed both in vivo and in vitro (Zhang et al., 2014).  
In this context, the aim of my PhD project was to generate a novel anti-ROR1 
monoclonal antibody-based therapy for ROR1+ malignancies. In keeping with 
this, a brief summary of ROR1 biology and underline its relevance as a target 
for cancer immunotherapy is provided. 
1.3.1 ROR1 Structure  
Receptor tyrosine kinase-like Orphan 
Receptor-1 (ROR-1) is a type I 
transmembrane protein consisting of 937 
amino acid residues with intra and 
extracellular portions. The intracellular part 
contains a tyrosine kinase domain that might 
be phosphorylated by other cytoplasmic 
signalling proteins (Gentile et al., 2011). For 
immunotherapeutic purposes, however, the 
extracellular part is of special interest, and it 
is composed of an immunoglobulin-like (Ig) 
domain, followed by a cysteine-rich domain 
(CRD), also called the Frizzled (Fz) domain, 
and lastly, a Kringle (Kg) domain (Fig. 1. 5). 
Notably, its Fz module constitutes the 
Fig. 1. 5. Receptor tyrosine 
kinase-like orphan receptor 
(ROR1) 
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extracellular ligand-binding region to Wnt5a (Roszmusz et al., 2001, Green et 
al., 2008, Fukuda et al., 2008). 
Of note, both ROR1 and ROR2 –the other member of the ROR family– were 
originally isolated from a neuroblastoma cell line more than 20 years ago 
(Masiakowski and Carroll, 1992). Since their natural ligands were not 
identified, they received the ROR designation. Data from Oishi et al. (Oishi et 
al., 1999) indicated that ROR1 is expressed during embryonic development 
and is down regulated post-partum (Matsuda et al., 2001). Recent studies 
show that ROR1 is expressed at low levels in hematogones (a subset of B-cell 
precursors) and at very low levels on lungs, pancreas and adipocytes (Berger 
et al., 2015, Hudecek et al., 2010). Accordingly, ROR1-deficient mice do not 
exhibit any morphological abnormalities; but they die within the first 24h after 
birth, presumably due to respiratory failure (Broome et al., 2011).  
1.3.2 Expression on normal and cancer tissues  
Although ROR1 expression has not been fully investigated in humans, gene 
expression profiling of ROR1 in normal blood leukocytes showed that 
granulocytes, B-cells and T-cells of healthy donors are ROR1 negative (Dave 
et al., 2012, Shabani et al., 2015). In contrast, flow cytometry data indicated 
that ROR1 was present on the cell membrane of adipocytes and hematogones 
(Hudecek et al., 2010). More recently, investigation of ROR1 expression at a 
protein level using an intracellular anti-ROR1 MAb, revealed that critical 
tissues such as brain, heart, lung and liver had no ROR1 expression, yet 
considerable cell-surface staining was detected on normal parathyroid, 
pancreatic islet cells and some regions of the gastrointestinal tract, particularly 
in the stomach and gastric body (Balakrishnan et al., 2017). 
With regards to malignant tissues, significant ROR1 expression has been 
found in CLL (Baskar et al., 2008) and other haematological malignancies, 
such as hairy cell leukaemia, mantle cell lymphoma, multiple myeloma, diffuse 
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large B-cell lymphoma, among others (Daneshmanesh et al., 2013). ROR1 
was also found in solid cancers (Zhang et al., 2012b), including a subset of 
ovarian cancer, triple negative breast cancer and lung adenocarcinomas 
(Balakrishnan et al., 2017).  
Importantly, ROR1 is implicated in tumour cell survival and metastasis through 
the non-canonical Wnt signalling (Fukuda et al., 2008). Recently, it has been 
suggested that Wnt5a autocrine signalling –through ROR1– allows CLL cells 
to overcome natural microenvironmental regulation and possibly enhance cell 
survival (Janovska et al., 2015). Furthermore, this biomarker has been 
associated with accelerated disease progression in CLL (Cui et al., 2016) and 
is considered as a prognostic marker in colorectal cancer (Zhou et al., 2017a), 
lung adenocarcinoma (Zheng et al., 2016) and triple negative breast cancer 
(Chien et al., 2016). Furthermore, silencing of ROR1 in breast cancer (Zhang 
et al., 2012a), ROR1 and ROR2 in ovarian cancer (Henry et al., 2016) or ROR1 
and fibromodulin (FMOD)-a collagen-binding protein- in CLL cells (Choudhury 
et al., 2010) resulted in impaired cell migration and invasion in solid tumours 
as well as apoptosis of CLL cells. Remarkably, this would imply that resistance 
to therapy and tumour escape by downregulation of ROR1 would not be as 
viable as it indeed was the downregulation of CD19 or CD20 observed after 
CD19 CAR therapy or treatment with anti-CD20 antibodies.  
1.3.3 ROR1 signalling and role in tumourigenesis  
It has been shown that in the context of lung adenocarcinoma, the expression 
of ROR1 can be induced in the absence of Wnt5a by: i) Met phosphorylation 
of the proline-rich domain of ROR1; although the ROR1-Met interactions and 
their biological effect remain to be elucidated (Gentile et al., 2011, Gentile et 
al., 2014). And by ii) induction of thyroid transcription factor-1 (TTF-1), a 
lineage-survival oncogene in lung adenocarcinomas. TTF-1 prompts ROR1 
expression, which in turn will activate c-Src in an EGFR-independent manner 
(Yamaguchi et al., 2012) (Fig. 1. 6A). 
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In other malignancies, such as breast cancer, ROR1 interacts with casein 
kinase 1ε and activates the PI3K/AKT/CREB pathway in order to prompt the 
activation of relevant genes involved in tumour cell growth and/or resistance 
to apoptosis (Zhang et al., 2012a, Shabani et al., 2015) (Fig. 1. 6B). 
With regards to leukaemias, particularly CLL, it has been demonstrated that 
ROR1 is involved in the non-canonical, β-catenin independent, Wnt/planar cell 
polarity (PCP) pathway through Wnt5a binding (Janovska and Bryja, 2017). In 
mammals, Wnt factors such as Wnt5a activate this Wnt/PCP signalling branch 
through binding to Fz receptors (Fz family) and co-receptors (ROR1, ROR2). 
Crucially, it is this pathway the one that governs polarity and migration in CLL 
cells, as it controls chemotactic responses and cell homing (Kaucka et al., 
2015, Kaucka et al., 2013).  
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Interestingly, Yu et al. (Yu et al., 2016) reported for the first time that Wnt5a 
induces cellular motility and proliferation by enhancing hetero-oligomerisation 
of ROR1 with ROR2; which in turn recruits guanine nucleotide exchange 
factors (GEFs). The presence of GEFs activates downstream GTPases RhoA 
and Rac1 in CLL cells. 
In the same study, researchers from this group suggested that the highly 
conserved Kg domain of ROR1 is involved in ROR1/ROR2 hetero-
oligomerisation and that the Fz domain in the extracellular portion of ROR1, 
as well as the proline-rich intracellular domain are necessary for recruitment 
Fig. 1. 6. ROR1 signalling pathways in cancer. (A) In the absence of Wnt5a; ROR1 expression 
can be induced through phosphorylation of its proline-rich domain by Met oncogene. Alternatively, 
in lung adenocarcinoma for example, thyroid transcription factor (TTF-1) prompts ROR1-
mediated c-Src-activation, which results in pro-survival AKT activation and inhibition of pro-
apoptotic p38 signalling in an EGFR-independent manner. (B) In the presence of Wnt5a; ROR1 
binding to Wnt5a triggers casein kinase 1 epsilon (CK1ε) signalling through PI3K, AKT and cAMP-
response-element-binding (CREB) protein. This leads to expression of genes involved tumour 
cell growth and resistance to apoptosis. AKT= Protein kinase B, c-Src= cellular Src kinase, PI3K= 
Phosphatidylinositol 3-kinase. Modified from Shabani et al., 2015. 
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of GEFs to ROR1/ROR2 complex (Fig. 1. 7). In line with this, the use of 
Cirmtuzumab, an anti-ROR1 monoclonal antibody, was able to block Wnt5a-
ROR1 signalling; resulting in reduced migration and proliferation of a ROR1-
expressing cell line (Yu et al., 2016). Nonetheless, further studies involving 
ROR1 biology and signalling in other malignancies are needed in order to 
determine whether the hetero-oligomerisation between ROR1 and ROR2 seen 
in CLL is cancer type specific or a common feature across ROR1+ tumours. 
 
Additionally, it has been reported that Wnt activity is associated with increased 
stem cell potential and more aggressive cancers (de Sousa and Vermeulen, 
2016); and Wnt5a signalling, in particular, is involved in the regulation of 
normal and cancer stem cell-like cells self-renewal, cancer cell proliferation, 
migration and invasion. Nevertheless, the role of Wnt5a in CSCs is varied and 
complex. It may suppress or promote tumour growth depending on receptor 
availability, which means that cellular context determines the effect of Wnt5a 
(Zhou et al., 2017b). All in all, evidence so far indicates that Wnt5a-ROR 
interactions sustain tumour progression but, as mentioned above, further 
Fig. 1. 7. Schematic of Wnt5a-ROR1 signalling through hetero-oligomerisation with ROR2 
in CLL. According to Yu et al., 2016, Wnt5a induces ROR1 and ROR2 hetero-oligomerisation 
that prompts recruitment of GEFs in order to promote both cell proliferation through Rac1 
activation and cell migration through RhoA. Modified from Yu et al., 2016.    
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studies are required in order to increase our understanding of the complex 
cross-talk between Wnt5a and ROR1 and other cell membrane receptors 
expressed in CSCs.   
1.3.4 Target for cancer immunotherapy  
The preferential expression of ROR1 on solid and haematological cancers, 
and its absence on critical, healthy tissue, renders ROR1 as an attractive 
target for immunotherapy. Not surprisingly, due to its expression profile, 
preclinical safety has been demonstrated with Cirmtuzumab in vitro (Choi et 
al., 2015); and in non-human primates, where toxicity to normal organs was 
not detected after infusion with anti-ROR1 CAR T-cells (Berger et al., 2015). 
Moreover, recent reports indicate ROR1 is expressed on cancer stem cell-like 
cells in both ovarian cancer (Zhang et al., 2014) and glioblastoma (Jung et al., 
2016). Crucially, this provides the ground-breaking possibility of eliminating 
CSC subpopulations by targeting ROR1, thereby drastically reducing the risk 
of relapse and metastasis.  
In keeping with this, MAbs and antibody-derivatives such as CAR therapy are 
currently under pre-clinical and clinical investigation in a wide range of ROR1+ 
malignancies using a variety of anti-ROR1 clones (Hudecek et al., 2010), 
(Hudecek et al., 2013). See Table 1. 3 for an overview of planned and/or on-
going clinical trials evaluating the therapeutic effect of ROR1-based 
treatments:  
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Table 1. 3. Current and planned clinical trials using ROR1-based immunotherapies as 
per Clinicaltrials.gov (ClinicalTrials.gov, 2017)  
CT No Type of Therapy Location Malignancy Status 
NCT02222688 
Cirmtuzumab  
(UC-961) 
San Diego, 
CA, USA 
Relapsed or 
refractory CLL 
Recruiting 
NCT02706392 ROR1 CAR (R12) 
Seattle, WA, 
USA 
ROR1+ solid and 
haematological 
malignancies 
Recruiting 
NCT02776917 
Cirmtuzumab & 
Paclitaxel 
San Diego, 
CA, USA 
Breast cancer 
Not yet 
recruiting 
NCT02860676 Cirmtuzumab 
San Diego, 
CA, USA 
CLL patients 
previously treated 
with Cirmtuzumab 
Enrolling by 
invitation 
NCT03088878 
Cirmtuzumab & 
Ibrutinib 
San Diego, 
CA, USA 
B-cell lymphomas 
Not yet 
recruiting 
 
Hence, based on the unique expression of ROR1 on malignant cells –
particularly CSCs but not healthy, critical tissue– and due to its safety profile, 
the overriding aim of this project is to generate and test novel anti-ROR1 
antibodies to ultimately produce therapeutic MAbs and/or antibody-derivatives 
against ROR1. A brief literature review on these topics is provided below. 
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1.4 Focus on: MAb-based therapies in cancer   
In the past two decades, significant advancements in our understanding of 
monoclonal antibody biology have allowed the use of a variety of MAb-based 
approaches for cancer treatment (Fig. 1. 8).  
 
One of the first steps in order to attain substantial clinical benefit in cancer 
patients without unwanted immunogenicity was the generation of chimeric 
antibodies in human isotypes derived from engineered murine MAbs (LoBuglio 
Fig. 1. 8. MAb-based therapeutics in oncology. From conventional naked antibodies 
specific for (a) TAA, (b) angiogenesis inhibition or (c) checkpoint blockade, to armed-
antibodies with (d) radioisotopes or (e) drug payloads, to antibody-derivatives such as (f) 
bispecific antibodies and (g) CARs, MAb-based therapeutics represent a pivotal component 
of state-of-the-art cancer care. CD3= T cell surface glycoprotein CD3 ε-chain, CTLA-4= 
cytotoxic T lymphocyte-associated antigen 4, PD-1= programmed cell death protein 1, PD-
L1= PD-1 ligand, TAA= Tumour-associated antigen, VEGF= vascular endothelial growth 
factor, VEGFR= VEGF receptor. Reproduced from Weiner, 2015.  
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et al., 1989, Maloney et al., 1997). Further modifications in order to produce 
humanised antibodies with greater cytotoxic potential have demonstrated 
significant utility in the clinic (Weiner, 2015). As a result, MAbs have become 
one of the largest classes of new agents for cancer therapy (Pillay et al., 2011). 
Thus, in the next few paragraphs, a brief introduction on therapeutic MAbs and 
antibody-derivatives, in terms of their biology, mechanism of action and current 
technology is presented. 
1.4.1 Monoclonal antibody biology 
Immunoglobulin G is one of the most abundant proteins in human serum and 
accounts for approximately 10-20% of plasma protein. It is the major class of 
five classes of immunoglobulins, namely IgM, IgD, IgG, IgA and IgE; and 
although IgG can be further divided in four subclasses: IgG1, IgG2, IgG3 and 
IgG4 (Schur, 1988); IgG1 is primarily employed as a therapeutic agent due to 
both its long half-life and effector functions. 
IgG1 MAbs have a basic structure of approx. 150kDa, consisting of two 
identical 25kDa light chains and two identical 50kDa heavy chains. Each light 
chain consists of an N-terminal variable domain (VL) and a constant domain 
(CL). Similarly, heavy chains consist of an N-terminal variable domain (VH) and 
three constant domains (CH1, CH2 and CH3) (Natsume et al., 2009).  
The association of the whole of the light chain with the VH and CH1 domains 
forms a Fab arm (Fab= Fragment antigen binding), where the V regions 
interact with the antigen. Of note, this antigen binding region is formed by 
differential assembly of Variable, Diversity (VH only) and Joining gene 
segments and inclusion of somatic mutations. The part of the antibody formed 
by the CH2 and CH3 domains is called Fc region (Fc= Fragment crystalline). 
The two Fabs and the Fc region are connected through a flexible linker, called 
hinge region (Vidarsson et al., 2014) (Fig. 1. 9). 
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Notably, the residues most proximal 
to the hinge region in the CH2 
domain are involved in effector 
functions as it contains a binding site 
for C1q (complement activation) and 
for Fc-gamma receptors (FcγR) on 
effector cells of the innate immune 
system. Specifically, the glycoform 
of the oligosaccharide covalently 
attached to the CH2 at asparagine 
297 (N297) is responsible for subtle 
but important changes of quaternary 
structure of the Fc. These glycans 
can also modulate the Fc-FcγR 
binding during specific immune 
responses in humans (Wuhrer et al., 
2009). Not surprisingly, glyco-
engineered afucosylated antibodies 
show enhanced Fc engagement with 
activatory FcγRIIIa and FcγRIIa, 
resulting in more potent ADCC and ADCP, respectively (Herter et al., 2014). 
Interestingly, the V region of 10-15% of all antibodies is also glycosylated and 
it has been suggested that this glycosylation affect antigen-binding 
characteristics whilst allowing binding to regulatory lectins. This in turn can 
modulate the activation-threshold for B-cell stimulation (Vidarsson et al., 
2014). Additionally, the interface between the CH2-CH3 domains contains the 
binding site for the neonatal Fc receptor (FcRn), responsible for the extended 
half-life of IgG, placental passage, and transport of IgG, to and from mucosal 
surfaces. 
Fig. 1. 9. Structure of a human IgG1 MAb. 
MAbs in human IgG1 consist of two light and two 
heavy chains. Heavy chains are paired by 
disulfide bonds in the hinge regions, whilst heavy 
and light chains are connected by a disulfide 
bond between CH1 and CL. Both VH and VL form 
the antigen binding site. The CH2 domain within 
the Fc region contain an oligosaccharide. 
Importantly, the glycoform of the latter 
determines the interactions between the Fc and 
effector mechanisms. Reproduced from 
Natsume et al., 2009.  
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1.4.2 Mechanisms of action 
Upon antibody engagement with its antigen, unconjugated antibodies targeting 
tumour-associated surface antigens exert their cytotoxicity by; i) direct 
transmembrane signalling to induce apoptosis, ii) complement-dependent 
cytotoxicity (CDC), iii) antibody-dependent cellular cytotoxicity (ADCC) and iv) 
antibody-dependent cellular phagocytosis (ADCP); depending on the nature 
of the antibody, target antigen and epitope. More recently, new evidence 
indicates that MAbs can also trigger a vaccinal effect. These mechanisms are 
briefly reviewed below as this thesis will focus on CDC activity only:  
1.4.2.1 Direct cell death 
Direct action of a monoclonal antibody can result in cell death in the absence 
of complement or immune effector cells. This is usually done through: i) 
receptor blockade, impeding an activating ligand to bind; ii) receptor 
dimerization inhibition, thereby blocking an activation signal or iii) by apoptosis 
induction through receptor agonist activity or receptor crosslinking (Scott et al., 
2012, Weiner, 2015).  
1.4.2.2 Complement-dependent cytotoxicity (CDC) 
Complement activation results from the C1q binding to at least two cell-bound 
antibodies in close proximity –although hexameric conformation of antibody 
complexes has been demonstrated to be highly efficient (Diebolder et al., 
2014). This in turn results in inflammation via C3 and activation of the cell-
killing membrane attack complex (MAC) eliciting cell death.  
Importantly, expression of CD46, CD55 molecules on target cells inhibits C3 
convertase, thereby preventing CDC. Similarly, CD59 expression disrupts 
MAC formation. Also, evidence that CD55 can negatively regulate T-cell 
mediated immunity has been reported (Liu et al., 2005, Rogers et al., 2014). 
Expression of these antigens on various solid cancers might explain why CDC 
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evidence in in vivo models of these diseases is less clear compared to 
haematological malignancies.   
While data from experiments carried out both in vitro (Golay et al., 2001, 
Bellosillo et al., 2001) and in some animal models (Golay et al., 2006) 
suggested CDC is a primary mechanism for Rituximab-mediated cytotoxicity, 
it is unclear to what degree CDC contributes to the clinical antitumour response 
and whether it occurs outside of the intravascular compartment.  
A clinical observation suggestive for the role of CDC in patients relates to 
residual chronic lymphocytic leukaemia (CLL) cells present following 
Rituximab therapy, having been shown to express elevated levels of CD59 
when compared against pre-therapy samples (Weiner, 2010). Crucially, the 
role of CDC-mediated deletion in Rituximab efficacy has been considered 
sufficiently substiantial as to merit generation of anti-CD20 antibodies 
engineered to enhance the complement fixation effect. Ofatumumab, a novel 
therapeutic anti-CD20 MAb which binds to the small membrane-proximal 
extracellular loop of CD20 was selected based on its enhanced CDC-mediated 
lysis (Barth et al., 2015). 
Of note, some MAbs can induce complement dependent cytotoxicity 
depending on antigen density, orientation and antigen conformation on the cell 
membrane. The isotype of the antibody and the cell type that is being targeted 
can also affect CDC (Weiner, 2015).  
1.4.2.3 Antibody-dependent cellular cytotoxicity (ADCC) 
Fc gamma receptors expressed in immune effector cells, but particularly 
FcγRIIIa (CD16), expressed on natural killer (NK) cells, mediate this type of 
antibody cytotoxicity. The Fc region of antibodies bound to their target cells 
interact with Fc receptors, which then signal through immunoreceptor tyrosine-
based activation motifs (ITAMs) and induce effector cell activation 
accompanied with the release of cytotoxic granules (perforin and granzymes), 
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which enter the targeted cell and results in cell death (Clynes et al., 1998, 
Bowles and Weiner, 2005).  
The concomitant release of cytokines by activated effectors will in turn 
stimulate the activation of other immune effector cells in the microenvironment. 
In contrast, cells expressing immunoreceptor tyrosine-based inhibitory motifs 
(ITIMs) can inhibit ADCC activity.   
1.4.2.4 Antibody-dependent cellular phagocytosis (ADCP) 
Opsonisation leading to phagocytosis of cancer cells by macrophages 
(antibody-dependent cell-mediated phagocytosis, ADCP) is another form of 
cytotoxicity induced by MAbs in cancer therapy (Weiner, 2015). In ADCP, 
FcγR activation leads to cytoskeletal rearrangements, allowing the formation 
of a phagosome in the effector cell (Freeman et al., 2016). The MAb-coated 
target cell is then endocytosed and degraded by lysosomal enzymes.  
1.4.2.5 Vaccine effect 
A further potential role for Fc-FcγR interactions in anti-cancer MAb therapy is 
a so-called “vaccine effect” (DiLillo and Ravetch, 2015) (Fig. 1. 10). As 
mentioned above, during ADCP, anti-tumour MAbs opsonise tumour cells and 
elicit cell death through Fc-FcγR interactions. This process generates 
antibody-tumour antigen immune complexes which engage activating FcγRIIa 
expressed on CD11c+ APCs. This results in stimulation of DC maturation and 
presentation of tumour antigens to tumour-reactive CD4+ and CD8+ T-cells, 
thereby leading to long-term anti-tumour cellular memory formation (Arce 
Vargas and Quezada, 2015). This recent evidence underlines the crucial role 
that interactions between Fc and specific FcγRs can play in cancer therapy 
(Beers et al., 2016, Yu et al., 2017) 
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As discussed earlier, other types of MAbs can elicit their anticancer activity by: 
i) inhibiting angiogenesis (eg. anti-VEGF MAbs), ii) blocking T-cell inhibitory 
pathways (anti-CTL4, anti-PD-1 MAbs), iii) delivering a radioisotope 
(radioimmunoconjugates) or drug/toxin payloads (antibody-drug conjugates, 
ADC), and by iv) re-directing T-cells towards malignant cells (bispecific T-cell 
engagers, BiTEs and chimeric antigen receptors, CARs). 
Fig. 1. 10. MAb anti-
tumour vaccinal effect. 
Cytotoxic antibodies 
targeting cancer cells form 
tumour-antigen immune 
complexes which engage 
FcγRIIa expressed on DCs. 
In turn, they promote anti-
tumour vaccinal effect 
through T-cell memory 
stimulation. Modified from 
DiLillo and Ravetch, 2015. 
DC= Dendritic cell. 
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1.4.3 Current technology in MAbs  
Depending on the desired mechanism of action to be exploited, MAbs can be 
engineered in various different ways (Fig. 1. 11). Some of the most popular 
approaches currently used in the clinic –except for CAR therapy discussed 
earlier– are presented below. 
 
1.4.3.1 Fc engineering  
Most therapeutic antibodies contain the human constant IgG1 isotype, as it 
has been shown that it can induce potent ADCC and CDC activities when 
compared to other heavy chain isotypes (Natsume et al., 2008). As mentioned 
previously, cytotoxicity is mediated by the interaction of hIgG1 with C1q 
component of the complement system, and with Fc gamma receptors on 
immune effector cells; in particular FcγRIIIa (CD16) on NK cells (Clark, 1997, 
Natsume et al., 2009, Bowles and Weiner, 2005), macrophages, monocytes 
and granulocytes (Weiner, 2015). Moreover, hIgG1 isotype confer stability to 
Fig. 1. 11. MAb modification for cancer therapy. Reproduced from Weiner, 2015. 
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the MAb and a long half-life of approximately 21 days in the bloodstream 
through binding to the neonatal Fc receptor (FcRn) (Jefferis et al., 1998). 
Due to the pivotal role of the Fc region in MAb therapeutics, a number of 
modifications have been attempted in order to enhance cytotoxicity (Yu et al., 
2017). For instance, the amino acid sequence of the Fc region of 
Ocaratuzumab was modified using a directed evolution approach in order to 
produce an antibody with increased affinity for CD16 (Bowles et al., 2006). As 
a result, Ocaratuzumab showed a 3-fold improved ADCC activity on primary 
CLL cells compared to either Rituximab or Ofatumumab (Cheney et al., 2014).   
A more common strategy is the afucosylation of the heavy chain constant 
region as it allows improved binding to Fc gamma receptors (Weiner, 2015). 
Stable production of non-fucosylated therapeutic antibodies is carried out by 
the utilisation of alpha-1,6-fucosyltransferase (FUT8) deficient Chinese 
hamster ovarian (CHO/FUT8-/-) cells. Many MAbs currently in clinical 
development have been afucosylated (Naddafi and Davami, 2015). Such is 
the case for Obinutuzumab, a mAb with enhanced ADCC activity, already in 
use for the treatment of CLL patients.    
As noted by (Weiner, 2015), however, a major ongoing research question in 
the field is whether IgGs with higher affinity for Fc receptors are clinically more 
effective than unaltered IgGs. In fact, when Obinutuzumab was compared with 
its non-glycoengineered version in vivo, similar anti-tumoural effect and 
tumour remission was observed (Herter et al., 2013). The authors of the study 
suggested that, in general, superior activity of GA101 is not related to 
glycoengineering but rather to direct effects. Nevertheless, more recent 
studies indicate that afucosylated antibodies do not only exhibit better ADCC 
through enhanced affinity to FcγRIIIa, but are also able to effectively bind to 
FcγRIIa, which warrants potential induction of a vaccinal effect (Arce Vargas 
and Quezada, 2015). 
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1.4.3.2 Antibody-drug conjugates (ADCs) 
As mentioned above, monoclonal antibodies can also be used as a delivery 
system of a radioisotope (radioimmunoconjugates), or a toxin/drug (ADC) 
payload.  
Antibody-drug conjugates possess a cleavable linker that connects the Fc 
portion of the monoclonal antibody to the drug or toxin it is carrying. The linker 
is usually pH-sensitive or enzymatically cleaved (Weiner, 2015), as it is 
desirable that ADCs are toxic only when they have got internalised by the 
cancer cell upon binding its target. Importantly, an outstanding advantage of 
ADCs is that this type of molecule exerts its cytotoxicity through the toxin it 
carries, unlike unarmed antibodies that rely on the immune system of patients 
(Baskar et al., 2012). 
Of note, up until now, three anti-ROR1 antibody drug conjugates have been 
designed and tested in vitro (BT1, based on clone 2a2 (Baskar et al., 2012)) 
as well as in vivo (OSU-2S, based also on clone 2a2 anti-ROR1 antibody (Mani 
et al., 2015), and Cirmtuzumab Vedotin (Cui B., 2015)). All three molecules 
have shown cytotoxicity on B-cell lymphoma models. Although no follow-up 
studies have been reported. Additionally, there is a commercially available 
ROR1 ADC based on clone R11, reported by Yang et al. (Yang et al., 2011). 
This clone has been conjugated to a selenocysteine (Sec) residue, and is 
called R11-scFv-Fc-Sec (Biolabs, 2017). No cytotoxicity data has been yet 
reported in the literature. 
1.4.3.3 Bispecific antibodies (BsAbs) 
Bispecific antibodies are composed of fragments of two monoclonal antibodies 
binding different antigens or epitopes. These molecules can be classified in 
two main groups, those that possess an Fc region and those that don’t 
(Kontermann and Brinkmann, 2015).  
    Chapter 1 
80 
 
In cancer research, the most common format of BsAb is known as Bispecific 
T-cell engager (BiTE).  These molecules contain the variable regions (scFv) of 
two MAbs, which are connected together via a peptide (linker). One arm of this 
bispecific antibody targets cancer cells whilst the other arm binds to activating 
receptors on immune effector cells (Kontermann and Brinkmann, 2015). This 
strategy allows retargeting immune effectors to cancer cells in the absence of 
an Fc region, an approach that has proved promising as more than 20 out of 
the 30 BsAbs in clinical development use this format (Fan et al., 2015). The 
main advantages of BiTEs are high tissue penetration due to their small size 
(55-60kDa) and potent anti-tumoural cytotoxicity using very low doses (approx. 
10pg/ml in in vitro studies) (Kontermann and Brinkmann, 2015). Certainly, 
Blinatumomab, an anti-CD19/anti-CD3 BiTE, has been recently granted 
accelerated FDA-approval for its use as second-line treatment in acute 
lymphoblastic leukaemia (Przepiorka et al., 2015).  
A different strategy in BsAbs therapeutics is to use the IgG-like format. 
Although large-scale production and purification may be more problematic, Fc-
bispecific antibodies possess many advantages such as increased stability, 
longer half-life and cytotoxicity potential (through CDC, ADCC, ADCP and 
vaccinal effect) (Fan et al., 2015, Arce Vargas and Quezada, 2015). The main 
clinical application of this design is the efficient blocking of signalling pathways. 
Indeed, several BsAbs targeting EGFR pathway are now in clinical trials. More 
recently, this approach has also been tested on B-cell lymphomas in vitro using 
an anti-CD20/anti-HLA-DR bispecific antibody, achieving more specific cell 
death of malignant cells compared to Rituximab or anti-HLA-DR antibodies 
alone (Zeng et al., 2015).  
A similar way to enhance anti-tumour activity, explored over the past decade, 
is targeting two antigens or epitopes at the same time with two monoclonal 
antibodies. Increasing amount of data suggest that co-administration of MAbs 
provides synergistic anti-tumour effects (Tebbutt et al., 2013). Symm004 and 
MM-151 are mixtures of EGFR-targeted antibodies which have been 
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developed to bind non-overlapping epitopes on EGFR and are currently in 
clinical trials for advanced solid malignancies (Machiels et al., 2015, Kearns et 
al., 2015). For haematological malignancies, anti-HLA-DR and anti-CD5 
combined therapy has been successfully tested in vitro an in vivo using B-cell 
lymphoma models (Loisel et al., 2011).  
As a whole, mixtures of monoclonal antibodies and bispecific antibodies 
targeting two antigens or two non-overlapping epitopes containing an IgG 
portion have provided promising results at a preclinical stage and some are 
already in clinical trials. Further research is needed in order to ascertain the 
effectiveness of these strategies in the clinic.  
Intriguingly, no mixture of MAbs or bispecific antibody has been yet proposed 
for ROR1 using previously reported anti-ROR1 antibodies. In this study, I will 
focus on the investigation of monoclonal antibodies against ROR1 as potential 
therapeutic tools. Additionally, the cytotoxic potential of a humanised ROR1 
BiTE on a CSC model in vitro will be explored.  
1.5 Aim and objectives   
The overriding aim of this project is to develop an innovative therapeutic 
approach that uses monoclonal antibodies and/or their derivatives against the 
receptor-tyrosine-kinase-like orphan receptor 1 (ROR1) –a protein present on 
the surface of malignant B-cells and other cancer cells but not on critical post-
partum tissues. These new ROR1 therapy will specifically target and kill 
CD19+CD5+ROR1+ malignant B-cells and other ROR1+ solid malignancies. 
 
The specific goals now are: 
Aim 1: To generate new antibodies against human ROR1. 
Objectives 
    Chapter 1 
82 
 
1. To produce ROR1 hybridomas from rats immunised with the 
extracellular portion of ROR1 through collaboration with the specialised 
antibody company (Aldevron).  
2. To generate single-cell clone hybridomas of ROR1 and extract their 
variable heavy (VH) and variable light (VL) regions, in collaboration with 
Dr Marco Della Peruta and Dr Satyen Gohil. 
3. To produce chimeric rat-human antibodies by cloning the rat VH and VL 
sequences to human IgG1, kappa constant regions. 
4. To assess binding of the new ROR1 chimeric antibodies on ROR1+ and 
ROR1- cell lines. 
 
Aim 2: To characterise the newly generated chimeric antibodies and 
assess their cytotoxicity on primary CLL cells. 
Objectives 
1. To identify the binding domain of our chimeric antibodies on the 
extracellular portion of ROR1 using flow cytometry.  
2. To quantify the affinity of our antibodies to their target by determining 
their binding kinetics using Surface Plasmon Resonance (SPR) 
technology (Biacore).  
3. To screen the cytotolytic activity of our ROR1 antibodies by 
Complement-Dependent Cytotoxicity (CDC) assay.  
4. To assess internalisation of our antibodies into ROR1+ cells by flow 
cytometry and pHAb amine dye labelling.  
 
 Aim 3: To further investigate potential therapeutic antibodies identified 
in previous studies. 
Objectives 
1. To perform a fine epitope mapping to ascertain the specific amino acids 
targeted by relevant clones.  
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2. To assess the complement-dependent cytotoxicity (CDC) in vitro of 
purified antibodies using cell lines and primary cells from CLL patients 
and healthy donors.  
3. To generate humanised antibodies against ROR1 based on relevant 
clones’ protein sequence (in collaboration with GenScript); assess their 
binding to ROR1 and evaluate their cytotoxicity on primary CLL and 
healthy donor cells by direct cell death, CDC, and ADCC assays.  
 
Aim 4: To generate an in vitro model of tumourspheres containing cancer 
stem cell-like cells (CSCs) in order to assess the effects that BiTE 
therapy against ROR1 has on this cell population. 
Objectives 
1. To generate tumourspheres from a PDAC cancer cell line (PANC-1) by 
3D spheroid formation assay, using ultra-low attachment plates.  
2. To perform: i) gene, ii) protein and iii) functional characterisation of 
PANC-1-derived tumourspheres by qPCR, confocal microscopy and 
transwell migration assay, respectively. 
3. To assess the effect of ROR1 BiTE therapy on the cell viability of 
tumourspheres and specific elimination of ROR1+ cell subpopulations. 
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Chapter 2 Materials and Methods 
2.1 Cell culture 
2.1.1 Propagation of cells 
Tissue culture work was performed in Biological Safety Cabinet Class 2 hoods. 
All cell lines were obtained from ATCC or DSMZ; additionally, they were sent 
for cell line profile authentication (ATCC short tandem repeat DNA database). 
Cells were counted using an improved Neubauer haemocytometer (Abcam), 
where 10μl of cells were mixed with 10μl Trypan Blue (Life Technologies). Only 
cells that had not taken up the dye were counted as live cells under a light 
microscope.  
In the next paragraphs, propagation of suspension and adherent cells, 
processing of primary cells and culture of hybridomas and pancreatic cancer 
cell line-derived tumourspheres is described. 
2.1.1.1 Propagation of suspension cell lines  
All suspension cell lines were kept at a density of 0.2-1x106c/ml. In general, a 
1/10 split twice a week was enough to maintain all suspension cell lines used 
throughout this thesis at 0.6x106c/ml. 
Human myeloid leukaemia K562 cells, obtained from ATCC, were cultured in 
Iscove’s Modified Dulbecco’s Media (IMDM, Sigma-Aldrich) supplemented 
with 10% heat-inactivated foetal bovine serum (HI-FBS, Gibco® Life 
Technologies) in a 5% CO2 humidified atmosphere at 37°C.  
MEC-1 cells (B-CLL in prolymphocytoid transformation to B-PLL), SUP-T1 (T-
cell lymphoblastic lymphoma), SKW 6.4 cells (Epstein-Barr virus (EBV) 
transformed B cells), Jeko-1 (Mantle cell lymphoma B cells) and Jurkat (acute 
T-cell leukemia) were cultured in Roswell Park Memorial Institute 1640 (RPMI-
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1640, Sigma-Aldrich) media supplemented with 10% HI-FBS in a 5% CO2 
humidified atmosphere at 37°C.  
2.1.1.2 Propagation of adherent cell lines  
Human Embryonic Kidney (HEK) 293T cells along with solid tumour cell lines 
from different cancer types such as: Pancreatic (PANC-1), breast (MCF-7), 
ovarian (SKOV3), were cultured in complete IMDM (HEK293T) and RPMI 
(solid cancer cell lines), according to ATCC guidelines.  
Cells were passaged at ~80% confluence, typically every 3 days for all 
adherent cell lines mentioned above. Cell passaging was performed by 
washing the cells with 1x PBS, followed by a 5min incubation at 37°C with 5ml 
1x trypsin/EDTA. After this, the reaction was stopped by adding complete 
media. Cells were transferred to a 15ml falcon, and centrifuged at 400g for 
5min. After discarding the supernatant, cells were put in a single-cell 
suspension using fresh complete media and plated in T175cm2 tissue culture-
treated flasks at 37°C with a 5% CO2 atmosphere.  
2.1.1.3 Processing of primary cells from CLL patients and PBMCs from healthy donors 
Whole blood was obtained from CLL patients after written consent or by 
venesection from consenting healthy donors. Blood from the latter was 
collected into 50ml syringes prepared with appropriate 0.5M EDTA solution to 
achieve a final concentration of 5mM EDTA to serve as an anti-coagulant.  
Whole blood was diluted 1:1 with PBS; with each 30ml of blood solution 
layered onto 15ml Ficoll-Paque in 50ml falcon tubes. Tubes were centrifuged 
at 750g for 40 minutes at room temperature applying minimum acceleration 
and without brake. Following centrifugation, the buffy coat layer, localised to 
the Ficoll: plasma interface, was removed by aspiration with a Pasteur pipette. 
PBMCs were washed twice: once with unsupplemented PBS and once with 
complete RPMI prior to final resuspension into a volume of complete RPMI 
matching the volume of the initial blood donation. 
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From these PBMCs, CLL cells were isolated by CD2-negative selection (CD2 
MicroBeads, human - Miltenyi Biotec). Briefly, a pellet of up to 107 primary cells 
resuspended in 80ul of sterile-filtered MACS buffer (PBS, 0.5% BSA, 2mM 
EDTA) was labelled with 20ul of CD2 microbeads, mixed and incubated for 
15min at 4C. Cells were then washed by adding 1ml of MACS buffer and 
centrifuged at 300g for 10min; supernatant was discarded. Pellet was 
resuspended in 500ul of MACS buffer and cells were separated from the CD2 
MicroBeads using, typically, a LS column as per manufacturer’s instruction. 
Unlabelled cells (CD2- cells) were collected. Alternatively, CLL cells were 
obtained by CLL isolation (CLL isolation kit, human - Miltenyi Biotec). The latter 
contained biotin-labelled antibodies against CD2, CD3, CD4, CD14, CD15, 
CD16, CD34, CD56, CD61, CD235a and FceRIa. Separation protocol was 
performed by incubating cells with the biotin-antibody cocktail. 
Immunoconjugated cells were then incubated with anti-biotin MicroBeads, and 
MACS column separation was continued as per manufacturer’s protocol. 
Unlabelled cells were collected. CLL cells were then washed in complete RPMI 
and frozen down in freezing media (90% HI-FBS + 10% DMSO).  
PBMCs obtained from healthy donors (HD) were also washed in complete 
RPMI and frozen down in freezing media. Alternatively, when used as 
effectors, PBMCs were cultured in 24-well, TC-treated plates at a density of 
2x106 cells/well. PBMCs were stimulated with 5ul/ml of PHA on the day of 
isolation. 24 hours later, 100U/ml of IL-2 was added with transductions 
performed 24 hours following IL-2 stimulation.  
2.1.1.4 Propagation of tumourspheres: 3D culture  
PANC-1 cells were diluted to a concentration of 104 cells/ml in either: i) MEBM 
supplemented with MEGM SingleQuots (Lonza) as per Zhang et al., 2014, or 
ii) Cancer Stem Cell (CSC) medium supplemented with CSC SuppMix 
(Promocell) as per Garikapati et al., 2017. A total of 4ml of cells at this 
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concentration were seeded in each well of ultra-low attachment 6-well plates 
(Greiner Bio-One). This methodology is based on 
Tumourspheres were fed every 3-4 days with 1.5ml of complete CSC media 
and passaged every 7-9 days. Briefly, spheroids were transferred to 50ml 
falcon tubes (Corning®). After 20-30min, or once tumourspheres were at the 
bottom of the tube, supernatant was carefully aspirated. Spheroids were 
washed with 5ml of 1X PBS and the previous step was repeated. 
Tumourspheres were segregated into a single-cell suspension by gentle 
resuspension with 1ml of 1x trypsin/EDTA. The reaction was stopped by 
adding 1ml of complete CSC medium. Cells were then counted using trypan-
blue and plated for continuous culture as described above, and/or for in vitro 
experiments. In section 2.1.1.6, a description on the generation of single-cell 
clone tumourspheres: CSC96 is provided. 
Once spheroids were formed in high numbers and showed optimal viability, 
cell lysates were prepared in order to extract both mRNA and protein as 
described in the following sections.  
2.1.1.5 ROR1 Hybridoma Culture (in collaboration with Aldervron, Dr Della Peruta and 
Dr Gohil) 
Through collaboration with Aldevron Freiburg GmbH, a specialised company 
on generation of novel antibodies, a total of 3 Wistar rats were immunised 
using the company’s proprietary DNA-based protocol: Briefly, publicly 
available human ROR1 coding sequence (GenBank) was cloned into 
Aldevron’s immunisation plasmid. The latter was introduced into the rats, the 
target protein was expressed, and an immune response was generated. Four 
applications of DNA using a gene gun were initially performed. Rat serum was 
then analysed by flow cytometry, followed by 4 additional applications. After 
confirming that serum from all three challenged rats showed presence of anti-
human ROR1 antibodies, animals were sacrificed after 102 days of 
immunisation. Lymph nodes were removed and pooled in order to produce 
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oligoclonal hybridoma cell lines according to the company’s protocols. Our 
collaborators identified a total of 38 positive hybridomas by testing their binding 
ability to cells transfected with either pB1-ROR1-hum (Aldevron) or with an 
irrelevant construct. As before, this was assessed by flow cytometry.   
Serum from the three immunised rats as well as all 38 hybridoma supernatants 
were sent to us by Aldevron, which were then tested on ROR1+ and ROR1- 
cells by flow cytometry. In parallel, Dr Marco Della Peruta was in charge of the 
culture of these hybridomas. Along with Dr Satyen Gohil, we passaged the 
polyclonal hybridomas in serum-free DMEM using 6-well plates (Corning®) at 
37°C and 8% of CO2. Enough cells were grown in order to then generate 
monoclonal hybridomas as described below. 
2.1.1.6 Single-cell cloning by limiting dilution 
In order to produce single-cell clones (for either hybridomas, new stable cell 
lines or CSCs), cells were diluted appropriately to ensure that, on average, one 
cell would be isolated into every second well of a 96-well plate (5 cells/ml, 
using 100ul/well). Plates were monitored at least twice a week, and cellular 
isolates were cultured until a clear population had been established. It it worth 
mentioning that, when available, cell sorting was also used for the generation 
of single cell clones from hybridomas and new stable cell lines. Briefly, cells 
were resuspended carefully but thoroughly in order to produce a single cell 
suspension (~1x106c/ml). In parallel, a 15ml falcon containing 1ml of HI-FBS 
was prepared in order to collect the sorted cells. 
When applying this technique for tumoursphere formation assays, U-bottom 
96-well suspension plates (Greiner Bio-One) were used. The resultant single-
cell CSCs were called CSC96. 
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2.1.1.7 Transient transfection of HEK293T cells for protein expression   
According to the number of constructs to be tested or proteins to be produced, 
transient transfection of HEK293T cells was performed in multiwell TC-treated 
plates or dishes as per Table 2. 1. 
Table 2. 1. Transfection mixtures according to multiwell plate/dish size 
Plate Genejuice, µl Media, µl  DNA, µg 
15cm-dish 65 1,235 34 
10cm-dish 30 470 12.5 
6-well 5 95 2 
12-well 2.5 47.5 1 
24-well 1.25 23.75 0.5 
 
For expression testing, a total of ~2.5x106 cells were seeded in a multiwell 
plate irrespective of the size. Therefore, for a 6-well plate, 2ml of cells per well 
were plated at a conc. of 0.20 x106 cells/ml. This was done 24h before 
transfection in order to attain around 60% confluence.  
For protein production, HEK293T cells from T175 flasks were split 1/3 in 15cm-
dishes (Greiner Bio-One), 24h prior transfection. An equivalent volume of 
Polyethylenimine (PEI – Sigma-Aldrich) was used as transfection reagent 
instead of Genejuice (Merck) when large amounts of 15cm-dishes were to be 
transfected (See Table 2. 1). 
In either case, transfection mixtures where prepared by adding the transfection 
reagent to plain media (no FBS). After 5min of incubation at RT, DNA was 
added. Following a 15min incubation, the transfection mix was gently 
resuspended and added to the cells in a dropwise manner all around the well. 
Notably, Genejuice and PEI are lipid-base transfection reagents that complex 
with DNA in order to mediate transport into cells during transfection. The 
incubation times therefore allow the formation of micelles containing the DNA 
to be transfected. 
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Supernatants harvested after 72h were centrifuged at 1000g for 10min in order 
to remove any cell debris. Supernatant were then transferred to fresh tubes 
and immediately tested on relevant cells or stored at 4°C until use. In the 
meantime, transfected HEK293T cells were washed with 1X PBS, trypsinised 
and put in FACS tubes in order to check for transfection. 
2.1.1.8 Cryopreservation and recovery of cells  
Different cell types were harvested whilst in optimal growth conditions and 
viability in order to be cryopreserved. Typically, after centrifugation, 3-5x106 
cells/ml were resuspended in ice-cold freezing media (10% DMSO in HI-FBS) 
and distributed in 1ml aliquots into 2ml cryovials (Corning®). Aliquoted cells 
were immediately placed in a Mr Frosty (Sigma-Aldrich) and kept at -80°C. The 
fresh isopropanol bath (up to 5 uses) in the Mr Frosty allows a controlled 
cooling rate of 1°C/min. Frozen cells were then transferred into liquid nitrogen 
for long-term storage.  
In order to recover cells, frozen cryovials were promptly thawed in a 37°C 
water bath. Immediately after, thawed cells were resuspended in 10ml of 
suitable media. After centrifugation at 400g for 5min, the supernatant was 
discarded in order to rinse off the DMSO contained in the freezing media. Cells 
were then cultured as appropriate. 
Thawed tumourspheres (frozen as single-cell suspensions) were washed with 
8ml of complete CSC media and then plated in ultra-low attachment 6-well 
plates o/n. The next day, CSCs were split as per section 2.1.1.4 and 
expanded in order to be used in subsequent experiments. 
2.1.2 Retroviral work 
2.1.2.1 Retroviral supernatant production 
HEK293T cells (2.5x106) were plated in 10cm-dishes 24h before transfection. 
Cells were then transfected as described above, using a total amount of 
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12.5µg of DNA consisting of: 3.125µg/plate of envelope, 4.69µg/plate of 
gagpol and 4.69µg/plate of retroviral vector plasmid of interest.  
After 48h, supernatants were collected and stored at 4°C, whilst fresh media 
was added to the cells. The 72h post-transfection harvest was then combined 
with the 48h time point supernatant. Supes were centrifuged at 1000g for 
10min to remove cell debris and stored at -80°C in snap-frozen aliquots. 
2.1.2.2 Retronectin coating of non-tissue culture treated 24-well plates 
Non-tissue culture treated 24-well plates were coated with 500µl of PBS 
containing 8µl of retronectin/ml, using Pasteur pipettes. Plates were then 
stored at 4°C wrapped with parafilm until use (at least 24 hours prior to cell 
transduction). It is noteworthy that retronectin-supplemented PBS was re-used 
twice by direct transfer to fresh 24-well plates and kept in the fridge until 
required. 
2.1.2.3 Retroviral transduction of suspension cell lines  
A volume of 1.5ml of thawed retroviral supernatant was added to retronectin-
coated plates. In the meantime, relevant cell lines were washed with 
appropriate complete media and resuspended at a concentration of 5x105 
cells/ml. Immediately after, 0.5ml of cells were added into wells containing the 
retroviral supernatant (2ml final volume). Cells were gently mixed and the plate 
was centrifuged at 1000g for 40min. Plates were then incubated at 37°C and 
5% CO2. Two days later, transduction was assessed by flow cytometry.  
2.1.3 Flow cytometry 
2.1.3.1 General staining protocol 
Unless otherwise stated, 1x105 cells were washed with PBS, stained with 
antibodies +/- viability dye, then washed and resuspended in PBS buffer and 
placed on ice until analysis. 
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Where multiple staining steps were required, samples were washed with PBS 
between individual staining steps. Isotype and/or non-transduced controls 
were included as required. All staining steps were performed at 4°C in the dark 
with 30min incubation per step unless indicated otherwise.    
Flow cytometry was performed using Becton Dickinson (BD) FacsVerse or BD 
LSR Fortessa instruments. 
2.1.3.2 Preparation of counting beads 
To allow cellular enumeration within a sample, or to enable effective 
comparison between samples, the latter were supplemented with a pre-
determined quantity of fluorescent ‘counting beads’ as an internal control. 
Beckman Coulter Flow-CheckTM fluorospheres are supplied at 1x106 beads/ml 
in an aqueous solution containing preservative surfactant. To prevent toxicity 
to cellular samples, beads were washed once with PBS supplemented with 
10%FBS prior to addition to samples. Following centrifugation (400g x 5min), 
beads were resuspended in an equal volume of FACS buffer with 10µl of 
beads added to each sample. 
2.2 Molecular Biology 
2.2.1 Molecular Cloning 
2.2.1.1 Splicing DNA by overlap extension PCR  
Expression plasmid transgene cassettes were generated using splicing by 
overlap extension PCR (SOE-PCR). Transgenes were generated in two or 
more fragments; with the N-terminal fragment containing 5’ restriction site 
(typically NcoI in SFG plasmids) and the C-terminal fragment containing the 3’ 
restriction site (typically MluI in SFG plasmid). Fusion and/or modification of 
fragments was achieved by designing overlapping internal oligonucleotide 
primers complimentary to both the flanking sequences and the desired 
modification.  
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The primary fragments were generated by PCR, using the following conditions: 
Melting temperature was 98°C for 2min, annealing temperature 65°C for 42s 
and extension temperature was 72°C. PCR was carried out for 35 cycles using 
Phusion polymerase (extension duration defined by amplicon length; 
approximately 70 seconds per 1000 base pairs of sequence to be amplified). 
Following PCR amplification, products were separated by gel electrophoresis 
and purified using the Wizard® SV Gel and PCR Clean-Up System (Promega). 
Primary PCR products were combined using a secondary fusion PCR reaction 
using appropriate numbers and the same conditions as above. Following PCR 
clean-up, PCR products were digested using suitable restriction enzymes and 
the insert was subcloned into appropriately digested destination plasmid. 
2.2.1.2 Gene synthesis by overlapping oligo assembly 
Where a novel sequence of DNA required to be generated, this was purchased 
from IDT (G-blocks Gene Fragments, <1000bp).  
Gene fragments were designed with appropriate 5’ and 3’ restriction sites to 
enable subcloning. Commercially-sourced DNA was typically amplified by 
PCR before restriction digest. 
2.2.1.3 Restriction endonuclease digestion 
Restriction digests were performed according to manufacturer’s instructions 
(NEB). Restriction enzymes able to generate “sticky ends” were preferred in 
order to facilitate DNA ligation. For inserts derived by PCR, the entire sample 
was digested.  
To generate vector backbone, or vector-derived insert fragments, 5µg of 
plasmid vector DNA was used. In either case, the reaction volume was 
adjusted with nucleotide-free water such that the final reaction volume was 
50µl. Buffer selection was defined by the manufacturer, with a final enzyme 
concentration of <5% of the final reaction volume. 
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2.2.1.4 DNA ligation 
Following gel extraction of the digested vector and insert fragments, DNA 
ligations were performed using Quick Ligase (NEB) according to the 
manufacturer’s instructions. A vector:insert molar ratio between 1:3 - 1:6 were 
used. Following 5min incubation at room temperature, 5ul of the resulting 
ligation mix was used for bacterial transformation of high efficiency C2987 
(NEB) chemically competent E. coli bacteria (DH5α-derived). 
2.2.1.5 Bacterial culture and heat-shock transformation 
DH5α E. coli bacteria were grown in liquid Luria-Bertani (LB) for mini, midi or 
maxi-preps or terrific broth (TB) media for mega and giga-prep culture. Media 
was supplemented with appropriate antibiotic and cultured at 37°C with 
agitation at 220rpm. For bacterial growth on plates, LB-agar infused with 
appropriate antibiotic was used and bacteria was cultured overnight in a static 
37°C incubator. 
Bacterial transformation was performed by heat-shock. Briefly, 25µl of bacteria 
were thawed on ice, 5µl of ligation mix (from PCR based cloning into C2987 
E. coli), or 1µl of mini-prep DNA (for retransformation) was added to the 
bacteria and incubated on ice for 30min. Bacteria were transiently heat-
shocked by incubation in a 42°C water bath for 30-40s, followed by incubation 
on ice for 5min. Bacteria were transferred to 300µl of SOC media and allowed 
to recover for 30 minutes on a shaking incubator at 37°C, 220rpm (this step 
was omitted only if the primary resistance was ampicillin). Following recovery, 
bacteria were plated onto an LB-agar dishes infused with appropriate antibiotic 
and incubated at 37°C overnight. 
2.2.1.6 DNA preparation: small and large-scale 
Following bacterial transformation and for screening purposes, small-scale 
DNA preparation (miniprep) was performed by picking single colonies from an 
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agar plate. These colonies were then grown overnight in 3ml LB media 
supplemented with 100µg/ml carbenicillin (or other appropriate antibiotics). 
The following morning, plasmid DNA was isolated using the Macherey-Nagel 
miniprep kit according to manufacturer’s instructions. Constructs were verified 
by restriction digest and/or DNA sequencing. 
Once the right constructs were obtained, large-scale generation of DNA 
(midiprep) for in vitro studies was prepared as follows: 200ml of LB were 
inoculated with the appropriate antibiotic and 250-500µl of bacterial culture 
and cultured for 16-18 hours in a bacterial shaking incubator; 220rpm at 37°C. 
Macherey-Nagel midiprep kit was used to isolate plasmid DNA as per 
manufacturer’s instructions. Midiprep DNA was verified by multiple separate 
restriction digests cutting in the vector backbone and transgene insert and by 
DNA sequencing. When even larger amounts of DNA were needed, 
megapreps using the Qiagen kit or gigapreps using the Invitrogen kit were 
performed according to manufacturer’s instructions. 
2.2.1.7 Measurement of DNA concentration 
DNA concentration is based on its property to absorb light at a wavelength of 
260nm, while the ratio of absorbances at 260:280nm and 260:230nm can be 
used to establish purity. If equal or higher than 1.8, these ratios indicate a high 
degree of DNA purity with little protein and solvent contamination, respectively. 
Purity and concentration of plasmid DNA was measure using a Nanodrop ND-
1000 spectrophotometer. 
2.2.1.8 Gel electrophoresis 
Restriction digests and PCR products were assessed by DNA separation using 
agarose gel electrophoresis. Depending on the expected DNA band sizes, 1-
1.7% agarose gels were prepared in 1x TBE buffer. Agarose solubilisation was 
achieved by microwave heating of the solution. Once solubilisation had been 
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achieved, the mix was cooled and infused with SybrSafe (Thermo Fisher 
Scientific) or GelStar (Lonza) –depending on experiment purposes- in order to 
enable UV visualisation of the DNA.  
Samples were mixed with 6x loading buffer prior to loading into the gel in order 
to visualise sample progression within the gel. An appropriate DNA ladder was 
also used as reference for DNA band size, usually Hyperladder I, 1kb (Bioline). 
Typically, agarose gels were run at 130V in 1xTBE buffer for 1h or until 
appropriate separation was achieved. DNA was then visualised using a Dark 
Reader Transilluminator (dark reader blue light box, Clare Chemical 
Research). 
2.2.1.9 Gel extraction and PCR clean-up 
After agarose gel electrophoresis, bands were visualised using a dark reader 
blue light box to prevent UV-mediated mutagenesis. Relevant bands were 
excised from the gel with a clean scalpel, transferred into clean 2ml tubes and 
gel extracted using the ion of DNA was then accomplished using the Wizard® 
SV Gel and PCR Clean-Up System (Promega), according to manufacturer’s 
instructions. 
The latter Promega kit was also used on PCR reactions, in order to remove 
contaminants from the sample prior to downstream processing. 
2.2.2 Preparation of nucleic acids from cells 
2.2.2.1 RNA extraction (RNeasy mini kit) 
Typically, 3-5x106 cells (human cancer cell lines, tumourspheres or rat lymph 
nodes/splenocytes) were resuspended in 350µl of buffer RLT supplemented 
with β-mercaptoethanol (Qiagen). To ensure effective cellular lysis, cells were 
vigorously vortexed before proceeding with the protocol enclosed in the 
RNeasy mini kit (Qiagen). For homogenisation purposes, QIAshredder 
columns were used, as suggested by the manufacturer. RNA was eluted in 
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35µl of nucleotide-free water and RNA concentration was determined by 
spectrophotometric measure using Nanodrop. 
2.2.2.2 cDNA preparation  
cDNA was generated from RNA through a two-step process: effective genomic 
DNA elimination and efficient reverse transcription. In the first step, a 28µl 
reaction mixture composed of 2µg of RNA, 4µl of gDNA wipeout buffer (7x) 
and nucleotide-free water was incubated at 42°C for 2min, followed by a 4°C 
incubation. In parallel, a reverse-transcription master mix for the second step 
was prepared, using 8µl of Quantiscript RT buffer (5x), which already includes 
Mg2+ and dNTPs, 2µl of Quantiscript Reverse Transcriptase and 2µl of RT 
Primer mix. This 12µl RT mix were then added to the first step reaction, 
resulting in a total volume of 40µl. Samples were incubated at 42°C for 30min 
followed by a 95°C incubation for 3min to inactivate the polymerase enzyme. 
To check for gDNA contamination and to confirm successful cDNA generation, 
a PCR reaction was set up using GAPDH as housekeeping gene. Forward and 
reverse primers for the human GAPDH sequence were 5’-
ATTCCATGGCACCGTCAAGGCTG-3’ and 5’-
TTGGCAGCGCCAGTAGAGGCAGGGAT-3’, respectively. 
2.2.3 Evaluation of gene expression by RT-PCR and qPCR  
Reverse transcription PCR (RT-qPCR) was performed with QuantiTect 
reverse transcriptase kit (Qiagen). The reaction was then followed by SYBR 
green PCR master mix (Qiagen) following the manufacturer’s instructions. 
mRNA levels were determined by qPCR and normalized to β-actin 
(housekeeping gene). The list of human primers used in this thesis are 
presented in Table 2. 2. 
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Table 2. 2. List of human primers 
Primers 
Description DNA Sequence 5' - 3' 
OL437.hActin_qPCR_Fw ATTAAGGAGAAGCTGTGCTACGTC 
OL438.hActin_qPCR_Rv ATGATGGAGTTGAAGGTAGTTTCG 
OL439.hROR1_paper-qPCR_Fw GAGGCAACCAAAACACGTCAGAG 
OL440.hROR1_paper-qPCR_Rv GGCACACTCACCCAATTCTTCC 
OL482.CD133_Fw CAGAGTACAACGCCAAACCA 
OL483.CD133_Rv AAATCACGATGAGGGTCAGC 
OL484.Notch-1_Fw GTCAACGCCGTAGATGACC 
OL485.Notch-1_Rv TTGTTAGCCCCGTTCTTCAG 
OL486.ALDH1-A1_Fw TGTTAGCTGATGCCGACTTG 
OL487.ALDH1-A1_Rv TTCTTAGCCCGCTCAACACT 
OL488.ALDH1-A2_Fw TGATCCTGCAAACACTGCTC 
OL489.ALDH1-A2_Rv CTGGAGCTGGGTGGTAAGAG 
OL490.ALDH1-A3_Fw TCTCGACAAAGCCCTGAAGT 
OL491.ALDH1-A3_Rv TATTCGGCCAAAGCGTATTC 
OL492.ALDH1-B1_Fw CTGGAGCTGGGTGGTAAGAG 
OL493.ALDH1-B1_Rv CTTTCTCCACGGTTCTCTCG 
OL494.ALDH1-L1_Fw ATCTTTGCTGACTGTGACCT 
OL495.ALDH1-L1_Rv GCACCTCTTCTACCACTCTC 
OL496.ALDH1-L2_Fw GCCTGGTCTCGTTACCAAAA 
OL497.ALDH1-L2_Rv GCCACTTTCACCTCTTCAGC 
OL498.Bmi-1_Fw AATCCCCACCTGATGTGTGT 
OL499.Bmi-1_Rv GCTGGTCTCCAGGTAACGAA 
OL500. CD24_Fw TGCTCCTACCCACGCAGATT 
OL501. CD24_Rv GGCCAACCCAGAGTTGGAA 
OL502.CXCR4_Fw GATCAGCATCGACTCCTTCA 
OL503.CXCR4_Rv GGCTCCAAGGAAAGCATAGA 
OL526.hSOX2-Saj_Fw GGG AAA TGG GAG GGG TGC AAA AGA GG 
OL527.hSOX2-Saj_Rv TTG CGT GAG TGT GGA TGG GAT TGG TG 
OL555.Vimentin-qPCR_Fw CACCCTGCAGTCATTCAGACA 
OL556.Vimentin-qPCR_Rv GATTCCACTTTCCGTTCAAGGT 
OL562.hROR2_qPCR_Fw GGCAGAACCCATCCTCGTG 
OL563.hROR2_qPCR_Rv CGACTGCGAATCCAGGACC 
OL584.hLgr4_qPCR_Fw CAGTACCCAGTGAAGCCATTC 
OL585.hLgr4_qPCR_Rv TGTTGTCATCCAGCCACAGA 
OL597.hABCA2_qPCR_Fw AGATGGACAAGATGATCGAG 
OL598.hABCA2_qPCR_Rv GCTTGTACTTCAGGATGAGG 
OL599.hABCB1_qPCR_Fw GAGGAAGACATGACCAGGTA 
OL600.hABCB1_qPCR_Rv CTGTCGCATTATAGCATGAA 
OL601.hABCC1_qPCR_Fw ACCCTAATCCCTGCCCAGAG 
OL602.hABCC1_qPCR_Rv CGCATTCCTTCTTCCAGTTC 
OL603.hABCG2_qPCR_Fw GGTGGAGGCAAATCTTCGTTATTAGA 
OL604.hABCG2_qPCR_Rv GAGTGCCCATCACAACATCATCTT 
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2.2.4 Solving hybridomas by 5’ RACE protocol: In collaboration with Dr 
Marco Della Peruta and Dr Satyen Gohil  
The overall protocol for hybridoma solving by 5’RACE is summarised in Fig. 2. 
1. 5’RACE PCR Strategy. 
 
 
 
2.2.4.1 3’-polyC tailing 
Following cDNA preparation, 3’ polyC tailing of cDNA was performed by 
incubation of cDNA with terminal transferase and dCTPs, as follows: 10ul of 
cDNA was incubated at 95°C for 1min then immediately chilled on ice. 6uL of 
nuclease-free water, 2ul terminal transferase buffer, 1ul dCTPs (10mM) and 
1ul terminal transferase were added and the mixture was incubated at 37°C 
Fig. 2. 1. 5’RACE PCR Strategy 
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for 30mins, followed by 75°C for 30mins. Following this the poly-C tailed cDNA 
was concentrated using Microcon columns 100K NMWL (Millipore, Sigma) 
according to kit instructions. 
2.2.4.2 Nested PCR for identification of heavy and light chain sequences 
Outer PCR was performed separately for heavy and light chain using 
appropriate primers. 50ul master mix was made including 47ul Platinum PCR 
SuperMix high fidelity kit (Invitrogen) (which includes Taq polymerase for 
amplification, selected to facilitate subsequent TOPO-TA cloning), 1ul polyC-
cDNA, 1ul forward primer, 1ul reverse primer. This was run on the 
thermocycler under the following conditions: 1) 94°C 2mins; 2)94°C for 30s; 3) 
56°C for 30s; 4) 68°C for 30s; 5) Repeat step from 2, 25 cycles; 6) 68°C for 
10mins. The PCR products were subsequently cleaned up using Qiagen 
QIAquick kit as per manufacturer’s instructions, and used as template for 
subsequent inner PCRs. 
Following outer PCR inner, ’nested’ PCRs were performed separately for 
heavy and light chain. Of note, identical PCR conditions to the outer PCR were 
used for amplification. 
Following amplification, the PCR products were run on 1% TBE gel. The 
resultant smear from 300-800bp for each chain were cut out and extracted 
using Qiagen QIAquick extraction kits, according to manufacturer’s 
instructions. Subsequently these bands were subcloned into TOPO-TA vector. 
2.2.4.3 Analysis of sequence data using the IMGT online database 
To ensure that all sequences were at the correct 5’ to 3’ orientation of DNA 
sequence, the polyG sequence was used as reference. Sequence data was 
inputted into IMGT V-quest server, which is able to identify heavy and light 
chain sequences based on homology with germline sequences, and in addition 
will determine if sequences are in-frame.  
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2.2.5 Generation of chimeric antibodies: rat VH and VL in human IgG1, 
kappa constant regions  
Following identification of productive heavy and light chain sequences these 
were cloned as full length heavy and light chains into SFG vector, by splicing 
by overlap extension PCR (Fig. 2. 2). 
 
 
2.3 Protein work 
2.3.1 Protein purification by FPLC (AKTA system) and dialysis 
All purification runs were performed using an AKTA chromatography system 
(GE Healthcare). Importantly, before running the sample, filtered 20% ethanol 
was run through all lines of the AKTA system (PumpWashExplorer function). 
Then the machine was primed by running Binding buffer, pH 7 (68ml Buffer A 
[200mM NaH2PO4.2H2O] + 32ml Buffer B [200mM Na2HPO4]) through lines A2 
and A11. Elution buffer, pH 2-4 (0.1M Citric acid) was run through line B1. The 
1ml-Protein A column (GE Healthcare) was later placed in the V3 position and 
Fig. 2. 2. Generation of chimeric antibodies. 
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Binding buffer was also run at 1ml/min flowrate for 5-10min. After this set-up, 
line A2 was placed in our sample (concentrated supe+Binding buffer at a 1:1 
ratio) and the appropriate “Protein A” programme run.  
After a few steps of optimisation, the Protein A programme was modified by 
including a further wash right before the elution step, which was also extended, 
resulting in the new and final programme: “Protein A Long”. 
To neutralise the pH of the fractions eluted in 0.1M citric acid, ~300ul of Tris-
HCl buffer (pH 9) were distributed in all fractions tubes prior elution. Tris-HCl 
buffer volume was calculated by prior pH testing using pH paper strips. This 
was done everytime new buffers were prepared. Relevant fractions were then 
collected, pooled together and dialysed in PBS (Sigma-Aldrich®) at 4°C using 
Slide-A-LyzerTM 10k MWCO dialysis cassettes (Thermo ScientificTM, Life 
Technologies). 
For AF488 conjugation, clone SA1 was dialysed in Borate buffer with 
EDTA (25mM Borate, 25mM NaCl, 1mM EDTA) at pH 8.  
2.3.2 Quantification by Bicinchoninic acid (BCA) Assay  
In order to quantify the dialysed protein, the PierceTM BCA Protein Assay kit 
(Thermo ScientificTM, Life Technologies) was used according to the 
manufacturer’s instructions. Briefly, diluted Bovine Serum Albumin (BSA) 
standards were prepared according to the Enhanced Protocol (5-250µg/ml) 
and for the microplate format. A volume of 25µl of either the standard or 
sample was pipetted into a 96-well plate, 200µl of the Working Reagent was 
then added, the plate mixed and incubated at 60°C for approx. 1h. The plate 
was later cooled down to RT and the absorbance was measured at 562nm on 
a plate-reader.  
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For analysis, the four-parameter (quadratic) curve was used for the standard 
curve as suggested on the kit’s protocol. 
2.3.3 Sample preparation for SDS-PAGE 
Samples were prepared as follows: 5ul of sample, 2ul of 10x reducing buffer, 
5ul of 4x loading dye and nuclease-free water made up to 20ul final volume 
with sample. The sample was then taken to 95°C for 5 minutes. Samples that 
were run under non-reducing conditions, were not exposed to reducing buffer 
or high temperatures. 
Prepared sample were then loaded onto a premade 4-12% SDS-PAGE gel 
(LifeTechnologies-NuPage) at 200V, 500mA for 45 minutes on constant 
voltage mode. 10ul of protein ladder (Novex) was run as a size marker. 
Following run, gels were either used for Coomassie staining or Western 
blotting. 
2.3.4 Coomassie staining 
Post-separation, the gel was transferred to a staining tray, covered with 0.25% 
Coomassie R-250 stain solution and stained o/n assisted with gentle agitation 
supplied by a rotating plate shaker. Staining solution was decanted and the 
gel was destained with a Coomassie destaining solution (40% methanol and 
10% glacial acetic acid in distilled water), again with gentle agitation. Further 
destaining solution was added as required until the protein bands became 
clearly visible. Finally, gels were documented using the G:BOX EF Imaging 
System (Syngene). 
2.3.5 Western Blotting  
Post separation, proteins were transferred to a Hybond nitrocellulose 
membrane (Amersham, GE Healthcare) using 200ml of Transfer buffer (10ml 
of 20x Transfer buffer [81.6g of Bicine, 104.6g of BisTris and 6g of EDTA in 1L 
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of distilled water], 40ml of methanol, 150ml of distilled water and 200ul of 
antioxidant). The program used was 25v, 125mA (constant) for 1h30min. 
The membrane was then stained with Red Ponceau (Sigma-Aldrich) for 30s, 
which was then replaced with Wash buffer (1x TBS-Tween) and kept in rotation 
for 30-45min, changing the buffer every 10min. The membrane was then 
blocked with 10ml Veto solution (5% polyvinyl pyrolidine [PVP] in 1x TBS-
Tween) + 0.5ml of HI-FBS in rotation. After 1h, the primary antibody incubation 
was performed by transferring the membrane to a 50ml falcon tube containing: 
10ml Veto, 0.5ml HI-FBS, 100ul 10% azide and 5ul goat anti-human ROR1 
antibody (R&D SystemsTM). The incubation was done overnight at RT in 
rotation. Of note, when Veto was not used, 5% milk in PBS-T was used as 
blocking buffer and for antibody staining. 
On day 2, the membrane was washed for 30-45min, changing the buffer every 
10min. After this, the membrane was transferred to a 50ml falcon tube 
containing 10ml veto, 0.5ml HI-FBS and 1ul of rabbit anti-goat IgG-HRP 
conjugated antibody (BioRad). For those membranes where the mIgG2a tag 
of our protein was assessed, 1ul of goat anti-mouse IgG-HRP conjugated 
antibody (Dako) was used directly. After 3h incubation in rotation, membranes 
were washed and treated with PierceTM ECL Western Blotting Substrate kit 
(Thermo Scientific, Life Technologies) following manufacturer’s guidelines. 
Films were developed using the SRX 101A Film Processor (Konica Minolta).   
2.3.6 Evaluation of binding kinetics by surface plasmon resonance: 
Biacore system 
Surface plasmon resonance evaluation was undertaken using a Biacore X100 
instrument at the UCL Institute of Structural & Molecular Biology. ROR1 
chimeric antibodies were immobilised using an anti-human IgG1 antibody 
capture kit and a CM5 sensor chip (GE Healthcare). All binding assays used 
1x HBS-EP+ running buffer (GE Healthcare) and seven different 
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concentrations (100, 50, 25, 12.5, 6.25, 3.13 and 1.56nM) of the extracellular 
portion of ROR1 bearing a Histidine tag (and dialysed using the same buffer) 
were then injected. These concentrations were run at a random order, 
including the negative control (0nM). Data analysis was performed using 
Biacore X100 Evaluation Software, version 2.0 (GE Healthcare). The sensor 
chips were regenerated with glycine-HCl (pH 2.0) without any loss of binding 
capacity. Calculation of association (kon) and dissociation (koff) rate constants 
was based on a 1:1 Langmuir binding model. The equilibrium dissociation 
constant (KD) was calculated from koff/kon. 
2.4 In vitro work 
2.4.1 Peptide-library ELISA 
Mimotope’s ROR1 peptide library contained more than ninety overlapping 
peptides.  Each peptide was composed of biotin (at the N-terminal), followed 
by a linker that connected it to a sequence of 11 amino acids of eROR1, 
followed by an amide group (NH2) at the C-terminal. Of note, each 11-amino 
acid peptide had 8 amino acids that overlapped the previous peptide whilst 
introducing 3 new amino acid to its sequence. 
Lyophilised eROR1 peptides were solubilised in 50% Acetonitrile using a water 
bath sonicator. Peptides were then diluted in 0.1% Azide in PBS-Tween 20 
(PBS-T). Control peptides (Mimotopes) were treated and processed in the 
same way. Control antibodies, also provided by Mimotopes were dissolved in 
purified water as per manufacturer’s instructions. Briefly, 96-well plates were 
coated with NeutrAvidin, blocked with 1% sodium caseinate and washed 
thoroughly before incubation with the solubilised peptides. After 1h incubation, 
plates were washed again and incubated o/n with clones SA1 and F. On the 
next day, plates were washed and incubated for 1h with an anti-human IgG 
antibody conjugated to horseradish peroxidase (HRP). Plates were washed, 
and antibody signal detected with Tetramethylbenzidine (TMB); the reaction 
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was later stopped with H2SO4. Samples were then analysed at 450nm 
wavelength using a plate-reader.  
2.4.2 Internalisation assays 
ROR1+ cell lines and/or primary cells from CLL patients were stained with 
relevant ROR1 MAbs on ice for 1h. After washing three times with ice-cold 
PBS to remove unbound antibody, the total number of cells was subdivided in 
different tubes, one per time point and two tubes for the 2h time point in order 
to include the endocytosis inhibitor control (phenylarsine oxide). Samples were 
either left on ice or incubated at 37°C for 15min, 30min, 1h, or 2h to facilitate 
internalization. 
For the 2h time point, duplicate samples were incubated in the absence or 
presence of 10mM phenylarsine oxide (Sigma-Aldrich). Subsequently, the 
cells were washed once with ice-cold PBS buffer and incubated with an anti-
human Fc secondary antibody on ice for 30 min. After three final washes with 
ice-cold PBS, the MFI of the cells was measured using a BD LSR Fortessa (5 
laser) instrument and FlowJo analytical software. The percentage of MFI 
reduction was calculated for each mAb relative to the secondary antibody 
control (MFI background) and MAb maintained on ice (MFI max) by using the 
following formula, as per Yang et al., 2011: 
[(MFI max-MFI background)-(MFI experimental-MFI background)] /  
(MFI max-MFI background)x100. 
Samples used in internalisation assays with trypan blue were prepared as 
mentioned above, except that no double staining was performed since 
antibodies were conjugated to AlexaFluor488. Binding MFI was measured 
before and after addition of 500ul/sample of 0.4% Trypan blue (Gibco, Life 
Technologies). 
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Internalisation assays using pH-Amine reactive dye (Promega) were 
performed as per manufacturer’s instructions and Nath et al., 2017. Briefly, 
purified antibodies at >2mg/ml were buffer exchanged from PBS to amine 
conjugation buffer (10mM sodium bicarbonate buffer, pH 8.5) using ZebaTM 
desalting columns (Pierce). In parallel, the pHAb amine reactive dye was 
dissolved at 10mg/ml in 25ul of 1:1 DMSO-water mix and vortexed for ~3min. 
A volume of 1.2ul of the freshly dissolved dye was added for 100ug of antibody, 
and incubated for 60min using an end-over-end mixer. Unreacted dye was 
removed by using desalting columns. Antibody concentration and fold increase 
in fluorescence response was calculated using the following equations: 
 
 
Sample preparation was performed as mentioned above. In short, cells were 
incubated with pH-Amine labelled antibodies for 30min at 4°C. After this, cells 
were washed with ice-cold PBS and immediately after, fluorescence was read 
at Ex/Em: 532nm/562nm (“0h” time point) using a plate-reader. Cells were then 
incubated at 37°C and 5%CO2 for 15min, 2, 5, 21 and 24h. After each time 
point, fluorescence was evaluated. Citrate buffer, pH 4 was used as positive 
control for fluorescence signal. 
2.4.3 Complement-dependent cytotoxicity (CDC) assay 
This assay was based on Yang et al., 2011 and the kind guidance provided by 
Dr Jenny Yeung (Prof Kerry Chester’s research group, UCL Cancer Institute); 
and was carried out as follows: SKW 6.4 GFP, Jeko-1 cells, and primary cells 
from both CLL patients and healthy donors (target cells) were harvested, 
washed, counted and resuspended in R10 media. Cells were plated in 96-well 
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V-bottom plates (Corning) at a density of 4x104 cells/well (100ul/well). Target 
cells were incubated for 10min at RT with 100ul of ROR1 MAbs, negative 
control (hIgG1, k isotype) and anti-CD20 antibodies: Rituximab (chimeric 
antibody) and GA-101 (Obinutuzumab – humanised antibody). Importantly, 
ROR1 MAbs contained in culture supernatants or FPLC-purified antibodies at 
a final concentration of 10ug/ml were used, depending on the nature of the 
experiment. In parallel, GA-101 was used at 0.5ug/ml whilst Rituximab was 
used at both 0.5 and 10ug/ml.  
Immediately after, 20ul of ice-cold baby rabbit complement (BioRad) was 
added (10% complement, final concentration). Samples were incubated for 2h 
at 37°C in 5% CO2. After this, cells were centrifuged at 500g for 5min and 
supernatant discarded. Samples were then washed using AnnexinV buffer 
(150ul/well) and centrifuged again. Cells were then co-stained with 1ul of 
AnnexinV-APC, 0.5ul of aCD5-APC Cy7 and 0.5ul of aCD19-FITC in 75ul of 
AnnexinV buffer. After 15min incubation in the dark, 2ul of PI in 75ul of 
AnnexinV buffer was added and incubated for approximately 10min.  
Samples were then transferred to 2ml 96-well plates containing 150ul of 
washed counting beads in PBS (as per section 2.1.3.2). Live cells were 
detected by AnnexinV/PI exclusion using a BD LSR Fortessa instrument 
(Becton Dickinson) and FlowJo analytical software. Briefly, the Y586/15 and 
R670/30 filters were used in order to detect PI and AnnexinV-APC staining, 
respectively; and dot plots showing both channels were set up (Fig. 2. 3). Also, 
two gates were drawn. One corresponding to the counting beads (P1); which 
was used in order to acquire the same number of events/sample. The other 
gate included all events (P2), except for the beads. It was on P2 that the PI 
and APC fluorescence signals were applied. 
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Cells that showed APC staining in the plasma membrane were positive for 
Annexin V-APC and were considered as apoptotic cells. Target cells that lost 
membrane integrity showed PI positivity as the dye got inside the cells; 
therefore, cells that were double positive for PI and AnnexinV were considered 
necrotic cells. In contrast, double-negative cells were considered as live, 
healthy cells. Live cell counts were normalised to the number of beads per 
sample. These values were then normalised to the isotype control and 
expressed as % of live cells. Bar graphs and statistics were calculated in 
GraphPad Prism 7 as per section 2.5.  
 
2.4.4 Evaluation of cytokine release by ELISA 
This was performed using a Biolegend IFNγ or IL-2 kits according to the 
manufacturer’s instructions. Briefly, a 96-well strip plate was incubated with 
protein capture antibody overnight at 4°C. The plate was washed thoroughly 
3x, blocked for 1h at room temperature with shaking and washed again 3x.  
Samples for assay were added (at appropriate dilutions) and incubated for 2 
hours at room temperature with shaking. The plate was washed 3x and IFNγ- 
or IL-2-detection antibodies (biotinylated) were added for a further 1 hour. The 
plate was washed 3x and avidin-horseradish peroxidase (HRP) was added. 
Fig. 2. 3. Representative AnnexinV/PI staining analyses by flow cytometry, following CDC 
assays on CLL cells. 
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After 30mins and following a further wash, detection substrate was added and 
after a further 15 minutes hydrogen peroxide stop solution was added.  
Colorimetric changes corresponding to IFNγ or IL-2 were detected using a 
plate-reader measuring absorption at 450nm. Concentration of cytokines was 
determined according to a standard curve produced by simultaneously 
assaying serial dilutions of an IFNγ or IL-2 solution of known concentration. 
2.4.5 WST1 Cell viability assay using tumourspheres 
PANC-1 parental cells or CSCs (5x103 cells/well) were plated in 96‑well TC-
treated or suspension plates, respectively (100ul/well). The day after, cells 
were incubated with purified ROR1 BiTE (1ug/ml) or relevant controls for 
10min at RT (50ul/well). Cells were then co-cultured with PBMCs from healthy 
donors (effectors) using a 1:1 E:T ratio (50ul/well) and incubated at 37˚C with 
5% CO2, as per in vitro studies reported by Gohil et al., 2017.  
After 72h, cell viability was measured by Cell Proliferation Reagent WST‑1 
(Roche Diagnostics) as per manufacturer’s instructions. In short, 20ul/well of 
WST-1 reagent was added to all samples (1/10 final dilution), plates were 
incubated at 37˚C with 5% CO2 and were read after 1, 2 and 4h using a plate-
reader at 440nm. Culture media was used as blank. 
2.4.6 Migration assay using tumourspheres 
Migration assays using a transwell system kit (96-well, 8um - PromoKine) were 
performed as manufacturer’s instructions. Briefly, 150ul of either serum-free 
RPMI, serum-supplemented RPMI or conditional media (culture media of 
adherent PANC-1 cells taken at 48h post splitting) were added to the bottom 
chamber. Single-cell suspensions (104cells/well) resuspended in 50ul of non-
supplemented CSC-media (tumourspheres) or serum-free RPMI (adherent 
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PANC-1) were added to the top chamber of the transwell system. Plates were 
incubated at 37°C and 5% CO2 for 72h.  
After incubation, the top chamber was removed, and the plate was taken to 
the microscope. Cells present in the bottom chamber only were photographed 
and documented using a microscope 4x objective.   
2.4.7 Immunocytochemistry and confocal microscopy   
The immunostaining protocol carried out in this study was based on (Goh et 
al., 2013) and on the kind guidance provided by Dr Sajjida Jaffer (ACN group 
– UCL Cancer Institute). Round coverslips (13mm) were ethanol-sterilised and 
dried under the hood overnight. The next day, they were placed in 24-well 
plates and coated with Matrigel resuspended in ice-cold DMEM (0.5ml/well). 
Plates were sealed with parafilm and left at 4°C overnight. 
The following morning, untreated PANC-1 adherent cells and PANC-1 derived 
tumourspheres at a concentration of 3x104c/well were seeded on Matrigel-
coated coverslips and incubated at 37°C, 5% CO2 for no less than 24h to 
ensure adherence.  
The next day, media was removed, and cells were washed with PBS 
(0.5ml/well). Samples were then stained with a commercial ROR1 Ab (clone 
2H6 - 1mg/ml) at a 1/200 dilution in Blocking solution (PBS + 0.1% BSA + 5% 
goat serum) for 1h. Cells were washed 3x with PBS and fixed with PFA 4% for 
20min (0.5ml/well). Cells were washed again 3x with PBS (0.5ml) and 
permeabilised with ice-cold 100% methanol for 5 minutes prior to blocking 
(0.5ml/well). 
Samples were blocked with Blocking solution for 30min at RT (0.5ml/well). 
Primary antibody 1/100 in blocking solution was added and cells were 
incubated o/n at 4˚C. For this study, Vimentin and ALDH1-A1 antibodies were 
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used as per Zhang et al., 2014. The following day, antibody staining solution 
was removed, and cells were washed 3x with PBS (0.5/well). Samples were 
then stained with appropriate secondary antibodies (Life Technologies) at a 
1/400 dilution in Blocking solution for 1h at RT. This was followed by 3 washes 
with PBS (0.5ml/well) and DAPI staining (50ul/sample) for 5 min for nuclear 
stain. Cells were washed 3 times with PBS prior to slide mounting.  
One drop of ProLong(R) Diamond (Thermo Fisher) was added onto the slide 
before putting the coverslip on top of the drop very carefully. Slides were then 
taken to 4°C for 1h, after which they were sealed using clear nail polish. 
Confocal images were obtained using a laser-scanning Zeiss LSM880 
confocal microscope. 
With regards to treated PANC-1 parental cells and CSCs, cells were co-
cultured with ROR1 BiTE (1ug/ml) or relevant controls as per WST-1 cell 
viability assays described above (section 2.4.5), except that instead of 
5x103c/well, a concentration of 104c/well were seeded in appropriate 96-well 
plates. After 72h of incubation, cells were harvested and cells from replicate 
wells were pulled together in order to seed them in 13mm coverslips 
(previously coated with matrigel and placed in 24-well plates). Immunostaining 
was then carried out as described above. For quantification purposes, more 
than 500 cells per treatment and biomarker staining were counted. Cells were 
classified according to their single or double biomarker expression and 
conveyed as % of the total cell count. 
2.5 Statistical analyses 
Statistical analyses including t-tests and two-way ANOVA calculations were 
performed using GraphPad Prism 7 for Windows (Graph-Pad Software, USA). 
Differences were considered statistically significant when p values were <0.05. 
Significance was represented by p<0.05 (*), p<0.01 (**), p<0.001 (***), 
p<0.0001 (****).
   
Chapter 3 Generation of ROR1 antibodies 
3.1 Introduction 
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) along with ROR2 
represent one of 20 families of receptor tyrosine kinases (RTKs) 
(Daneshmanesh et al., 2012, Green et al., 2008). In the past few decades, a 
growing amount of data has shown that RTKs are typically involved in cell-cell 
interactions, differentiation, survival, proliferation, cell metabolism, migration 
and signalling (Zhang and Zhang, 2016). Hence, mutations or overexpression 
of RTKs have been described in many cancer types and are already being 
explored as potential targets for cancer therapy. Remarkably, ROR1 is 
selectively overexpressed in various haematological and solid malignancies 
but not in most normal adult tissue (Shabani et al., 2015). 
Similar to other oncogenic RTKs, ROR1 overexpression may be targeted in 
cancer. According to (Zhang, 2012), there are two main strategies to do this: 
i) targeting the intracellular domain by tyrosine kinase inhibitors or ii) targeting 
the extracellular portion of the receptor by monoclonal antibodies (MAbs) 
and/or their derivatives. In this study, the latter approach will be explored; thus, 
a brief introduction on antibody generation is provided below.  
3.1.1 Monoclonal antibody generation 
As discussed in the Introduction section (Chapter 1), monoclonal antibodies 
are molecules of a single antigen specificity (i.e. bind to the same epitope) and 
are produced from a single B-lymphocyte clone (Liu, 2014). In general, there 
are two methods for generating monoclonal antibodies: i) phage display library 
and ii) hybridoma technology. The latter will be discussed in the next 
paragraphs. 
3.1.1.1 Hybridoma technology  
Hybridomas are generated by the fusion of B lymphocytes –derived from an 
immunised animal– with immortal myeloma cells that do not secrete any sort 
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of antibody themselves and that lack the hypoxanthine-guanine-
phosphoribosyltransferase (HGPRT) gene. The latter will make the hybridoma 
sensitive to (hypoxanthine-aminopterin-thymidine) HAT medium, which will be 
used for positive selection of successful hybridomas (Zhang, 2012). As 
explained by (Little et al., 2000), cell fusions are grown in HAT medium in order 
to discriminate successful fusions from unfused cells: i) HPGRT-negative 
myeloma cells that have not acquired the natural resistance from the primary 
B-cells and ii) B-cells alone that would eventually die off as they would not 
have inherited immortality from myeloma cells. 
Early cultures of fused cells contain a mixture of antibodies produced by a very 
diverse population of B-cells; these cultures are hence still polyclonal. At this 
stage, hybridomas can be screened against the target of interest by flow 
cytometry or ELISA. Once positive cultures are identified, single-cell cloning 
can be performed, and screening is again carried out. Positive hybridomas are 
then recloned and retested for activity (Liu, 2014, Li et al., 2010). See Fig. 3. 
1.  
Fig. 3. 1. Hybridoma technology approach for the generation of monoclonal 
antibodies. Reproduced from Zhang, 2012 
    Chapter 3 
115 
 
It is noteworthy that an advantage of hybridoma technology over phage display 
libraries is that the produced antibodies retain their native structure, including 
the Fab and Fc portions. It has been previously shown that the latter is pivotal 
in terms of cytotoxic function, as it mediates complement-dependent (CDC) 
and antibody-dependent cellular cytotoxicity (ADCC) (Kubota et al., 2009, 
Natsume et al., 2009). Alternatively, to increase cytotoxic potency, it has 
become common practice to isolate the variable regions from monoclonal 
antibodies (commonly as scFv) and link these molecules to a variety of toxic 
partners. Some of the most common derivatives are: radioconjugates, 
antibody-drug conjugates, immunotoxins, chimeric antigen receptors (CARs), 
and bispecific antibodies in various formats (Mackall, 2014).  
The use of monoclonal antibodies and their derivatives was explored as 
possible routes for ROR1 therapy. In the first instance, and to reduce 
unwanted immunogenicity, rat-derived monoclonal antibodies in human 
constant regions will be generated and investigated; antibody molecules in this 
format are also known as chimeric antibodies.  
3.1.2 Chimeric antibodies  
Since the first monoclonal antibodies used in the clinic were mouse-derived, it 
was the first time that side effects caused by their murine origin were observed; 
these adverse effects are known as “human anti-murine antibody” (HAMA) 
response (Schroff et al., 1985). Repetitive dosing with murine monoclonal 
antibodies were therefore not advisable. 
To overcome this issue, recombinant DNA approaches have been developed 
so that the binding portion of a monoclonal antibody could be merged with 
human constant regions. Constructs encoding for this chimeric DNA resulted 
in the expression of monoclonal antibodies that were partially murine and 
partially human. 
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In the context of therapeutic antibodies, the ability to elicit a cytotoxic immune 
response that does not stem from their organism of origin is desirable. MAbs 
efficacy relies on: i) their specificity, ii) bivalent binding to their target (for 
blockade/neutralisation of target and apoptosis induction) and iii) effector 
functions prompted by their Fc regions (CDC and ADCC). Therefore, the right 
Fc region (isotype) needs to be carefully chosen according to the therapeutic 
purpose of the antibody (Natsume et al., 2009). 
3.1.2.1 Human IgG and therapeutic antibodies 
Despite the fact that all four IgGs share more than 90% amino acid identity, 
each subclass possess a distinct profile in terms of antigen binding, immune 
complex formation, complement activation, triggering of effector cells, half-life 
and placental transport (Vidarsson et al., 2014). Consistent with this, it has 
been reported that human IgG1 and IgG3 are potent triggers of effector 
mechanisms, whilst IgG2 and IgG4 prompt more subtle responses (Bindon et 
al., 1988, Tao et al., 1993). Moreover, IgG1 has been the main isotype of 
choice in the clinic due to its half-life (approximately 21 days) and superior 
effector functions (Clark, 1997, Natsume et al., 2009). 
To conclude, one of the best examples of a chimeric antibody used in clinic is 
Rituximab (Rtx), the anti-CD20 antibody that revolutionised the treatment of B-
cell malignancies (Keating et al., 2005, Rai and Jain, 2015). As commented in 
previous sections, Rtx is a murine antibody in human IgG1, kappa constant 
regions. Below in Table 3. 1, selected next generation anti-CD20 antibodies 
that have IgG1 (engineered or not) as their isotype are presented. 
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Table 3. 1. Effector functions of selected anti-CD20 MAbs. Based on (Natsume A. et al., 
2009) 
MAb Developer Isotype 
Effector functions 
compared to 
Rituximab (Rtx) 
Ofatumumab GSK/Genmab IgG1 Potent CDC 
Ocrelizumab Genentech IgG1 
Potent ADCC and 
decreased CDC 
Veltuzumab Immunomedics IgG1 Comparable to Rtx 
AME-133 AME Mutated IgG1 Potent ADCC 
Obinutuzumab 
(GA101) 
Roche/GlycArt 
Glycoengineered 
IgG1 
Potent ADCC/direct 
apoptosis, no CDC 
 
 
In this chapter, data showing the generation of anti-ROR1 rat chimeric 
antibodies in human IgG1, kappa constants will be presented and discussed. 
3.2 Aims 
1. To produce ROR1 hybridomas, in collaboration with Aldevron, and 
evaluate their specificity by flow cytometry.  
2. To generate single-cell clone hybridomas of ROR1 and extract their 
variable heavy (VH) and variable light (VL) regions, in collaboration with 
Dr Marco Della Peruta and Dr Satyen Gohil. 
3. To produce chimeric rat-human antibodies by cloning the rat VH and VL 
sequences to human IgG1, kappa constant regions. 
4. To assess binding of the new ROR1 chimeric antibodies on ROR1+ and 
ROR1- cell lines. 
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3.3 Results 
3.3.1 Aim 1: Production and evaluation of ROR1 hybridomas 
3.3.1.1 Rat immunisation against the extracellular portion of ROR1: In collaboration 
with Aldevron  
To successfully produce ROR1 hybridomas, our group set up a collaboration 
with Aldevron, a specialised company on generation of novel antibodies. 
Aldevron used a DNA-based protocol in order to immunise three Wistar rats 
with the extracellular portion of ROR1, as described in the Materials & Methods 
section (See Chapter 2).  
After eight rounds of immunisation, our collaborators detected ROR1 
antibodies in the rats’ sera by flow cytometry analysis. These samples were 
then delivered to us for further confirmation. We first wanted to identify what 
dilution worked better for flow cytometry detection. As a result, rats’ sera was 
tested by flow cytometry using different dilutions: neat, 1/10, 1/100, 1/1 000 
and 1/10 000 on ROR1+ cells (data not shown). It was identified that a 1/1 000 
dilution of rat serum in PBS was the most informative in order to test for ROR1 
binding.  
Rat serum at the appropriate dilution was next incubated with MEC-1 GFP 
(ROR1-), MEC-1 ROR1 (ROR1high) and SKW GFP (ROR1low) cell lines. 
Primary cells from Chronic Lymphocytic Leukaemia (CLL) patients, expressing 
different levels of ROR1, were also tested. An anti-rat IgG antibody conjugated 
to DyLight647 fluorophore was used as negative control (Fig. 3. 2). 
In Fig. 3. 2, specific binding of “Rat 1” serum on ROR1+ and ROR1- cells are 
shown. Presence of ROR1 antibodies was evidenced by positive binding to all 
ROR1+ cells but not MEC-1 GFP cells (ROR1-). Of note, the intensity of binding 
signal was proportional to level of ROR1 expression on the surface. 
Confirmation of ROR1 specific binding prompted the continuation of the 
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hybridoma protocol, whereby lymph nodes of all three immunised rats were 
removed and pooled together in order to fuse them with rat myeloma cells and 
generate rat hybridoma cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.1.2 Evaluation of ROR1 polyclonal hybridomas by flow cytometry  
Aldevron reported successful generation of 38 hybridomas positive for ROR1 
binding. In the first instance, supernatants from these cells were sent to us for 
further evaluation. 
Hybridoma supernatant from all 38 samples were tested by flow cytometry on 
ROR1- (MEC-1 GFP) and ROR1+ cell lines (MEC-1 GFP ROR1 and SKW 
GFP). In Table 3. 2, binding levels expressed as % of frequency and Median 
Fluorescence Intensity (MFI) of all 38 oligoclonal hybridomas on MEC-1 GFP 
and ROR1 are shown. With regards to primary cells from CLL patients, CLL 
Fig. 3. 2. Flow cytometry evaluation of rat immunisation against ROR1. A 
1/1000 dilution of rat serum (Rat 1) in PBS was tested on ROR1- and ROR1+ cell 
lines as well as CLL primary cells. An anti-rat IgG-DyLight647 secondary 
antibody was used as negative control on each cell type. Percentage of frequency 
is shown in the top right corner of histograms. CLL=Chronic Lymphocytic 
Leukaemia.  
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cells expressing different levels of ROR1 (CLL14, CLL9A and CLL44) were 
also included in these analyses.  
Table 3. 2. ROR1 Binding of polyclonal hybridomas on MEC-1 GFP (ROR1-) and MEC-1 
ROR1 (ROR1+) cell lines. Summary table showing the % of frequency and median 
fluorescence intensity (MFI). Overlay column represents the % of frequency when MEC-1 GFP 
and MEC-1 ROR1 are overlaid. Colours designate binding strength: >85% (bright green), 80-
84.9% (light green), 50-79.9% (yellow), 10-49.9% (pink), <9.9% (red). 
  
% MFI % MFI
19 5D7 1.6 61,273.61 90.6 72,069.55 89.0
14 8C1 2.2 38,027.23 90.5 70,359.24 88.3
1 8C3 1.1 44,784.75 89.2 70,287.21 88.1
7 3A8 1.5 62,007.26 89.6 70,705.81 88.1
5 10C4 0.8 40,340.41 88.8 67,938.10 88.0
20 6H4 2.1 70,080.39 90.1 72,341.44 88.0
22 9H11 1.9 41,694.26 89.1 68,376.60 87.2
31 7E9 2.2 55,798.64 89.3 70,055.74 87.1
10 7A7 2.1 56,637.60 88.9 69,210.26 86.8
12 1C3 1.5 61,097.83 88.2 68,257.54 86.7
38 5B2 1.5 101,735.52 87.3 69,060.04 85.8
8 8E6 1 46,668.86 86.7 64,454.33 85.7
4 8H3 1.3 62,990.46 86.8 64,431.04 85.5
26 3E2 2.1 78,780.02 87.1 66,515.54 85.0
37 5F4 2.2 47,417.44 87 68,029.30 84.8
3 8E2 0.7 75,997.27 85.3 56,603.20 84.6
34 4B10 3.4 51,606.93 87.9 69,907.79 84.5
2 9F3 0.9 42,978.79 85.3 61,784.14 84.4
16 1A4 3.4 28,657.66 87.4 67,447.81 84.0
23 9B10 2.3 44,533.09 86.1 64,289.96 83.8
32 2H6 4.6 44,151.68 85.5 64,368.22 80.9
21 7G10 2.4 42,935.96 72.7 50,513.58 70.3
24 9A6 1.7 107,224.78 69.8 45,481.58 68.1
18 4E7 1.8 60,146.05 66.9 46,576.86 65.1
13 1F4 1.3 40,476.32 63.5 35,745.56 62.2
29 10H3 1.3 60,210.35 62.5 33,269.10 61.2
30 5C8 1.7 49,382.46 62.4 33,259.51 60.7
36 9E4 1.9 58,055.64 58.3 33,418.63 56.4
11 10F6 2 77,666.22 35.3 27,581.53 33.3
17 5H9 2.1 84,958.41 13.6 30,323.60 11.5
15 4F4 1.8 77,181.62 5.7 41,269.05 3.9
27 10D2 1.5 46,042.65 4.4 49,702.23 2.9
25 5H5 1.6 55,046.38 3.2 44,205.06 1.6
35 1E8 1.6 60,535.81 3.2 27,483.88 1.6
33 4F9 1.3 60,403.03 2 67,109.79 0.7
9 6A2 1.5 37,682.61 2.1 63,234.04 0.6
6 9B4 1.5 35,846.83 1.8 64,576.07 0.3
28 7B11 2.8 46,798.21 1.8 45,046.18 -1.0
MEC1 GFP MEC1 ROR1
SAMPLE Overlay, %N
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In Fig. 3. 3, histograms corresponding to four representative hybridoma 
supernatants show the ROR1 binding detected on the cell lines and primary 
CLL cells mentioned above. Similar to previous observations, signal intensity 
was proportional to ROR1 expression of the different targets. This was 
particularly evidenced by the difference of binding between MEC-1 ROR1 
(high) and SKW GFP (ROR1 low). In the same way, this was observed on CLL 
cells expressing different levels of ROR1.  
Since ROR1 expression on SKW GFP cells is comparable to CLL cells, we 
present, as an additional example, data obtained when testing all these 
supernatants on SKW GFP cells (Fig. 3. 4). Together, these results confirmed 
that successful generation of ROR1 polyclonal hybridomas was achieved. 
Thus, in order to produce monoclonal antibodies, the next step was to single-
cell clone them. 
 
  
    Chapter 3 
122 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. 3. Binding of ROR1 polyclonal hybridomas assessed by flow 
cytometry. Supernatants from all 38 ROR1 polyclonal hybridomas were tested on 
different cell lines and primary CLL cells. Representative histograms from 4 
polyclonal hybridomas are shown. The secondary ab (anti-rat IgG-DyLight647) 
alone and Rat 1 serum acted as negative and positive control, respectively. Black 
line= Negative cells or secondary ab alone, Green line= Supernatant+secondary 
ab. The % of frequency is displayed in the top right corner of each histogram. 
Neg. control 
    Chapter 3 
123 
 
 
  
F
ig
. 
3
. 
4
. 
B
in
d
in
g
 o
f 
R
O
R
1
 p
o
ly
c
lo
n
a
l 
h
y
b
ri
d
o
m
a
s
 o
n
 S
K
W
 G
F
P
 c
e
ll
s
. 
S
u
p
e
rn
a
ta
n
ts
 f
ro
m
 a
ll 
3
8
 R
O
R
1
 p
o
ly
c
lo
n
a
l 
h
y
b
ri
d
o
m
a
s
 (
a
t 
a
 1
/1
0
0
 d
ilu
ti
o
n
) 
w
e
re
 t
e
s
te
d
 o
n
 S
K
W
 G
F
P
 c
e
lls
. 
T
h
e
 s
e
c
o
n
d
a
ry
 a
b
 (
a
n
ti
-r
a
t 
Ig
G
-D
y
L
ig
h
t6
4
7
) 
a
lo
n
e
 a
n
d
 
R
a
t 
1
 s
e
ru
m
 a
c
te
d
 a
s
 n
e
g
a
ti
v
e
 a
n
d
 p
o
s
it
iv
e
 c
o
n
tr
o
l,
 r
e
s
p
e
c
ti
v
e
ly
. 
B
la
c
k
 l
in
e
=
 N
e
g
a
ti
v
e
 c
e
lls
 o
r 
s
e
c
o
n
d
a
ry
 a
b
 a
lo
n
e
, 
G
re
e
n
 
lin
e
=
 S
u
p
e
rn
a
ta
n
t+
s
e
c
o
n
d
a
ry
 a
b
. 
T
h
e
 %
 o
f 
fr
e
q
u
e
n
c
y
 i
s
 d
is
p
la
y
e
d
 i
n
 t
h
e
 t
o
p
 r
ig
h
t 
c
o
rn
e
r 
o
f 
e
a
c
h
 h
is
to
g
ra
m
. 
    Chapter 3 
124 
 
3.3.2 Aim 2: Generation of ROR1 monoclonal hybridomas 
3.3.2.1 Single-cell cloning by single-cell sorting/limiting dilution: In collaboration with 
Dr Marco Della Peruta and Dr Satyen Gohil 
 
Having confirmed the specific ROR1 binding of our 38 polyclonal hybridomas, 
we set out to generate ROR1 single-cell clone hybridomas. 
Single-cell cloning was performed by limiting dilution or single-cell sorting into 
96-well plates. Colonies were grown until confluent (approximately 2 weeks) 
and a total of 178 single-cell clones were generated and tested on 
GFP+ROR1+ (SUP-T1 ROR1) and GFP-ROR1- (SUP-T1 NT) cell lines.  
In Fig. 3. 5, representative dot plots of supernatants screened for specific 
ROR1 binding are shown. Unlike MEC-1 cells used previously, SUP-T1 cell 
lines (NT and ROR1) could be clearly differentiated in a flow cytometry dot plot 
by their GFP expression. Therefore, in order to maximise efficiency, SUP-T1 
NT (GFP-) and SUP-T1 ROR1 (GFP+) were mixed at a 1:1 ratio and incubated 
with supernatants from single cell clone hybridomas, followed by a washing 
step and secondary antibody staining (anti-rat IgG). Cells alone or in a mixture 
incubated with secondary antibody alone or non-stained were included as 
negative controls.  
Additionally, and for illustrative purposes, data presenting the screening of all 
178 single-cell clones can be found in Fig. 3. 6. 
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Fig. 3. 5. ROR1 binding by flow cytometry. A total of 178 single-cell clones were tested by 
double staining flow cytometry on a mixture of ROR1+-GFP+ and ROR1--GFP- cell lines. 
Representative dot plots are shown. Anti-rat IgG was used as secondary antibody and served 
as negative control for antibody staining. At the bottom, cells line alone or in a mixture are 
shown as controls. Negative single cell clones for ROR1 detection appear as shadowed in 
red. 
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3.3.2.2 5’ RACE PCR: In collaboration with Dr Marco Della Peruta and Dr Satyen Gohil 
To ultimately isolate the variable heavy (VH) and light (VL) regions of our ROR1 
antibodies, we needed to use the 5’ Rapid Amplification of cDNA Ends (RACE) 
PCR technique. This method allows amplification of a specific cDNA region 
starting with the knowledge of a small stretch of sequence from within an 
internal region of the cDNA (Frohman, 1993). 
Applied to antibodies, this technique allows the isolation and cloning of the VH 
and VL regions by PCR using primers annealing to the 5’ and 3’ ends of the 
antibody sequence. Since the 3’ end of the variable regions corresponds to the 
immunoglobulin constant regions, specific primers for the isotype of each clone 
can be used. However, this is not the case for the 5’ end as there are many 
families of V-regions and it is unknown which one corresponds to what 
hybridoma.  
Therefore, instead of performing multiple PCRs using a panel of forward 
primers designed to amplify all V-region families, a universal approach is 
adopted by which the cDNA is poly-C tailed by incubation with Terminal 
Transferase and dCTPs. PCR is then performed using a poly-G forward primer 
(including an anchor region) and a reverse primer specific to each constant 
region. Finally, a subsequent nested PCR is performed using an internal 
reverse primer and an external forward primer specific to the anchor region of 
the initial poly-G forward primer (See Fig. 2.1 – Chapter 2). 
Therefore, before starting processing cDNA from our single-cell clones, we 
first determined the isotype of all ROR1 positive single-cell clone hybridomas. 
To this end, we used an ELISA-based rat immunoglobulin isotyping kit 
(eBioscience), which allowed us to identify both the heavy and light chain 
constant regions (See Fig. 3. 7).  
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Having identified the isotype of all ROR1 single-cell clone hybridomas, we 
grew the latter in 6-well plates or 10cm dishes in order to produce enough 
number of cells for RNA extractions. RNA was then reverse transcribed to 
cDNA.  
To ensure quality of samples, cDNA was tested by using rat GAPDH primers 
able to differentiate between genomic DNA and cDNA. Briefly, rat GAPDH 
primers bound to two non-consecutive exons so that cDNA amplification would 
produce a 600bp band size, whilst genomic DNA would generate a 900bp PCR 
product (since intronic regions would also be amplified). An agarose gel 
showing a representative result after PCR amplification is shown in Fig. 3. 8. 
  
Fig. 3. 7. Single-cell clone hybridoma isotyping by ELISA. ELISA-based rat 
immunoglobulin isotyping kits from eBioscience or BD Bioscience were used to 
identify both the heavy and light constant regions of all ROR1 single-cell clone 
hybridomas. 
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Following cDNA production and evaluation, 5’RACE PCR reactions were 
performed as described in the Materials & Methods section (Chapter 2). In 
short, cDNA was poly-C tailed and later amplified with a poly-G forward primer 
and an isotype-specific reverse primer. A nested PCR was then performed in 
order to maximise amplification of variable regions.  
PCR products were run on a 1% agarose gel and stained with GelStar in order 
to maximise visibility. Of note, this method typically produces a smear of PCR 
products from 200-1000bp. However, when full length chains are successfully 
amplified, a defined band can be detected. 
Fig. 3. 8. Evaluation of cDNA quality using GAPDH primers. 
cDNA was tested for genomic DNA contamination using rat GAPDH 
primers able to differentiate between the two. cDNA amplification 
resulted in a 600bp PCR product, whilst gDNA amplification was not 
detected (900bp). Water acted as negative control. 
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In Fig. 3. 9, we show representative gels displaying 5’ RACE PCR products, 
before and after gel extraction. Amid the expected smear, clear and defined 
bands could be observed at approx. 600bp and 400bp corresponding to the 
variable heavy and light regions, respectively. PCR products using nuclease-
free water were also run. Bands of the correct size were gel-extracted and sent 
for direct sequencing or inserted into TOPO cloning vectors for subsequent 
sequencing. 
 
Sequencing data was then analysed using the IMGT V-quest database of rat 
germline immunoglobulin and consensus gene and allele sequences (Brochet 
et al., 2008). IMGT V-quest, a bioinformatics tool developed by the 
international ImMunoGeneTics information system (IMGT), allows the 
identification of the variable (V), diversity (D) and joining (J) genes and alleles 
of any submitted antibody sequence to their platform. 
Fig. 3. 9. Isolation and amplification of VH and VL regions by 5’ RACE PCR. cDNA 
from single-cell clone hybridomas were isolated by 5’ RACE PCR. Amplified products 
were run in 1% agarose gels and stained with GelStar for maximum sensitivity. 
Representative gels before and after gel extraction of relevant bands are shown. 
Nuclease-free water for 5’ RACE PCR amplification acted as negative control. 5’ 
RACE= 5’ Rapid Amplification of cDNA Ends. 
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In Fig. 3. 10, representative IMGT V-quest outputs for both VH and VL 
sequences are presented. The alignment for the V- (D-) and J-GENE included 
the alignment score and the identity percentage with the five closest genes 
and alleles. The software also evaluated the presence of a stop codon in the 
sequence and if it was in-frame. Full length chains with matching and in-frame 
V-, (D-) and J-sequences were classified as “productive”.    
From the single-cell clone hybridomas, a total of 32 VH and VL regions 
encoding for 16 unique antibody sequences came out as “productive”. 
3.3.3 Aim 3: Cloning of rat scFv to hIgG1, k constant regions 
Following verification of antibody sequences, 16 chimeric antibodies in full 
human IgG were generated using DNA splicing by overlap extension PCR. As 
indicated on Materials & Methods section (Fig. 2. 2), the variable chains (rat 
VH and VL) along with the constant regions (human IgG1 and human kappa) 
were PCR amplified using appropriate primers that would add both relevant 
restriction enzyme sites and an overlapping sequence.  
Fig. 3. 10. IMGT V-quest identification of heavy and light chain sequences derived from ROR1 
single-cell clone hybridomas. Shown is a representative result of heavy and light chain sequences 
that matched the rat germline immunoglobulin and consensus sequences (V, (D) and J genes) using 
the IMGT V-quest database. Matching clones that had an in-frame signal sequence were classified 
as “productive”. IMGT= The International ImMunoGeneTics information system. 
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A second PCR was then performed in order to splice the corresponding 
variable and constant regions together. The resulting inserts were subcloned 
into retroviral vectors carrying different reporter genes: eBFP (light chain) and 
eGFP (heavy chain) (Fig. 3. 11). 
Correct cloning of all new constructs was evaluated by enzymatic digestion 
followed by agarose gel electrophoresis and sequencing analysis. These 
evaluations confirmed the successful subcloning of all 16 antibody sequences, 
Fig. 3. 11. Cloning of rat scFv into human IgG1, k constant regions. (A) DNA splicing 
of variable and constant regions resulted in the generation of retroviral vectors coding for 
each: VL-human kappa and VH-human IgG1 chains. Each construct carried a reporter gene: 
eBFP and eGFP for the light and heavy chains, respectively. (B) Transfection of both 
plasmids was needed in order to produce rat-human chimeric antibodies comprised of rat 
anti-human ROR1 variable chains in human IgG1, k constants. eBFP= Enhanced blue 
fluorescent protein, eGFP= Enhanced green fluorescent protein. 
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which resulted in the generation of 32 new constructs (16 for the light and 16 
for the heavy chains). 
 
3.3.4 Aim 4: Assessment of chimeric ROR1 antibodies by flow 
cytometry 
We next sought to produce ROR1 chimeric antibodies by transient transfection 
of HEK 293T cells using two plasmids per antibody. In Fig. 3. 12, we show 
representative dot plots displaying transfection efficiency of 293T cells at 72h 
after co-transfection of light and heavy chains. We screened different clones 
encoding for the same antibody sequence (in this case, one for the light chain: 
L2 and three for the heavy chain: H2, H9 and H11).  
Confirmation of successful transfection led me to evaluate the ROR1 binding 
ability of the chimeric antibodies contained in the culture supernatants. At 72h 
post-transfection, culture supernatants were tested on GFP+ROR1+ (SUP-T1 
ROR1) and GFP-ROR1- (SUP-T1 NT) cell lines. After 30min incubation, cells 
were washed and stained with an anti-human IgG-DyLight647. Culture media 
from non-transfected cells acted as negative control.  
Both histograms and dot plots generated by flow cytometry showed specific 
detection of ROR1, which confirmed the correct expression of chimeric 
antibodies against ROR1. 
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Fig. 3. 12. Generation of rat scFv into human IgG1, k constant regions. HEK 293T 
cells were transiently co-transfected with the light and heavy chain plasmids of chimeric 
ROR1 antibodies. Different clones coding for the same antibody sequence were tested 
each time. (A) Transfection Efficiency: Representative dot plots of 293T cells transfected 
using different clones (one for the light chain: L2 and three for the heavy chain: H2, H9 
and H11) are shown. Both the GFP and BFP expression was evaluated for heavy and 
light chain transfection, respectively. Non-transfected 293T (293 UT) cells acted as 
negative control. (B) ROR1 Binding: Culture supernatants were collected at 72h post 
transfection. After centrifugation, supernatants were incubated with GFP+ROR1+ (SUP-
T1 ROR1) and GFP-ROR1- (SUP-T1 NT) cell lines. Supernatant from non-transfected 
293T cells acted as negative control. After a wash step, all samples were stained with an 
anti-human IgG1-Dylight 647 antibody. Shown are representative histograms and dot 
plots obtained after assessment of ROR1 binding by flow cytometry. 
A. 
B. 
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Similarly, in Fig. 3. 13, we show the flow cytometry evaluation of ROR1 binding 
using all 16 chimeric antibodies. Of these, 12 clones presented specific 
detection of GFP+ROR1+ cells but not GFP-ROR1- cells. It is noteworthy that 
additional to our chimeric antibodies, previously reported clones 4a5 (murine-
derived) (Kipps, 2012) and R12 (rabbit) (Yang et al., 2011) were also cloned 
into hIgG1, kappa constants. These antibodies were also tested for ROR1 
specificity and were included in these studies as reference. A summary of all 
ROR1 chimeric antibodies generated can be seen in Table 3. 3. 
 
 
 
  
Fig. 3. 13. Specific binding of chimeric rat-human anti-ROR1 clones to 
ROR1+ cells by flow cytometry. Sixteen rat hybridoma single-cell clones were 
fused to hIgG1, k regions. Of these, 12 showed specific binding to ROR1+ cells. 
Ab supernatants from transfected 293T were tested by double staining flow 
cytometry on ROR1+GFP+ and ROR1-GFP- cell lines. Previously published 4a5 
(murine) and R12 (rabbit) clones were included as reference (blue square). Anti-
human IgG was used as secondary antibody. 
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Table 3. 3. Summary of ROR1 Chimeric antibodies specific for ROR1. Previously reported 
clones 4a5 and R12 (in blue) were also cloned in hIgG1, k constants and were included in 
these studies as reference. 
 
 
 
 
 
 
 
As a whole, in this chapter it has been shown that although 32 retroviral 
constructs encoding for 16 chimeric ROR1 antibodies were generated, only 12 
were able to specifically detect and bind to ROR1-expressing cells. The 12 
new ROR1 antibodies will be further investigated in the next chapters. 
3.4 Discussion 
Fundamental to the aim of developing ROR1-based immunotherapies, was the 
generation of anti-ROR1 monoclonal antibodies. To this end, hybridomas 
derived from three immunised Wistar rats against the extracellular portion of 
ROR1 were produced.   
It is noteworthy that rats and not mice were preferred as the ROR1 identity 
between human and the former was 90%, instead of the 97% identity found 
between human and mouse. Despite of this, our collaborator (Aldevron) had 
to perform eight rounds of immunisation in order to get ROR1 positivity in the 
Antibody clone Binds to ROR1 
E7 Yes 
G5 Yes 
G3 Yes 
A Yes 
I Yes 
Pi Yes 
U No 
Psi No 
O Yes 
K2 No 
J6 Yes 
F Yes 
X No 
V Yes 
Mu Yes 
B5 Yes 
4a5 Yes 
R12 Yes 
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rats’ sera. Arguably, this might have been of benefit as the effect of boosting 
enhances immunoglobulin class switching and the generation of higher affinity 
antibodies through somatic hypermutation (Nelson et al., 2000). 
Flow cytometry evaluation of the rats’ sera and subsequent 38 polyclonal 
hybridomas confirmed the presence of ROR1 antibodies as evidenced by 
specific binding to ROR1-expressing cell lines and primary CLL cells. 
Screening for ROR1 detection at the polyclonal stage was necessary in order 
to choose which hybridomas to take forward. However, no further assumptions 
could be made since their polyclonality and differences in concentration would 
not have allowed us to ascertain the most promising candidates.  
Since all 38 hybridomas were positive for ROR1, they were all processed for 
single-cell cloning in order to generate monoclonal antibodies. This decision 
was driven by the knowledge that although antibodies derived from polyclonal 
hybridomas have the advantage of detecting multiple epitopes -whilst having 
a relatively simple and inexpensive production- batch to batch variation might 
be observed. This could include differences in antibody reactivity and titre 
(Nelson et al., 2000, Abcam, Wootla et al., 2014). In contrast, monoclonal 
antibodies target a single epitope and can be produced continuously. This is 
of particular importance for research and therapeutic purposes, as their 
reproducibility make them powerful tools for investigation of molecules and 
biological processes as well as clinical diagnosis and treatment.  
Once single-cell clone hybridomas were produced, isotype determination was 
undertaken in order to facilitate isolation of the variable regions. Importantly, 
isotype determination also helps identify the presence of a single isotype, 
further confirming that the antibody under investigation is truly monoclonal.  
VH and VL extraction was followed by the generation of chimeric antibodies. As 
discussed above, cloning of the variable regions into human constant chains 
was needed in order to avoid unwanted antibody immunogenicity (Schroff et 
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al., 1985). Furthermore, in terms of antibody derivatives such as Antibody-
Drug Conjugates (ADCs), the use of human IgG could also be considerably 
beneficial. A study by (Ober et al., 2001), showed that whilst mouse neonatal 
Fc receptor (FcRn) binds IgGs from various species, human FcRn binds only 
human, guinea pig and rabbit IgG, but not mouse or rat IgG. Since the ADC-
FcRn interaction is pivotal for preventing unwanted cell death and increasing 
the circulatory half-life of the ADC, these findings shed light on the importance 
of using a human isotype for ADC therapy (Peters and Brown, 2015, Hamblett 
et al., 2016, Sato et al., 2009). 
Not surprisingly, most therapeutic antibodies contain the human IgG1, kappa 
isotype, as it has been shown that hIgG1 can induce potent ADCC and CDC 
activities when compared to other heavy chain isotypes (Natsume et al., 2008). 
Furthermore, Jefferis et al., showed that it confers stability and a half-life of 
approximately 21 days to the antibody molecule (Jefferis et al., 1998). As a 
result, it was decided to generate chimeric antibodies in hIgG1, k constants.  
Using DNA splicing techniques, I produced 32 retroviral constructs encoding 
for 16 unique antibodies against ROR1. Additional to this, sequences from 
previously reported clones against ROR1 (4a5 (Kipps, 2012) and R12 (Yang 
et al., 2011)) were put in the same chimeric format.  
After flow cytometry evaluation on ROR1+ and ROR1- cells, it was found that 
12 clones were still able to specifically bind to ROR1 as chimeric antibodies. 
Recently, observations that isotype does not only affect antibody activity but 
also specificity (Casadevall and Janda, 2012, Beers et al., 2016), structure 
(Janda et al., 2016) and affinity (Tudor et al., 2012) might explain the sudden 
lack of binding to ROR1 when clones U, Psi, K2 and X were put in the chimeric 
format. 
Further characterisation of our 12 chimeric antibodies against ROR1 will be 
discussed in the next chapter. 
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3.4.1 Conclusions 
- In collaboration with Aldevron, 38 rat polyclonal hybridomas against 
human ROR1 have been successfully produced.  
- Our group generated more than 150 single-cell hybridomas and tested 
their ROR1 specificity by flow cytometry on both ROR1 positive and 
negative cells.  
- The variable heavy (VH) and variable light (VL) regions of rat monoclonal 
antibodies were extracted, cloned, and sequenced.  
- IMGT V-quest analysis allowed us to identify “productive” and in-frame 
sequences.  
- A total of 32 constructs in retroviral vectors were generated. They 
encoded for 16 chimeric rat-human antibodies (rat VH and VL sequences 
in human IgG1, kappa constant regions).  
- Transient co-transfection of these plasmids in HEK 293T cells allowed 
the production of all chimeric antibodies for further investigation.  
- Flow cytometry analyses revealed that 12 out of 16 clones in the 
chimeric format were still able to specifically bind to ROR1-expressing 
cells.  
- Previously reported clones 4a5 and R12 were produced as chimeric 
antibodies and included in these studies as reference. Specific binding 
to ROR1 was also assessed by flow cytometry. 
3.4.2 Future work 
It would be worth exploring whether the lack of binding seen in clones U, Psi, 
K2 and X is exclusive to their cloning into human IgG1, k constant regions. 
This would be of particular interest for clones U and Psi as analysis using their 
hybridoma supernatant revealed that they bind to the Frizzled domain of ROR1 
(data not shown). 
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Chapter 4 Characterisation of chimeric ROR1 antibodies 
4.1 Introduction 
In the previous chapter, it was demonstrated that the variable heavy (VH) and 
light (VL) regions of 16 anti-ROR1 antibodies were successfully cloned into 
human IgG1, kappa constant regions. This resulted in the generation of 16 rat 
anti-human ROR1 antibodies; of which, 12 clones were able to specifically bind 
to ROR1-expressing cells. 
The aims of the studies outlined in this chapter were to further characterise our 
chimeric antibodies in terms of: i) identification of their binding domain by flow 
cytometry, ii) binding kinetics determination by surface plasmon resonance, iii) 
cytolytic activity, and iii) ability to get internalised into ROR1+ cells. 
4.1.1 Epitope mapping 
When an individual is exposed to an immunogen, a humoral response is 
provoked. As a result, a plethora of antibodies is produced against different 
regions of the foreign substance. These regions are called antigenic 
determinants, or epitopes, and they usually comprise 6-8 amino acids (Nelson 
et al., 2000).  
Epitope mapping is therefore the process of identification of these molecular 
determinants. This is certainly a crucial step in the characterisation of 
monoclonal antibodies with therapeutic purposes as it enables the localisation 
of antigenic regions, and the effect that antibodies targeting them could have 
in cell function (Baerga-Ortiz et al., 2002).  
Several methods have been developed in order to map binding epitopes of 
monoclonal antibodies. The biophysical and biochemical properties of this 
interaction have allowed the use of different techniques ranging from pepscan, 
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co-crystallisation of the antigen:antibody complex followed by x-ray diffraction, 
to nuclear magnetic resonance (NMR), Biacore technology, amino acid 
mutagenesis and other binding analyses. Recently, combinatorial approaches 
using phage display peptide libraries and computational algorithms such as 
Mapitope appear to be effective in mapping conformational epitopes (Gershoni 
et al., 2007). 
In this study, an approach that is readily accessible yet able to map both linear 
and conformational epitopes was chosen, and it is presented in the first section 
of Results. There, binding analysis using cell lines expressing truncated 
domains of our protein of interest will be discussed. 
4.1.2 Binding kinetics determination by surface plasmon resonance 
Another important parameter in the characterisation of monoclonal antibodies 
is the measurement of the binding kinetics of antigen-antibody interactions, 
namely affinity. Biacore systems is the preferred approach as it is based on 
surface plasmon resonance (SPR) technology. SPR allows the investigation 
and quantitation of molecular interactions in real time, using a label-free 
technology, making it useful for a broad range of biological applications, 
including antigen-antibody complexes (Jason-Moller et al., 2006). 
One major advantage of SPR biosensor-based assays is the option to 
separately determine association (kon) and dissociation (koff) rate constants. 
The knowledge of these distinct kinetic parameters provides detailed 
information that may be pivotal when screening for therapeutic antibodies. For 
instance, one demand could be that the antibody should bind fast (high kon) 
and bind tightly (low koff) (Hahnefeld et al., 2004).  
Affinity can be determined in three independent ways using Biacore systems: 
i) calculation from kinetic constants, ii) measurement of steady-state binding 
levels and iii) determination of affinity in solution. For simple 1:1 binding 
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models, such as antigen-antibody interactions, affinity can be calculated from 
kinetic constants: kon and koff (Sciences, 2012). 
Similarly, the equilibrium dissociation constant (KD) can be determined by 
calculating the ratio of the koff and kon (koff/kon) between two molecules. It is 
used to evaluate the strength of the interaction between the antigen and the 
antibody, and it is expressed in terms of concentration (M).  
KD and affinity are inversely related. At equilibrium, the rate of antigen-antibody 
complex formation is equal to the rate of dissociation. Measurement of the 
reaction rate constants can be therefore used to define the affinity constant 
(1/KD). Thus, the smaller the KD value, the greater the affinity of the antibody 
for its target (Abcam, 2017). 
Binding kinetics of the chimeric antibodies were investigated using the Biacore 
system. Data from these analyses is presented in the second section of 
Results. 
4.1.3 Antibody cytotoxicity  
4.1.3.1 Fc-mediated cytotoxicity: Unconjugated antibodies 
As described in the Introduction (Chapter 1), naked or unconjugated 
antibodies can exert their cytotoxicity by five main mechanisms of action: i) 
antibody-directed cell death, ii) complement-dependent cytotoxicity (CDC), iii) 
antibody-dependent cellular cytotoxicity (ADCC), iv) antibody-dependent 
cellular phagocytosis (ADCP) and v) vaccinal effect. Of these, the last four 
involve Fc recognition by the immune system; namely complement system, 
NK cells and macrophages, respectively.   
Most therapeutic antibodies currently used in the clinic trigger immune 
recognition and activation (Scott et al., 2012). Thus, cytotoxicity screening of 
our antibodies was performed through CDC activity evaluation.  
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4.1.3.2 Antibody internalisation: Potential for ADC therapy  
Antibody-drug conjugates (ADCs) are armed antibodies with a cytotoxic 
payload. One of the key advantages of ADCs is that their therapeutic action is 
independent from the immune response, which can be considerably affected 
in cancer patients (Baskar et al., 2012).  
ADCs combine the specificity of monoclonal antibodies with the cytotoxicity of 
toxins, chemotherapeutic agents or radioisotopes (Peters and Brown, 2015). 
ADCs rely on internalising antibodies in order to deliver their toxic payload. 
Antibody internalisation is in turn mediated by endocytosis. A short discussion 
of the mechanisms of endocytosis currently known as well as the inhibitors 
used in order to study antibody internalisation is presented below.  
4.1.3.2.1 Mechanisms of endocytosis  
Endocytosis is a cellular process by which extracellular material and plasma 
membrane is trafficked into the cell (Dutta and Donaldson, 2012). Endocytic 
mechanisms regulate the interactions of cells with their environment, and can 
be classified into two broad categories: phagocytosis (the uptake of large 
particles) and pinocytosis (the uptake of fluid and solutes) (Conner and 
Schmid, 2003). Phagocytosis, in this context, is restricted to specialised 
mammalian cells. Pinocytosis on the other hand occurs in all cells by at least 
three main mechanisms: clathrin-mediated endocytosis (CME), clathrin-
independent endocytosis (CIE) and macropinocytosis (Fig. 4. 1).  
Describes the isolation of highly purified coated vesicles from different sources 
and demonstrates that clathrin is the major coat protein, setting the stage for 
mechanistic 
CME, previously known as receptor-mediated endocytosis, has been 
extensively investigated for the past four decades. The study of this 
mechanism was further developed ever since (Pearse, 1976) isolated coated 
vesicles and identified that clathrin was the major protein. Certainly, CME 
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requires adaptor proteins, amongst them clathrin and dynamin, in order to 
select and concentrate cargo into vesicles, and detach them from the cell 
membrane. In contrast, CIE occurs independently from adaptor proteins, and 
mostly does not require dynamin for vesicle scission (Damke et al., 1995). 
Although this mechanism is less understood, it is known that it is cholesterol-
dependent and that there are certain forms that are caveolae- and RhoA-
dependent (Mayor and Pagano, 2007). Lastly, macropinocytosis involves the 
actin-dependent formation of ruffled extensions of the cell membrane around 
an extracellular region followed by internalisation of said region (Doherty and 
McMahon, 2009, Dutta and Donaldson, 2012).  
Recent studies have suggested that macropinocytosis might mediate 
endocytosis in cancer (Ha et al., 2016), and it can include internalisation of 
several cell receptors. Internalisation of receptor tyrosine kinases (RTKs) such 
as ROR1 however seems to occur preferentially, although not exclusively, by 
CME (Doherty and McMahon, 2009).  
 
4.1.3.2.2 Endocytosis inhibitors 
In an effort to better understand the different types of endocytosis, scientists 
have used a range of non-specific chemical inhibitors. More recently, a new 
Fig. 4. 1. Different mechanisms of endocytosis. Phagocytosis and macropinocytosis are 
both driven by actin (hatched lines). Clathrin-mediated endocytosis (CME) is the main 
mechanisms whereby cell surface proteins are internalized by associating with adaptor 
proteins which in turn recruit clathrin (black stars). CME endosomes detach from the cell 
membrane by recruiting dynamin GTPase (black circles) to the bud neck. Clathrin-
independent endocytosis (CIE) is depicted as one form, although several variations of CIE 
have been reported. Modified from Dutta & Donaldson, 2012. 
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generation of pharmacologic agents and genetic approaches have emerged in 
order to target and study a particular form of endocytosis. 
One of the classical chemical endocytosis inhibitors is phenylarsine oxide 
(PAO), a trivalent arsenical compound. Unlike other chemical inhibitors, PAO 
does not significantly alter other cellular functions when used at concentrations 
<20uM (Gibson et al., 1989). Although its mode of action is not clearly known, 
it has been shown that CME, macropinocytosis and phagocytosis are all 
blocked by PAO (Dutta and Donaldson, 2012). In this study, evaluation of 
antibody internalisation by the use of PAO and other approaches will be 
discussed. 
4.2 Aims 
1. To identify the binding domain of our chimeric antibodies on the 
extracellular portion of ROR1 using flow cytometry.  
2. To quantify the affinity of our antibodies to their target by determining 
their binding kinetics using Surface Plasmon Resonance (SPR) 
technology (Biacore).  
3. To screen the cytotolytic activity of our ROR1 antibodies by 
Complement-Dependent Cytotoxicity (CDC) assay.  
4. To assess internalisation of our antibodies into ROR1+ cells by flow 
cytometry and pHAb amine dye labelling.  
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4.3 Results 
4.3.1 Aim 1: Identification of binding domain by flow cytometry  
Having generated 16 of our own chimeric rat anti-human antibodies in human 
IgG1 and having shown that 12 of them bind specifically to ROR1 (Chapter 3), 
I aimed to identify their binding domain on the extracellular portion of ROR1. 
To do this, our lab generated stable cell lines that expressed either full-length 
extracellular ROR1 (eROR1) or varying regions of its extracellular domains: 
Ig-like alone, Ig-like+Frizzled (Fz), Fz alone, Fz+Kringle (Kg) and Kg alone 
(Fig. 4. 2A). Briefly, SUP-T1 cells, which are ROR1-, were transduced with 
retroviral supernatants encoding for the ROR1 regions mentioned above.   
Our antibodies were next evaluated on transduced SUP-T1 cells (Fig. 4. 2B), 
while non-transduced SUP-T1 (SUP-T1 NT) cells were used as negative 
control. The secondary antibody (anti-human Fc) served as negative control 
for antibody staining. 
Fig. 4. 2 shows that 10 of our 12 antibodies bound to the Ig-like domain. In 
contrast, clone V (dark yellow) seems to bind to the intermediate portion 
between the Ig-like and the Fz domains -since no binding is detected when 
incubated with cells expressing either of those domains alone. Interestingly, 
clone F (dark green) is the only antibody that binds to the Frizzled domain. Of 
note, clone Mu (dark grey) is the only chimeric antibody that shows very low 
binding to eROR1, almost none to the Ig-like domain and a detectable but still 
very modest binding to the Ig-like+Fz domains. Thus, it is possible that Mu 
antibody binds to ROR1 in a similar way as clone V does. 
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4.3.2 Aim 2: KD determination by surface plasmon resonance (SPR) 
technology: Biacore  
Having identified the binding domains of our chimeric ROR1 antibodies, I next 
explored their binding kinetics using surface plasmon resonance (SPR) 
technology (Fig. 4. 3). SPR evaluation using a Biacore X100 instrument was 
undertaken at the UCL Institute of Structural & Molecular Biology. As indicated 
in the Materials and Methods chapter, ROR1 chimeric antibodies were 
immobilised using an anti-human IgG1 antibody capture kit and a CM5 sensor 
chip. Seven different concentrations, ranging from 1.5-100nM, of the 
extracellular portion of ROR1 bearing a Histidine tag were then injected.   
 
Fig. 4. 2. Epitope mapping of chimeric ROR1 MAb by flow cytometry. (A) SUP-T1 cells were 
transduced with retroviral vectors containing either the full extracellular portion of ROR1 or only one 
or two extracellular domains. Non-transduced SUP-T1 (SUP-T1 NT) cells served as negative 
control. (B) All 12 chimeric antibodies were incubated with SUP-T1 NT and the new stable cell lines  
at 4°C for 30min. Cells were washed and stained with a secondary antibody (anti-human Fc-
Dylight647), which was used as negative control. eROR1= extracellular ROR1, Ig-like= 
Immunoglobulin-like domain, Fz= Frizzled domain, Kg= Kringle domain. 
A. 
B. 
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Fig. 4. 3. KD determination by surface plasmon resonance. Sensorgrams obtained using a 
Biacore X100 instrument are shown. Briefly, ROR1 antibodies were immobilized using a CM5 chip 
and seven different concentrations of the Histidine-tagged ROR1 protein (extracellular region) 
were injected, (shown in different colours). Concentrations ranged from 1.5 to 100nm. Und= 
Undetermined KD. 
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Surface plasmon resonance analysis showed that clones B5, A and Pi 
possessed the strongest affinities (1.51, 1.81 and 1.98nM, respectively), whilst 
clone F appeared to have the weakest binding affinity (5.46nM). Although all 
12 of our chimeric antibodies were evaluated, KD from clones V and Mu could 
not be calculated as the kinetic constants could not be determined. This 
correlates with flow cytometry data, where modest binding to ROR1 was 
observed. Table 4. 1 further illustrates the binding kinetics of our ROR1 
chimeric antibodies.  
Table 4. 1. Affinity values (KD) of chimeric ROR1 antibodies  
ROR1 Antibody Kon, (105)M-1s-1 Koff, (10-4)s-1 KD, 10-9M 
E7 4.168 8.490 2.037 
G3 1.086 2.660 2.450 
G5 1.593 4.164 2.614 
A 5.774 10.44 1.809 
B5 4.639 6.980 1.505 
F 1.531 8.362 5.460 
J6 2.492 8.351 3.351 
I 2.093 5.100 2.436 
Pi 1.763 3.487 1.979 
O 1.735 6.075 3.501 
Mu *** *** *** 
V *** *** *** 
*** The KD value could not be determined for these antibodies. 
 
4.3.3 Aim 3: Screening of the cytolytic activity of our ROR1 antibodies 
by Complement-Dependent Cytotoxicity (CDC) assay  
Essential to my ultimate goal to produce an effective immunotherapy against 
ROR1, was the identification of one or more cytotoxic antibodies. My previous 
results revealed that the affinity of our binders ranged in nanomolar 
concentrations. High affinity antibodies are indeed necessary to facilitate a 
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good antibody-target interaction which in turn results in a more efficient therapy 
(Scott et al., 2012). Therefore, we decided to screen the cytolytic activity of our 
antibodies on primary cells from Chronic Lymphocytic Leukaemia (CLL) 
patients and Peripheral Blood Mononuclear Cells (PBMCs) from a healthy 
donor. 
 
This complement-dependent cytotoxicity (CDC) screening was performed 
using antibody supernatants prepared by transient cotransfection of the heavy 
and light chain plasmids using 293T cells. Previous experiments carried out in 
our lab showed that typical antibody concentration in 293T supernatants was 
approximately 0.5ug/ml (data not shown). The isotype and Rituximab (Rtx) 
controls were therefore used at this concentration. For Rituximab however an 
additional concentration of 10ug/ml was used; this was included in order to 
have a true positive control for the assay. 
 
In Fig. 4. 4A, the CDC activity elicited by all 12 of our own ROR1 chimeric 
antibodies is shown. Clones R12 and 4a5 were again used as reference, whilst 
a human IgG1, kappa antibody and Rituximab (anti-CD20 antibody) acted as 
isotype and positive controls, respectively. Of all antibodies evaluated, clone 
A was the only one that showed significant cytotoxicity compared to the isotype 
(p<0.001). Remarkably, clone A was also better at killing CLL cells (<45% live 
cells) than R12 and 4a5 (>80% live cells) but was still not as CDC active as 
Rituximab (<10% live cells).  
The expression levels of both CD20 and ROR1 antigens on the surface of CLL 
samples was also assessed (Fig. 4. 4B). Interestingly, clone A cytotoxicity 
seems to be ROR1 level dependent, although further experiments are required 
in order to conclusively claim this is the case. Also, the highest cytolytic activity 
is seen on CLL2 (ROR1high), whilst the lowest cytotoxicity is detected on CLL1 
(ROR1low). Similarly, Rituximab is able to kill CD20 expressing cells very 
efficiently (CLL1 and 2), although this is not the case for CLL3, which is virtually 
negative for CD20. 
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4.3.4 Aim 4: Assessment of Internalisation   
Antibody internalisation can have important implications as it could provide us 
with the opportunity to develop armed antibodies that could be conjugated to 
toxic payloads, such as toxins, radioisotopes or chemotherapeutic agents 
(Peters and Brown, 2015). This class of therapeutic antibodies are called 
Antibody-Drug Conjugates (ADCs). Interestingly, ADCs could have a 
therapeutic advantage over naked antibodies (unconjugated), in terms of 
potency and efficacy, as their cytotoxicity relies on the payload they carry 
rather than the immune system of patients (Baskar et al., 2012). Thus, I next 
investigated whether our antibodies were able to get internalised into ROR1+ 
cells by flow cytometry and pH-Amine dye labelling. 
4.3.4.1 By flow cytometry  
SKW 6.4 cells, Epstein-Barr virus-transformed B cells endogenously 
expressing comparable levels of ROR1 as CLL patients (See Fig. 3. 3), were 
incubated on ice with all 12 ROR1 chimeric antibodies. After 30min, cells were 
washed with ice-cold PBS, and either left on ice or incubated at 37°C for 1h. 
Subsequent staining with an anti-human Fc-Dylight 647 was used to detect 
any primary antibody that had remained on the cell surface. Previously 
reported clones R12 and 4a5 were also included in this assay as negative and 
positive1 controls, respectively (Fig. 4. 5).  
From all tested antibodies, clone V (green circle) showed almost complete MFI 
reduction. A modest but detectable decrease in MFI levels was observed in 
clones A and F (purple circles), similar to the one detected for clone 4a5. As 
previously reported, clone R12 did not show considerable MFI reduction after 
1h incubation at 37°C.  
                                            
1 GF Widhopf II et al. 2014 have reported low although still detectable internalisation of 4a5 
by flow cytometry. Due to lack of a better positive internalisation control, clone 4a5 use was 
referential.  
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MFI reduction could be caused by dissociation or internalisation or a 
combination of both (Yang et al., 2011). In order to further investigate what 
was triggering this drop in MFI for clones V, A and F, an endocytosis inhibitor 
was used in the next experiments.  
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4.3.4.1.1 Endocytosis inhibition  
Phenylarsine oxide (PAO), a trivalent arsenical compound, is the typical 
chemical chosen to block Clathryn-mediated endocytosis (CME), although it 
can also inhibit macropinocytosis and phagocytosis. CME is the best studied 
mechanism of endocytosis, and it has been established that receptor tyrosine 
kinases (RTKs), such as ROR1, predominantly use this form of internalisation 
when engulfed by the cell membrane and drawn inside the cell (Doherty and 
McMahon, 2009). 
To distinguish between dissociation and internalisation, SKW 6.4 cells were 
incubated on ice in the presence of the selected antibodies for 30min. Cells 
were then washed with ice-cold PBS and either left on ice or incubated at 37°C 
for 15min, 1h or 2h. Of note, additional time points were introduced in order to 
further assess and facilitate internalisation. For the 2h time point, a duplicate 
sample was incubated with PAO (10µM). Immediately after incubation, all 
samples were washed with ice-cold PBS and stained with an anti-human Fc-
Dylight 647 for 30min (See Fig. 4. 6). Cells were analysed by flow cytometry 
and MFI reduction was calculated as described in Chapter 2. 
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Fig. 4. 6. Internalisation assay of selected clones on SKW 6.4 GFP cells by flow 
cytometry. Cells were stained with selected clones at 4°C and either left on ice or incubated 
at 37°C for 15min, 1h and 2h. Cells were then analysed using an anti-human IgG as 
secondary antibody. (A) Histograms and (B) Trends over time showing the MFI reduction over 
time are presented. The % of MFI reduction was calculated as described in the Materials and 
Methods chapter. Phenylarsine oxide (PAO), an endocytosis inhibitor, acted as negative 
control (PAO-120). 
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Flow cytometry analysis showed that although clone V had an important MFI 
reduction, it was mainly due to dissociation as PAO did not considerably block 
the drop in MFI after 2h incubation at 37°C. A combination of internalisation 
and dissociation was more evident for the other 3 clones, being internalisation 
the dominating factor for clone 4a5. This was even more evident for clone A. 
To verify these results, the experiment was repeated using SKW 6.4 cells and 
included 2 samples of primary cells from CLL patients, expressing either high 
or low levels of ROR1 (Fig. 4. 7). Samples were processed as mentioned 
above and analysed by flow cytometry. Interestingly, these data confirmed that 
whilst both dissociation and internalisation were involved in MFI reduction, for 
clone V, dissociation was the main reason for decrease in MFI. This was even 
clearer on CLL cells, where virtually no internalisation of clone V was detected.  
The disappearance of clones F, 4a5 and A from the cell surface of CLL cells 
was very similar between samples and seemed to be independent of ROR1 
levels. In contrast to clone V, internalisation of F, 4a5 and A appeared to be 
as the main contributing factor to MFI reduction. A similar observation was 
detected on SKW 6.4 cells; although on this cell model, clone A was the only 
antibody where MFI drop was almost completely blocked by PAO. Only partial 
blocking was detected for clones F and 4a5. These findings suggest that 
although clones F, 4a5 and A might get partially internalised, the latter might 
be the most promising one. Clone A was therefore further investigated.  
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4.3.4.1.2 Trypan blue (TB) quenching effect 
To assess whether clone A was an internalising antibody with potential to be 
developed as an antibody-drug conjugate (ADC), it was conjugated to the 
AlexaFluor488 fluorophore so that direct analysis of the antibody could be 
performed. 
 
To this end, our group set up a collaboration with Dr Vijay Chudasama’s 
research group at the UCL Dept. of Chemistry. Dr Chudasama’s group has 
developed a novel site-selective technique that incorporates a serum-stable 
linker bearing a strained alkyne, a functional group that can be reacted cleanly 
in the presence of all amino acids in a so-called “click” reaction. Importantly, 
this reaction does not negatively affect antibody properties, including their 
specificity (Chudasama et al., 2016, Nunes et al., 2015). 
Therefore, I produced a large amount of clone A in-house and purified it by 
FPLC, using the AKTA system as detailed in the Materials & Methods section. 
Elution fractions were run on SDS-PAGE and stained with Coomassie dye in 
order to select those fractions containing the antibody (See Fig. 4. 8). Clone 
A, henceforth called clone SA1, was then dialysed in Borate buffer with EDTA, 
pH 8.0. Antibody was then concentrated in order to attain a 3-6mg/ml 
concentration, a requirement that needed to be met in order to ensure 
successful conjugation of clone SA1 to AlexaFluor 488, using the “click” 
technology developed by our collaborators. 
  
    Chapter 4 
160 
 
  
F
ig
. 
4
. 
8
. 
A
K
T
A
 p
u
ri
fi
c
a
ti
o
n
 o
f 
c
lo
n
e
 A
 a
n
ti
b
o
d
y
 u
s
in
g
 a
 5
m
l 
P
ro
te
in
 A
 c
o
lu
m
n
. 
A
 t
o
ta
l 
v
o
lu
m
e
 o
f 
3
0
0
m
l 
o
f 
s
u
p
e
rn
a
ta
n
t 
fr
o
m
 t
ra
n
s
ie
n
tl
y
 
tr
a
n
s
fe
c
te
d
 2
9
3
T
 w
e
re
 h
a
rv
e
s
te
d
 7
2
h
 p
o
s
t-
tr
a
n
s
fe
c
ti
o
n
. 
2
9
3
T
 w
e
re
 c
u
lt
u
re
d
 i
n
 F
B
S
 s
u
p
p
le
m
e
n
te
d
 I
M
D
M
 u
n
ti
l 
tr
a
n
s
fe
c
ti
o
n
. 
1
2
h
 a
ft
e
r 
c
e
ll
 
m
e
d
ia
 w
a
s
 r
e
p
la
c
e
d
 w
it
h
 f
re
s
h
 p
h
e
n
o
l-
re
d
 f
re
e
 I
M
D
M
 s
u
p
p
le
m
e
n
te
d
 w
it
h
 u
lt
ra
-l
o
w
 I
g
G
 H
I-
F
B
S
. 
S
u
p
e
rn
a
ta
n
t 
w
a
s
 c
e
n
tr
if
u
g
e
d
, 
fi
lt
e
re
d
 a
n
d
 
d
ilu
te
 w
it
h
 P
ro
te
in
 A
 B
in
d
in
g
 b
u
ff
e
r 
in
 a
 1
:1
 r
a
ti
o
, 
in
 o
rd
e
r 
to
 b
e
 t
h
e
n
 p
u
ri
fi
e
d
 b
y
 F
P
L
C
. 
E
lu
ti
o
n
 f
ra
c
ti
o
n
s
 A
8
-B
1
2
 w
e
re
 r
u
n
 i
n
 a
 S
D
S
-P
A
G
E
 
a
n
d
 s
ta
in
e
d
 w
it
h
 C
o
o
m
a
s
s
ie
 d
y
e
. 
F
ra
c
ti
o
n
s
 A
9
-A
1
5
 (
p
u
rp
le
 s
q
u
a
re
) 
w
e
re
 p
o
o
le
d
 t
o
g
e
th
e
r 
a
n
d
 d
ia
ly
s
e
d
 i
n
 B
o
ra
te
 b
u
ff
e
r 
w
it
h
 E
D
T
A
, 
p
H
 8
.0
. 
    Chapter 4 
161 
 
Dr Antoine Maruani, a postdoctoral researcher at Dr Chudasama’s group was 
in charge of the antibody labelling. Using the same “click” technology applied 
to ADCs, Dr Maruani successfully conjugated clone SA1 to the fluorophore in 
a clean and homogeneous manner, as evidenced by an SDS-PAGE stained 
with Coomassie dye and exposed to UV light in order to show an efficient 
conjugation (See Fig. 4. 9). 
 
 
Before proceeding with the internalisation assay, I decided to test and compare 
the binding of the following antibodies: i) Clone SA1, produced and purified in-
house and dialysed in PBS as per usual (SA1 Ctrl), ii) Clone SA1, produced 
and purified in-house and dialysed in Borate buffer with EDTA, pH 8.0 (SA1 
Unconjugated), and iii) Clone SA1, dialysed in Borate buffer with EDTA, pH 
8.0 and conjugated to AlexaFluor488 (SA1 AF488). These antibodies were 
incubated with either non-transduced or eGFP-ROR1 transduced SUP-T1 
Fig. 4. 9. SDS-PAGE stained with Coomassie blue/under UV lamp. SA1 dialysed in Borate buffer 
with EDTA, pH 8.0 (native antibody) along with SA1 coupled with a linker after site-selective 
modification, and SA1 conjugated to Alexafluor488 using the same site-selective linker were run in 
a SDS-PAGE. The gel was stained with Coomassie dye and exposed to UV lamp in order to detect 
a fluorescence signal. 
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cells (SUP-T1 NT and SUP-T1 61, respectively). Incubation was done for 
30min at 4°C. After this, cells were washed and stained with an anti-human 
Fab-DyLight647 secondary antibody (Fig. 4. 10). Importantly, an anti-Fab and 
not an anti-human Fc antibody was used for this experiment. The rationale for 
this was that the site-selective conjugation of the fluorophore involved the Fc 
region of the SA1 antibody, potentially blocking the anti-Fc antibody binding to 
SA1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. 10A shows the specific binding of all versions of clone SA1 antibody to 
SUP-T1 61 cells (GFP+ROR1+), presenting all 3 antibodies very similar % of 
A. 
B. 
Sample Name 
 
Fig. 4. 10. Binding evaluation of unconjugated and conjugated clone SA1 on ROR1- and 
ROR1+ cell lines. Clone SA1 dialysed in PBS (SA1 Ctrl), SA1 dialysed in Borate buffer with 
EDTA, pH 8.0 (SA1 Unconjugated), and SA1 dialysed in Borate buffer and conjugated to 
AlexaFluor 488 (SA1 AF488) were incubated with eGFP-ROR1- (SUP-T1 NT) and 
eGFP+ROR1+ cells (SUP-T1 61). After the first staining, cells were washed and stained with 
an anti-human Fab-Dylight647 secondary antibody. (A) Individual dot plots of eGFP against 
ahFab647 of all 3 antibodies tested against SUP-T1 NT and SUP-T1 61 are shown. (B) The 
overlap of antibodies tested on eGFP+ROR1+ cells is shown for comparison. eGFP= 
enhanced green fluorescent protein, ahFab= anti-human Fab-Dylight647 antibody. 
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frequency. It is in Fig. 4. 10B however where the difference in binding can be 
detected. The overlap dot plot indicates that the binding of clone SA1 dialysed 
in PBS (in blue) have the best binding to SUP-T1 61 cells compared to the 
other two versions of SA1 dialysed in borate buffer. Importantly, there seems 
to be no major difference between SA1 Unc. (in yellow) and SA1-AF488 (in 
green), suggesting that the addition of the fluorophore via the site-selective 
linker might not be responsible for the decrease of binding; a phenomenon that 
rather might be explained by the change of dialysis buffer. 
Having confirmed that SA1-AF488 ab was still able to bind to ROR1+ cells, I 
proceeded to test its ability to get internalised into ROR1-expressing cells. For 
this experiment, the Trypan blue (TB) quenching effect was used to distinguish 
antibody molecules internalised from those attached to the cell membrane 
(Thiele et al., 2001, Patino et al., 2015). Briefly, SA1-AF488 was incubated 
with Jeko-1 cells, a Mantle cell lymphoma cell line that endogenously express 
high levels of ROR1. After 30min incubation, cells were washed with ice-cold 
PBS and either left on ice or incubated for 15min or 2h at 37°C. AlexaFluor488 
fluorescence was then analysed before and after addition of TB (Fig. 4. 11). 
In Fig. 4. 11A, at time point “0h”, fluorescence was completely eliminated after 
TB addition, validating the quenching effect of this reagent. At time points 
“15min” and “2h”, it is observed that -before TB addition- AlexaFluor488 signal 
is partially reduced compared to time “0h”; suggesting that the disappearance 
of fluorescence is due to dissociation of the antibody from the cell surface. This 
is consistent with my previous results, where a combination of dissociation and 
internalisation were responsible for MFI reduction.  
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For the remaining signal detected at the “15min” time point, it was observed 
that it was caused by both antibody bound to the cell membrane and antibody 
molecules present inside the cell, as evidenced by signal detection even after 
addition of TB. At the “2h” time point however the main factor contributing to 
AlexaFluor488 detection was internalisation. Fig. 4. 11B provides with a bar 
graph representation of the MFI ratio (MFIR) calculated by dividing the MFI of 
Jeko-1 cells stained with SA1-AF488 (in the absence or presence of TB) and 
the negative control.   
Fig. 4. 11. Binding evaluation of clone SA1-AF488 on Jeko-1 cells using the quenching 
effect of Trypan Blue (TB). Jeko-1 cells were stained with SA1-AF488 antibody for 30min at 
4°C. Cells were then washed with ice-cold PBS and either left on ice or incubated at 37°C for 
15min or 2h. Samples were analysed by flow cytometry in the absence or presence of TB. 
(A)Histograms of the fluorescence intensity of AlexaFluor488 before addition of TB (in blue) 
and after (in yellow) are shown. Non-stained cells acted as negative control (red histogram). 
Both % of frequency and MFI values are included within the histograms and in tables, 
respectively. (B) Bars represent the MFI ratio between samples stained with SA1-AF488 ab 
and negative control. MFIR= Median fluorescence intensity ratio.  
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4.3.4.2 pHAb-Amine dye labelling  
pHAb-Amine dyes are pH sensor dyes that have very low fluorescence at 
pH≥7. However, a dramatic increase in fluorescent signal is detected at pH<6; 
when they internalise into the cells and traffic into acidic pH vesicles like the 
endosome or lysosome (Nath et al., 2016).   
The key advantage of this reagent is that antibodies labelled with pHAb dyes 
will not fluoresce upon binding to the cell membrane due to the neutral pH of 
the media. After receptor-mediated internalisation however antibodies will get 
transported into early endosomes and lysosomes, where the dye will fluoresce 
due to the acidic pH of said vesicles. This detectable and significant increase 
in fluorescence at low pH makes this approach suitable for monitoring antibody 
internalisation. 
Therefore, to validate previous observations, clones SA1 and F were labelled 
with a pHAb Amine dye kit (Promega). This time, based on studies by Nath et 
al., 2016, internalisation over a 24h period was assessed. To this end, SKW 
6.4 and Jeko-1 cells, both expressing endogenous ROR1, were incubated with 
pHAb Amine-labelled SA1 and F. As before, cells were incubated with these 
antibodies for 30min at 4°C. After this, cells were washed with ice-cold PBS 
and immediately read at Ex/Em: 532nm/562nm (“0h” time point). Cells were 
then incubated at 37°C and 5%CO2 for 15min, 2, 5, 21 and 24h. After each 
time point, fluorescence was evaluated using a plate-reader. Of note, citrate 
buffer pH 4 was used as positive control for fluorescence signal (Fig. 4. 12). 
 
 
 
 
    Chapter 4 
166 
 
 
An increasing difference in fluorescence levels between clone F and clone SA1 
labelled with pHAb amine dye was observed throughout all time points. The 
inclusion of Citrate buffer, pH 4.0 served to test for the successful conjugation 
of both antibodies to the pHAb amine dye, as fluorescence would only be 
detectable at low pH. A calculation of the fold increase in fluorescence can be 
seen in Table 4. 2. 
Table 4. 2. Measure of pHAb amine-labelled antibody response to pH, using the “Fold 
increase” formula shown in the Materials & Methods section (Chapter 2) 
Antibody SKW 6.4 Jeko-1 
SA1 8.22 9.92 
F 11.10 28.51 
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Fig. 4. 12. pH-dependent fluorescence using pHAb Amine reactive labelled clones F and 
SA1 ROR1 MAbs on ROR1+ cell lines. SKW 6.4 and Jeko-1 cells were incubated with pHAb 
Amine-labelled SA1 and F antibodies for 30min on ice. After a thorough wash, fluorescence 
was read at Ex/Em: 532nm/562nm for the “0h” time point. Cells were then incubated at 37C 
for 15min, 2, 5, 21 and 24h. Fluorescence was read after each time point. Citrate buffer, pH 
4.0 acted as positive control for fluorescence signal. Data from all time points was normalised 
to positive control fluorescence values. * indicates statistical significance of the differences 
between SA1 and F groups at those time points, as calculated using two-way ANOVA analysis 
(p<0.05). 
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Fluorescence readouts from all time points were normalised to those from the 
positive control. Data confirms that internalisation can be detected even after 
15min and that it intensifies over time, becoming significantly higher than the 
one caused, on both cell lines, by F antibody at both 21 and 24h time points. 
Remarkably, this approach confirms that not all antibody gets internalised, as 
evidenced by the level of fluorescence detected. As seen in previous results, 
data from this experiment also suggest that a combination of both dissociation 
and internalisation take place for both antibodies. Of which, dissociation is the 
main factor for clone F as it is internalisation for clone SA1.  
4.4 Discussion  
In this chapter, data have shown that, out of 12 ROR1-binding antibodies, 10 
recognise the Ig-like extracellular domain of ROR1. This is likely due to the 
fact that this domain represents the most immunogenic portion of ROR1. An 
interesting observation was that clones V and Mu might possess a 
conformational epitope that requires the presence of both the Ig-like and the 
Fz domain. Alternatively, they could bind to a stretch of amino acids or 
continuous epitope located at the junction of these two domains. This could be 
further investigated by other methods of epitope mapping, such as peptide 
library ELISA.  
Clone F stands out as the only chimeric antibody able to bind the Fz domain 
alone; which is a notable feature as it has been shown that it is through the Fz 
domain that Wnt5a mediate its signalling (Fukuda et al., 2008). Furthermore, 
none of our antibodies targeted the Kg domain of ROR1. This is not surprising 
as human and rat have a sequence identity of 99% for these two domains, as 
revealed by UniProt alignment (data not shown).  
Although the gold standard for epitope mapping is x-ray analyses of 
antigen:antibody complexes, this technique requires a high degree of 
instrumentalisation and expertise. Plus, it is not readily applicable to many 
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antigens and antibodies (Gershoni et al., 2007). Hence, the identification of 
binding domains by the use of cell lines expressing truncated domains of 
ROR1 was particularly suitable; with the additional advantage that it allows the 
study of both discontinuous (conformational) and continuous (linear) epitopes.  
I then investigated the binding kinetics of our chimeric antibodies by surface 
plasmon resonance (Biacore systems), and found that all tested clones had 
nanomolar affinities. Unfortunately, KD values for clones V and Mu could not 
be calculated as their binding kinetics were not able to be determined. A 
possible explanation for this might be the complex interaction of these clones 
with ROR1. This is consistent with flow cytometry data which showed both 
modest and difficult binding to ROR1, possibly caused by a discontinuous 
epitope. 
Out of the 10 clones successfully analysed by SPR, clones B5, A and Pi 
possessed the strongest affinities: 1.51, 1.81 and 1.98nM, respectively. 
Interestingly, the only antibody targeting the Fz domain (clone F) showed the 
lowest KD value (5.46nM).  
Since the overriding goal of this thesis is to develop an anti ROR1-based 
approach for cancer immunotherapy, the next step was to evaluate the 
cytolytic activity of our antibodies by CDC. ROR1 antibodies have been first 
shown to elicit cytotoxicity on samples from patients with chronic lymphocytic 
leukaemia (CLL) (Borcherding et al., 2014, Choi et al., 2015, Daneshmanesh 
et al., 2012, Lapalombella et al., 2010, Widhopf et al., 2014). Accordingly, all 
12 of our chimeric antibodies on CLL samples were tested and it was found 
that clone A was the only antibody able to produce significant CDC activity 
after 2h. Rituximab however showed a more potent cytotoxicity under the 
same conditions. It is hypothesised that the low CDC activity exerted by all the 
other clones might be due to low ROR1 antigen density on target cells coupled 
with low antibody affinity.  
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Naked antibodies exert their cytotoxic activity mainly through the activation of 
the immune system via their Fc region (Scott et al., 2012). Antibody-drug 
conjugates (ADCs), on the other hand, combine the specificity of monoclonal 
antibodies and the toxicity of, predominantly, chemotherapeutic drugs (Peters 
and Brown, 2015). This feature may be particularly advantageous as its 
therapeutic effect do not rely on the immune system of cancer patients. I 
therefore set out to explore if any of our clones was an internalising antibody. 
Internalisation was first studied by flow cytometry. Data showed that out of all 
tested antibodies, clones V, F and A showed MFI reduction after 1h incubation 
at 37°C, using cells that express endogenous ROR1 (SKW 6.4). In this context, 
MFI reduction could be explained by either dissociation or internalisation (Yang 
et al., 2011); as a result, these clones were evaluated further. 
To distinguish between dissociation and internalisation, Phenylarsine oxide 
(PAO), an endocytosis inhibitor, was included in these studies. The key 
advantage of PAO is that it blocks the main types of endocytosis by which 
RTKs get engulfed into the cells, namely CME and macropinocytosis (Doherty 
and McMahon, 2009). Furthermore, when used at concentrations <20µM, it 
does not significantly interfere with other cells functions (Gibson et al., 1989). 
In my experiments, PAO was used at 10µM as it has been shown that this 
concentration is enough to inhibit endocytosis (Gibson et al., 1989, Yang et 
al., 2011). 
PAO inclusion revealed that both dissociation and internalisation were 
responsible for the MFI reduction seen in all three antibodies. Experiments 
performed on both SKW 6.4 and CLL cells showed more clearly that despite 
this combination of factors, dissociation was the main feature for clone V. Also, 
dissociation partially explained the drop in MFI levels for clone F and, to a 
lesser extent, clone A. Consequently, internalisation was the main contributing 
factor for the latter, as evidenced by almost complete blocking of MFI reduction 
at the 2h time point, particularly on SKW 6.4 cells.  
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To validate these observations, clone A (aka SA1) was conjugated to 
AlexaFluor488 using a novel site-selective linker developed by Dr 
Chudasama’s research group. This so-called “click” reaction is particularly 
useful in ADC technology, as it significantly reduces the levels of heterogeneity 
usually responsible for the lack of efficiency seen in some ADC preparations, 
without negatively affecting antibody properties (Maruani et al., 2016, Nunes 
et al., 2015, Maruani et al., 2015). Through this collaboration, clone SA1-
AF488 was produced, and subsequently tested on Jeko-1 cells, which also 
express endogenous ROR1. 
Prior to internalisation experiments, I sought to verify that conjugation of SA1 
-using the same “click” reaction applied to ADCs- did not affect its binding to 
ROR1. To this end, a head-to-head comparison of: i) SA1 antibody dialysed in 
PBS, ii) SA1 antibody dialysed in Borate buffer, pH 8.0 and iii) SA1-AF488 
dialysed in the latter buffer was performed. Flow cytometry data showed that 
conjugation of AlexaFluor488 to SA1 did not alter antibody binding. However, 
the change in dialysis buffer, from PBS to Borate buffer, pH 8.0 seemed to 
visibly affect the efficiency of antibody-antigen recognition.  
Internalisation was then investigated by exploiting the quenching effect that 
Trypan blue (TB) has on extracellular compounds labelled with a fluorophore 
detectable in the FITC channel, such as AlexaFluor488 (Sahlin et al., 1983, 
Thiele et al., 2001). Although the precise mechanism of quenching remains 
unclear, it is known that TB is able to absorb light in the range of FITC when 
bound to proteins (Thiele et al., 2001). Due to its physico-chemical properties, 
TB cannot pass intact membranes of live cells. Thus, the recorded 
fluorescence strictly originates from internalised antibody in viable cells (Thiele 
et al., 2003, Patino et al., 2015) 
Flow cytometry data after TB addition confirmed previous observations, 
whereby a combination of both dissociation and internalisation were detected. 
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Internalisation however was again identified as the main contributing factor for 
clone SA1-AF488, as evidenced by signal detection in the presence of TB. 
Lastly, a third approach was used to validate internalisation of clone SA1: 
pHAb dye labelling. This method uses pH sensor dyes that have virtually no 
fluorescence at neutral pH but become highly fluorescent at acidic pH, such 
as that found inside cellular vesicles (Nath et al., 2016). Clones F and SA1 
were labelled with these pHAb dyes, and internalisation was assessed on both 
SKW 6.4 and Jeko-1 cells over a 24h period. Data confirmed that both 
dissociation and internalisation take place for both antibodies; being 
dissociation the main explanation for clone F and internalisation for SA1 
antibody. 
It is worth mentioning that using a visual approach such as confocal 
microscopy would have been more informative and would have probably 
provided conclusive data. Unfortunately, this methodology was not readily 
available in our lab at that stage of this thesis. Nonetheless, taken together, 
these data suggest that: i) clone F, due to its binding to the Fz domain, and ii) 
clone SA1, due to its CDC activity and internalisation profile might have 
therapeutic potential and merit further investigation.  
4.4.1 Conclusions 
- A total of 10 ROR1 chimeric antibodies specifically recognise the Ig-like 
extracellular domain of ROR1. 
- Clone F is the only ROR1 antibody that binds to the Fz domain.  
- Clones V and Mu seem to either recognise the portion between the Ig-
like and the Fz domains, or a conformational epitope formed only when 
both domains are present.  
- All tested clones presented nanomolar affinities. Of these, clones B5, A 
and Pi possessed the highest KD values, unlike clone F, which had the 
weakest affinity.  
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- Further optimisation of Biacore analyses for clones V and Mu is needed 
in order to successfully determine their binding kinetics. 
- Clone A was the only chimeric antibody to elicit significant CDC activity 
on CLL primary cells, although it was not as potent as the one produced 
by Rituximab. 
- Dissociation was found to be the main cause for MFI reduction of clone 
V, and partially for clones F and A. Accordingly, internalisation was the 
main contributing factor on the disappearance of clone A from the cell 
surface.  
- The latter observations were further confirmed by direct conjugation of 
clone A (aka SA1) to AlexaFluor488 fluorophore, and by labelling of 
clones F and SA1 using pHAb amine dyes.  
- Clones F and SA1 will be investigated further in the next chapters. 
4.4.2 Future work 
More extensive characterisation of our ROR1 antibodies is needed in order to 
identify relevant tools for investigative research or for diagnostic applications. 
A key step in this process is to perform antibody profiling using different assay 
systems (Nelson et al., 2000). This is of particular importance as some 
antibodies may perform well in some systems but not in others. Briefly, this 
relates to how an antibody binds its target epitope in the context of the system 
used, a phenomenon known as assay restriction (Jefferis et al., 1985).  
With regards to internalisation assays, confocal microscopy would be a 
preferable approach over flow cytometry as it would not only allow the 
investigator to visually assess antibody internalisation, but -depending on the 
staining strategy- it would potentially provide with information of antibody 
trafficking inside the cell. 
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Chapter 5 Further analysis of clones F and SA1 
5.1 Introduction 
Flow cytometry data presented in Chapter 4 showed that clones SA1 and F 
bound to the Ig-like and Frizzled (Fz) domains of ROR1, respectively. Here, 
the first aim was to further investigate the uniqueness of binding of these two 
clones by four different methods: i) peptide library ELISA, ii) Western blot, iii) 
single amino acid mutations, and iv) flow cytometry-based competition assays. 
Based on previous CDC screening data, the second aim was to focus 
cytotoxicity studies on clone SA1. To this end, its CDC activity on cell lines and 
primary cells from both CLL patients and healthy donors was assessed. 
Importantly, for these evaluations, purified SA1 antibody at standard 
concentrations previously reported in pre-clinical studies (Barth et al., 2015, 
Herter et al., 2013) was used. 
Lastly, in order to enhance its therapeutic potential, the third aim involved 
humanisation of the variable regions of clone SA1 through collaboration with 
GenScript. In the following sections, findings obtained from: i) fusion of 
humanised variable domains to human constant regions (IgG1, k), ii) binding 
analyses of humanised antibodies to ROR1-expressing cells by flow 
cytometry, and iii) cytotoxicity assays of the novel humanised clones on 
primary cells from CLL patients and healthy donors will be discussed. 
Cytotoxicity potential was again evaluated through a CDC assay; where clone 
SA1 and two clinically approved anti-CD20 antibodies were used for 
comparison.  
Of note, clone F was also chosen for humanisation. Unlike SA1, and based on 
its cytotoxicity as a full IgG antibody, the therapeutic potential of clone F was 
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explored using solely antibody derivatives, such as chimeric antigen receptors 
(CARs) and bispecific T-cell engagers (BiTEs) by other members of our group.   
Since humanisation is a pivotal step in the development of therapeutic 
antibodies, and considering that the majority of approved monoclonal 
antibodies used in cancer therapy are humanised antibodies (Pillay et al., 
2011), a brief introduction on this subject is provided below. 
5.1.1 Humanisation of monoclonal antibodies  
As discussed in Chapter 3, the first attempt to reduce unwanted 
immunogenicity of mouse-derived antibodies involved genetic engineering 
techniques that resulted in the generation of chimeric mouse-human 
antibodies (Boulianne et al., 1984). Nevertheless, it has been reported that, in 
some cases, chimeric antibodies were still able to prompt a human anti-
chimeric antibody (HACA) response (Hwang and Foote, 2005). Therefore, the 
next logical step was to further engineer chimeric antibodies in order to 
produce humanised binders. 
In general, humanised antibodies possess a protein sequence that is 
essentially identical to that of a human variant, except for the non-human origin 
of its complementarity determining region (CDR) segments. The latter are 
essential for antibody recognition and subsequent binding to the epitope of its 
target antigen (Wootla et al., 2014).  
So far, researchers have developed several rational approaches in order to 
produce humanised monoclonal antibodies (Safdari et al., 2013), among them: 
CDR-grafting, framework (FR) shuffling (Dall'Acqua et al., 2005), resurfacing 
(Padlan, 1991), and super-humanisation (CDR homology) (Tan et al., 2002). 
I will focus the rest of this brief introduction to CDR-grafting, as this was the 
first method developed for humanisation purposes (Jones et al., 1986); and, 
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to date, remains widely-used in the field. Notably, CDR-grafting has been used 
to generate most of the humanised antibodies currently available in the clinic 
(Safdari et al., 2013).  
5.1.1.1 CDR-grafting 
CDRs are the segments within the variable regions of an antibody responsible 
for antigen recognition. The CDR-grafting approach therefore involves 
insertion of the appropriate non-human CDRs into a human antibody “scaffold” 
(human framework sequences). As a result, this humanisation method may 
have some structural consequences that can potentially produce 
conformational changes, ultimately affecting antigen binding affinity 
(Dall'Acqua et al., 2005). Importantly, an approach that is regularly used to 
circumvent this issue is the identification of human FRs with the highest 
homology to the FR regions of the non-human antibody. By the use of these 
potential FR acceptors, CDR conformation and V domain orientation is likely 
to remain unaffected. (Safdari et al., 2013, Cheung et al., 2012).  
One of the most relevant examples of humanised antibodies produced using 
this approach is Alemtuzumab, an anti-CD52 antibody, originally used in the 
treatment of CLL patients (Lozanski et al., 2004). In line with this and other 
monoclonal antibodies used in cancer therapy, CDR-grafting was the method 
of choice for humanisation of our own ROR1 antibodies. 
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In Fig. 5. 1, a schematic representation of the humanisation process of a rat 
monoclonal antibody is presented.  
 
5.2 Aims 
1. To perform a fine epitope mapping in order to ascertain the specific 
amino acids targeted by clones SA1 and F.  
2. To assess the complement-dependent cytotoxicity (CDC) in vitro of 
purified SA1 antibody using cell lines and primary cells from CLL 
patients and healthy donors.  
3. To generate humanised antibodies against ROR1 based on SA1’s 
protein sequence (in collaboration with GenScript); and to assess their 
binding to ROR1 and evaluate their cytotoxicity on primary CLL and 
healthy donor cells by direct cell death, CDC, and ADCC assays.  
  
Fig. 5. 1. Schematic humanisation process of chimeric rat-human MAbs by CDR-grafting. 
Humanised antibodies derived from rat-human chimeric versions still possess rat CDRs that have been 
grafted in human framework acceptor sequences, thereby significantly reducing unwanted 
immunogenicity. CDR= Complementarity determining region. 
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5.3 Results 
5.3.1 Aim 1: Fine epitope mapping: Clones F and SA1  
To further investigate whether clones SA1 and F were able to detect a unique 
epitope (i.e. distinct from the ones recognised by clones previously reported in 
the literature), four different approaches were undertaken:  
5.3.1.1 By overlapping peptide-library ELISA: In collaboration with Mimotopes Ltd 
Monoclonal antibodies can detect continuous (linear) or discontinuous 
(conformational) epitopes (Nelson et al., 2000). In order to investigate the 
former, an overlapping peptide library based on the extracellular portion of 
ROR1 (Fig. 5. 2) was synthesised in collaboration with Mimotopes Ltd. 
 
Fig. 5. 2. Extracellular ROR1 (eROR1). (A) Schematic of the extracellular portion of ROR1, 
indicating its three domains. (B) Alignment of human, mouse and rat amino acid sequences of 
eROR1. The regions encoded by these sequences are annotated. Ig-like= Immunoglobulin-like, 
Fz= Frizzled, Kg= Kringle. 
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Mimotope’s ROR1 peptide library contained more than ninety overlapping 
peptides.  Each peptide was composed of biotin (at the N-terminal), followed 
by a linker that connected it to a sequence of 11 amino acids (aa) of eROR1, 
followed by an amide group (NH2) at the C-terminal (See Fig. 5. 3A). Of note, 
each 11-aa peptide had 8 amino acids that overlapped the previous peptide 
whilst introducing 3 new aa to its sequence. 
Lyophilised eROR1 peptides were solubilised in 50% Acetonitrile and 
processed for ELISA evaluation as described in the Materials & Methods 
section (Chapter 2). Briefly, 96-well plates were coated with NeutrAvidin, 
blocked with 1% sodium caseinate and washed thoroughly before incubation 
with the solubilised peptides. After 1h incubation, plates were washed again 
and incubated o/n with clones SA1 and F. On the next day, plates were washed 
and incubated for 1h with an anti-human IgG antibody conjugated to 
horseradish peroxidase (HRP).  Plates were washed, and antibody signal 
detected with Tetramethylbenzidine (TMB); the reaction was then stopped with 
H2SO4. A graphic representation of this sandwich ELISA can be found in Fig. 
5. 3B. 
In Fig. 5. 3C, the reactivity of clones SA1 and F to the overlapping peptides by 
ELISA are shown. As expected, clone SA1 produced a clear and defined peak 
in peptides 13-17, which corresponded to the apical portion of the Ig-like 
domain. This data is consistent with previous observations obtained by flow 
cytometry (Chapter 4). Peaks below an absorbance (Abs) value of 0.5 were 
considered background as even the negative control (peptide and antibody 
provided by Mimotopes) had an absorbance value of approximately 0.4. In 
contrast, the absorbance produced by the positive control (also provided by 
Mimotopes) reached a peak value of 1.0 as did SA1 with peptides 13-17. 
Clone F, on the other hand, did not produce any relevant peaks above 
background, although positive and negative controls worked accordingly. 
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Independent repeats of this experiment confirmed this observation, which led 
me to hypothesise that clone F might not have a continuous epitope.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. 3. Epitope mapping of ROR1 clones SA1 and F by peptide-library ELISA. (A) Structure of 
biotinylated ROR1 peptides. Each one was composed of: Biotin (at the N-terminal), linker (SGSS), 11 
amino acids, and an amide group (NH2) at the C-terminal. The position of overlapping amino acids are 
highlighted in yellow. (B) Schematic of the sandwich ELISA approach used for epitope mapping. (C) 
Reactivity of clones SA1 and F with ROR1-derived overlapping peptides. Different colours indicate the 
domain the peptides encoded for. Positive (green) and negative (red) control peptides and antibodies 
were provided by Mimotopes. Experiments were done in triplicates. One out of three independent 
experiments is shown. Red arrow indicates binding to relevant peptides. Peaks below 0.5 Abs were 
considered background. Error bars represent SD. 
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Although clone F produced two detectable peaks in the Fz domain (Fig. 5. 3C), 
they were considered irrelevant as they appeared around peptides number 65-
68 and 90-93 (already identified as background in clone SA1 analysis). Also, 
their Abs value was near or below the 0.5 criterion. This dataset suggested 
that whilst clone SA1 had a linear epitope in the apical region of the Ig-like 
domain, clone F had potentially a discontinuous epitope, making it 
undetectable by peptide library ELISA. 
5.3.1.2 By Western Blotting  
Previous results obtained by peptide library ELISA led me to investigate 
whether clones SA1 and F had conformational epitopes. To this end, soluble 
extracellular ROR1 protein was run in SDS-PAGEs under reducing and non-
reducing conditions for Western blot analysis. Clones SA1 and F were then 
used to detect soluble ROR1 followed by incubation with a relevant secondary 
antibody conjugated to HRP (Fig. 5. 4). 
 
Fig. 5. 4. Investigation of conformational epitopes by Western Blot. SDS-PAGE was 
carried out using soluble extracellular ROR1 protein under reducing (80-110kDa) and non-
reducing (>110kDa) conditions. After protein transfer, membranes were incubated with clones 
SA1 and F, and binding was detected by anti-human IgG conjugated to HRP. kDa values are 
included for protein size reference. Red arrows indicate the expected size of ROR1 detected 
under reducing conditions. HRP= Horseradish peroxidase  
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In Fig. 5. 4, strong detection of eROR1 run under non-reducing conditions 
(>110kDa) could be seen when either SA1 or F were used. However, under 
reducing conditions (i.e. when the disulphide bridges were disrupted leaving 
ROR1 in its primary/secondary structure), only SA1 was still able to detect the 
protein. Consistent with previous data, clone F did not bind to reduced ROR1, 
as evidenced by the absence of a ROR1 band at 80-110kDa (red arrows).  
Similarly, when cell lysates from ROR1- and ROR1+ cell lines (expressing full 
length or truncated extracellular domains of ROR1) were assessed by Western 
Blot, clone F was able to detect ROR1 only when samples were run in non-
reducing conditions. Clone SA1, in contrast, bound to reduced and non-
reduced samples with the same efficiency (See Fig. 5. 5). 
Taken together, peptide library ELISA and Western blot data indicated that 
clone SA1 binds to a continuous (linear) epitope in the Ig-like domain of ROR1, 
whereas clone F detected a discontinuous (conformational) epitope in the 
Frizzled domain. However, the essential amino acids needed for ROR1 
recognition still needed to be identified. 
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5.3.1.3 By single amino acid point mutations  
To ascertain the critical amino acids required for clones SA1 and F recognition 
of ROR1, the next experiments were planned based on data previously 
obtained by flow cytometry, peptide library ELISA and Western blot. 
Since clone SA1 bound to the Ig-like domain, specifically to peptides 13-17, I 
analysed their sequences and identified the top 3 amino acids most likely to 
be involved in ROR1 recognition (within a 5aa region contained in the 13-17 
peptides). By DNA splicing techniques, primers were designed in order to 
introduce each of the three single amino acid mutations or all five together. 
Mutated sequences were cloned by Phusion PCR into retroviral plasmids 
already present in the lab (See Chapter 2). This cloning strategy allowed the 
generation of four new constructs: “Point mutation 1”, 2 and 3, and “5aa 
mutation”. All constructs carried a GFP reporter gene. Correct cloning was 
verified by restriction enzyme digestion and sequencing. 
Once the correct sequences were obtained, retroviral supernatants were 
prepared by transient transfection of HEK293T cells. 72h post transfection, 
supernatants were harvested and used for transduction of SUP-T1 NT cells on 
RetroNectin-coated plates. Similarly, 72h later, GFP expression was assessed 
by flow cytometry in order to confirm successful transduction (Fig. 5. 6A).  
Fig. 5. 6B, shows the binding of clone SA1 to the newly generated stable cell 
lines expressing different mutations in the Ig-like domain of ROR1. Also, since 
Jeko-1 (Mantle-cell lymphoma - MCL) and PCL-12 (Chronic lymphocytic 
leukaemia - CLL) cell lines expressed high and low levels of endogenous 
ROR1, respectively, they were included in this analysis as reference. 
Additionally, clones 4a5 and R12 (anti-ROR1 antibodies previously reported in 
the literature) were also included in order to evaluate whether they shared 
epitopes with clone SA1. Furthermore, the patent of clone D10, the prototype 
of Cirmtuzumab (the ROR1 MAb currently in the clinic) became available at 
this point of the project. Therefore, I cloned its sequence into hIgG1, kappa 
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retroviral vectors in order to put it in the same chimeric format as our ROR1 
antibodies. Binding of chimeric D10 to the cell lines mentioned above was also 
assessed. 
  
Fig. 5. 6. Epitope mapping of SA1 MAb by single amino acid mutations using flow cytometry. 
(A) Stable cell lines expressing relevant mutations in the Ig-like domain were generated by retroviral 
transduction of SUP-T1 NT cells. GFP expression was evaluated in order to assess transduction 
levels. (B) Clone SA1 binding was tested on all four new stable cell lines expressing different 
mutations in the Ig-like domain. Jeko-1 UT and PCL-12, which endogenously express high and low 
levels of ROR1 respectively, were included in our studies as reference. The secondary antibody 
alone (anti-human IgG-DyLight647) acted as negative control. Also, previously reported clones 
R12, 4a5 and the newly available D10 were also included for comparison. Red circles indicate cell 
lines expressing crucial mutations disrupting SA1 binding to ROR1. 
A. 
B. SA1 
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Flow cytometry data shows that “Point mutation 1” critically affected the 
binding of SA1 to the Ig-like domain, although weak ROR1 binding was still 
detectable. In contrast, no binding was observed on cells expressing “Point 
mutation 2”. There was also no binding to the “5aa mutation” cell line as it 
contained “Point mutation 2”. Importantly, binding of 4a5, R12 and D10 to 
ROR1 was not affected by any of the mutations. Thus, this data indicated that 
clone SA1 binds to a unique epitope in ROR1 that is not shared with other anti-
ROR1 antibodies. 
With regards to clone F, previous results indicated that it bound to the Fz 
domain of ROR1 and that it recognised a conformational epitope. Having no 
further information on potential binding regions within this domain, I aligned 
the amino acid sequences encoding for rat, mouse and human Fz in order to 
identify probable relevant amino acids (Fig. 5. 2).  
Two non-conserved amino acids were found, which were therefore potentially 
involved in clone F binding. Thus, as with clone SA1, I used DNA splicing and 
cloning techniques to generate three new retroviral constructs: “Point mutation 
F1”, F2, and “Mutation F1+F2”. Restriction enzyme digestions and sequencing 
were used to confirm correct cloning. As mentioned above, retroviral 
supernatants were produced and used to transduce SUP-T1 NT cells. These 
constructs also carried GFP as reporter gene, therefore transduction levels 
were assessed by GFP expression (Fig. 5. 7A).  
Having confirmed good levels of transduction, clone F was tested on the three 
new stable cell lines by flow cytometry (Fig. 5. 7B). SUP-T1 cells expressing 
wild-type Fz were also tested and included in these studies as positive control, 
whilst staining with the secondary antibody alone acted as negative control.  
Flow cytometry data showed that “Point mutation F1” did not affect F detection 
of ROR1. However, this clone was not able to recognise cells expressing either 
“Point mutation F2” and, consequently, “Mutations F1+F2”. These results 
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confirm that clone F binds to the Fz domain of ROR1 and that “Point mutation 
F2” but not F1 is critical for the formation of its discontinuous epitope. Of note, 
binding to ROR1 by clone F was not compared to other reported clones, as all 
anti-ROR1 antibodies and/or their derivatives that are currently in clinical trials 
bind to the Ig-like domain; making clone F a unique tool for ROR1 
immunotherapy 
 
A. 
B. 
Fig. 5. 7. Epitope mapping of F MAb by single amino acid mutations. (A) Stable cell lines 
expressing relevant mutations in the Fz domain were generated by retroviral transduction of SUP-T1 
NT cells. GFP expression served to assess transduction levels. (B) Clone F binding was tested on all 
three new stable cell lines. The secondary antibody alone (anti-human IgG-DyLight647) acted as 
negative control. Cell expressing wild-type Fz (Fz SUP-T1) were included as positive control. Red 
circles indicate cell lines expressing crucial mutations disrupting F binding to ROR1. Fz= Frizzled. 
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5.3.1.4 Competition assay by flow cytometry 
To further confirm whether clone SA1 had a distinct epitope that was not 
shared with other anti-ROR1 antibodies, the binding of SA1 to ROR1 with other 
relevant clones through a flow cytometry-based competition assay was 
performed.  
Based on previous studies (de Jong et al., 2005), it was hypothesised that 
consecutive- and/or simultaneous-staining of ROR1+ cells, using clone SA1 in 
combination with other anti-ROR1 antibodies, would allow the identification of 
any overlapping epitopes by flow cytometry analysis. 
To this end, the variable region of clone SA1 was fused to a mouse IgG2a, 
kappa constants following the same protocols discussed in previous chapters. 
All other chimeric antibodies were kept in their existing rat-human format. This 
was required as it enabled simultaneous detection of the SA1 rat-mouse IgG2a 
antibody and the other anti-ROR1 rat-human IgG1 antibodies using different 
secondary antibodies. Also, for ease of analysis, ROR1+GFP+ cells were used. 
Fig. 5. 8A shows strong ROR1 binding when antibodies were used as single 
agents, which confirmed their correct expression and specificity for ROR1. 
Since SA1 and F antibodies detected different extracellular domains, this 
combination was included in these studies as negative control for overlapping 
epitopes.  
In Fig. 5. 8B, three different columns are presented. Dot plots on the first 
column correspond to ROR1 binding assessed when SUP-T1 ROR1 cells 
were stained with clone SA1 (mIgG) in the first instance. After a washing step, 
cells were stained with a competitor antibody (hIgG), followed by another 
washing step. Both antibodies were then detected by a third staining step using 
the appropriate secondary antibodies. In the second column, a similar 
approach was taken when staining these cells, except that this time it was the 
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antibody in hIgG1, k format the one used for the first staining step, followed by 
SA1 staining. On the third column, both antibodies were used at the same time.  
In all cases, a clear and defined shift of all events was observed; indicating 
that, independent of the order in which cells were stained, antibodies used in 
the first staining step did not impede binding of the antibodies used in the 
second step. This was further confirmed when both antibodies were assessed 
at the same time. Hence, these results confirm that clone SA1 binds to a 
unique epitope within the Ig-like domain, which is not shared (not even 
partially) with any of the other clones tested.  
 
 
Fig. 5. 8. Competition assay by flow cytometry. Clone SA1 in murine IgG2a, k (mSA1) along 
with other ROR1 MAbs in human IgG1, k were used for staining ROR1-transduced cells. MAb 
staining was done as (A) single agents or (B) in combination with clone mSA1. Anti-human IgG 
(eFluor450) and anti-mouse IgG (DyLight649) were used as secondary antibodies. Combined 
staining using clones F and mSA1 acted as negative control for overlapping epitopes. 
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5.3.2 Aim 2: CDC activity of FPLC-purified SA1 antibody 
It has been shown that clone F binds to the Fz domain of ROR1, making it a 
unique tool for ROR1 immunotherapy; however, previous data revealed that 
its cytolytic potential in the antibody format was not significant when compared 
to the isotype control. Therefore, other members of our group explored its 
immunotherapy efficacy in other formats (antibody derivatives).  
In parallel, cytotoxicity studies focused on clone SA1, as previous screening 
of CDC activity (Chapter 4) revealed that this chimeric antibody elicited 
superior cytolysis compared to other ROR1 binders, including clones 4a5 and 
R12. Thus, in the following paragraphs, the CDC activity of SA1 on cell lines 
and primary cells from CLL patients and healthy donors (HD) will be discussed. 
Unlike previous experiments -where culture supernatants were used- a 
10ug/ml dose of purified antibody by Fast Protein Liquid Chromatography 
(FPLC) (Fig. 5. 9) was employed, as per preclinical studies of anti-CD20 
monoclonal antibodies (Herter et al., 2013, Barth et al., 2015). 
Fig. 5. 9. FPLC purification (AKTA) of clone SA1 using a 1ml Protein A column. 293T cells were cultured in 
FBS supplemented IMDM until transfection. 12h after later, co-transfection media was replaced with fresh 
phenol-red free IMDM, supplemented with ultra-low IgG HI-FBS. Prior to FPLC purification, supernatant was 
centrifuged, filtered and dilute with Protein A Binding buffer in a 1:1 ratio. Aliquots taken at every step of the 
purification process were run in a SDS-PAGE and stained with Coomassie dye. Rituximab (Rtx) was used as 
reference. Red arrows indicate heavy and light chain bands. Red square points out the final version of clone SA1 
(i.e. purified antibody after dialysis). 
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CDC activity of clone SA1 was first assessed on B-cell lymphoma cell lines 
expressing high (Jeko-1) or low (SKW 6.4 GFP) levels of ROR1 (Fig. 5. 10A). 
An isotype control and a chimeric anti-CD20 antibody (Rituximab: Rtx) were 
used as negative and positive controls, respectively.  
In Fig. 5. 10A, AnnexinV/PI staining data from cells treated with SA1 (10ug/ml) 
in presence of 10% rabbit complement for 2h, showed that SA1 was able to 
elicit significant cytotoxicity on both cell lines compared to the isotype 
(p≤0.0001). Furthermore, when ROR1 expression was high, similar levels of 
cell killing induced by both SA1 and Rtx (>95% cell death). As expected, for 
ROR1low cells, SA1 cytotoxicity was not as potent (80%) as the one produced 
by Rtx (>95%).  
Next, clone SA1 was tested on PBMCs from healthy donors (Fig. 5. 10B). 
Positive and negative controls were the same as above. As expected, no 
significant cell death was observed for clone SA1. In contrast, a significant 
although small reduction (20%) on anti-CD20-treated PBMCs was detected. 
Finally, SA1 was tested on primary cells from 8 untreated CLL patients, 
expressing different levels of ROR1 (Fig. 5. 10C and Table 5.  1). Significant 
cell death compared to the isotype was observed when CLL cells were treated 
with either clone SA1 (75-98% cell death, p≤0.0001) or Rtx (>98%, p≤0.0001). 
An interesting observation was that correlation between ROR1 density on 
target cells and cytotoxicity was not evident; suggesting that a larger number 
of CLL samples might need to be investigated. 
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Table 5.  1. List of samples from CLL patients.  Treatment, ROR1 expression and 
percentage of live events remaining after SA1 antibody therapy are presented. 
Sample Treatment ROR1, MFI 
Live events 
(after SA1 CDC 
therapy), % 
CLL5  Untreated 198.01 2.85 
CLL1  Untreated 84.9 17.69 
CLL6  Untreated 224.42 8.31 
CLL7  Untreated 144 3.57 
CLL8  Untreated 150.01 19.47 
CLL9  Untreated 164.91 0.13 
CLL10  Untreated 58.22 11.98 
CLL2D  Untreated 276.4 26.57 
Fig. 5. 10. Complement-dependent cytotoxicity of clone SA1 ROR1 MAb on (A) Jeko-1 (Mantle-
cell lymphoma) and SKW 6.4 GFP (EBV-B cells), (B) PBMCs from healthy donors (n=3) and (C) 
CLL cells (n=8). Clone SA1 chimeric MAb was tested at 10ug/ml in the presence of 10% baby rabbit 
complement. CDC was measured by AnnexinV/PI staining. Significant and specific toxicity was 
achieved on ROR1 cell lines and CLL cells, compared to the isotype (p≤0.0001). Rituximab (Rtx) was 
used as positive control (p≤0.0001). Datasets from all 3 panels were normalised and compared to 
the isotype control for statistical calculations. All experiments were done in triplicates. Error bars 
represent SD. Statistical test: 2-way ANOVA with Dunnett’s multiple comparison test. *p≤0.05, 
**p≤0.01, ****p≤0.0001. HD= Healthy donor. PI= Propidium iodide. 
    Chapter 5 
192 
 
So far, the findings of this study indicate that, although less potent than 
Rituximab, clone SA1 was able to elicit significant CDC activity on primary CLL 
cells. However, a further factor to consider is that –although all samples 
expressed the CD20 antigen– cytotoxicity prompted by Rtx (>98%) was higher 
than the one reported by others (60-80% cell death (Kennedy et al., 2004, 
Pawluczkowycz et al., 2009)). Nevertheless, cautiously encouraged by these 
results, a humanisation program for clone SA1 was set up.  
 
5.3.3 Aim 3: SA1 humanisation (in collaboration with GenScript) 
Our research group set up a collaboration with GenScript for the humanisation 
of clone SA1. In the following paragraphs, i) the cloning of humanised variable 
regions into hIgG1, k constants, ii) their binding to ROR1+ cells and iii) their 
cytotoxicity assessed by CDC assay will be discussed. 
5.3.3.1 Cloning 
By using the complementarity determining regions (CDR) grafting method, 
GenScript provided us with 5 VH and 5 VL humanised regions. SA1 rat-derived 
variable domain sequences were searched against the human IgG germline 
database. The top 5 human framework sequences with the highest homology 
to SA1 were chosen as human acceptors for each light and heavy variable 
chains. Amino acid sequences of 5 humanised VH and 5 humanised VL were 
obtained after grafting the CDRs of SA1 to the human acceptor frameworks.  
DNA sequences encoding each humanised region were synthesised (G-
blocks® Gene Fragments <1000bp), whilst primers introducing relevant 
restriction enzyme sites and overlapping sequences were designed in order to 
fuse the humanised variable domains to human constants. As before, DNA 
splicing methods and retroviral vectors already present in the lab were used 
for cloning. This technique allowed the successful generation of 10 constructs 
(i.e. 5 retroviral vectors encoding for each the light (VL1-VL5) and heavy (VH1-
VH5) chains). Correct cloning of all 10 constructs was verified by sequencing.  
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Of note, F antibody was also selected for humanisation. Cloning was 
performed by other members of our group in order to produce clone F in the 
single chain variable fragment (scFv) format but not as a full IgG antibody.  
5.3.3.2 Binding 
To identify the best combination of humanised VL and VH sequences, all 25 
possible combinations of these 10 sequences were used for transfection of 
HEK293T. After 72h, antibodies contained in culture supernatants were 
incubated with SUP-T1 ROR1 cells (GFP+ROR1+).  
To account for differences in transfection levels that could confound these 
analyses, GFP (VH) and BFP (VL) expression of HEK293T cells were also 
evaluated. Flow cytometry data showed that co-transfection levels of all 
constructs were comparable as they ranged between 50-60% (Fig. 5. 11). 
Antibody binding was then detected by flow cytometry using a secondary 
antibody, which also acted as negative control (Fig. 5. 12).  
Fig. 5. 12 illustrates how most of the combinations of humanised constructs 
presented poor or moderate binding to ROR1. Remarkably, all pairings 
involving construct VL1 showed good binding, of which VH1-VL1 and VH3-VL1 
were identified as the best combinations. The latter will be referred to as HuA1 
and HuA3, respectively. 
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Fig. 5. 11. Transfection evaluation of HEK293T co-transfected with humanised SA1 
candidates by flow cytometry. HEK293T cells were co-transfected with 5 different VL (BFP+) 
and 5 VH (GFP+) constructs, which resulted in 25 different combinations. 72h post transfection, 
the GFP and BFP expression of HEK293T cells were assessed by flow cytometry. Transfection 
levels of all pairing ranged between 50-60%. 
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Fig. 5. 12. ROR1 binding of humanised SA1 candidates. HEK293T cells were co-transfected 
with 5 different VL and 5 VH constructs, which resulted in 25 different combinations. 72h post 
transfection, supernatants were harvested and incubated with SUP-T1 ROR1 cells 
(GFP+ROR1+). The anti-human IgG-Dylight647 secondary antibody served as negative control.  
Red circles point to those combinations that showed superior binding to ROR1. 
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Having identified the top two binders, ROR1 detection by flow cytometry was 
compared to the one produced by chimeric rat-hIgG1 clone SA1. Again, the 
secondary antibody served as negative control (Fig. 5. 13).  
Differences in ROR1 binding between clones HuA1 (41%) and HuA3 (43.5%) 
were not observed. However, it was evident that both of them presented 
decreased levels compared to clone SA1, which showed 49.4% binding to 
ROR1+ cells. 
Although flow cytometry data indicated that the humanised candidates 
presented a slight reduction in ROR1 binding, investigation of their cytotoxic 
properties was undertaken.  
  
Fig. 5. 13. Flow cytometry comparison of ROR1 binding of HuA1 and HuA3 
candidates against clone SA1. Chimeric clone SA1 and humanised clones HuA1 and 
HuA3 were incubated with SUP-T1 ROR1 cells (GFP+ROR1+) for comparison. The anti-
human IgG-Dylight647 secondary antibody served as negative control.   
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5.3.3.3 Complement-dependent cytotoxicity (CDC) 
In terms of cytotoxicity, the first step was to assess the CDC activity of the 
humanised clones and compare it to chimeric SA1. To this end, antibodies 
contained in culture supernatants from HEK293T cells were used. These cells 
were transfected at the same time with SA1, HuA1 and HuA3 constructs. Also, 
a hIgG1, k isotype (negative control) and two clinically approved anti-CD20 
antibodies (Rtx= chimeric Rituximab and GA-101= humanised Obinutuzumab) 
were included in these studies for comparison.  
MAbs supernatants from SA1-, HuA1- and HuA3-transfected cells along with 
controls at 0.5ug/ml were incubated with primary cells from 3 CLL patients and 
a healthy donor. An additional control at 10ug/ml (Rtx) was also included (as 
per Chapter 4 – Fig. 4.4). Incubation of MAbs and target cells was performed 
in the presence of 10% rabbit complement for 2h at 37°C and 5% CO2. After 
incubation, cell death was detected by AnnexinV/PI staining using flow 
cytometry. All datasets were normalised and compared to the isotype control 
for statistical tests (Fig. 5. 14A). 
Data shown in Fig. 5. 14A indicate that both chimeric and humanised clones 
produced statistically significant cell death compared to the isotype control; 
albeit SA1 still presented superior CDC activity than both HuA1 and HuA3 
clones.  
Similarly, Rtx (at both concentrations) and GA-101 elicited significant 
cytotoxicity compared to the isotype. As expected, Rtx exhibited a more potent 
cytotoxicity than GA-101 as the latter is known to possess a weak CDC (Herter 
et al., 2013). In both cases, however, reduced cell killing was observed when 
these MAbs were tested on “CLL3”. The latter observation is consistent with 
the poor CD20 expression found on “CLL 3” cells (Fig. 5. 14B). 
Also, since the samples, method and assay illustrated in Fig. 5. 14A were the 
same as the one presented previously in Fig. 4.4 -where the CDC activity of 
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all chimeric antibodies was assessed- data showing those results have been 
included for illustrative purposes (Fig. 5. 14C). 
Although all ROR1 antibodies evaluated in this experiment displayed 
significant cytotoxicity, there was a noticeable difference between the CDC 
activity of SA1 and the humanised clones, particularly with clone HuA1. This 
might be explained by the reduced binding of HuA1 and HuA3 to ROR1, seen 
in Fig. 5. 13. 
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As a whole, these data suggest that after the humanisation program, SA1-
derived clones HuA1 and HuA3 had a decreased binding to ROR1. Not 
surprisingly, the significant CDC activity seen previously with chimeric SA1 
was reduced in its humanised versions.   
In an effort to counteract this lack of cytotoxicity, bispecific antibodies in full 
IgG targeting either ROR1 and CD3 or ROR1 and PD-1 format were generated 
(Kim et al., 2016b) (See Fig. 5. 15A). These constructs were tested on three 
solid cancer cell lines by co-culturing them with effector cells (PBMCs from 
healthy donors) (Fig. Fig. 5. 15B). Unfortunately, MTS assay data suggested 
non-specific binding of clone SA1 to ROR1- cells (MCF-7, breast cancer), 
which led to non-specific cytotoxicity. These results were confirmed by 
independent experiments and ELISA quantification of interferon-gamma (IFN-
γ) and interleukin 2 (IL-2) cytokines (Fig. Fig. 5. 15C).  
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To test for non-specific binding to MCF-7, both clones SA1 and F were 
incubated with these cells, and binding was evaluated by flow cytometry (Fig. 
5. 16). Also, gene and protein analyses performed on these cells showed no 
presence of ROR1, confirming non-specific binding of SA1 but not clone F to 
MCF-7 cells. These findings were unexpected as non-specific binding was not 
detected previously when suspension cell lines or PBMCs from healthy donors 
were assessed. 
 
All in all, no further studies with this reagent were pursued and instead my 
investigation focused on an antibody derivative generated by using clone F 
scFv. 
  
Fig. 5. 16. ROR1 MAbs binding to MCF-7 cells (ROR1-) assessed by flow cytometry. MCF-7, a 
ROR1- breast cancer cell line, was stained with SA1 or F antibodies. Commercial ROR1 antibody, 
clone 2a2 conjugated to APC, was also used for comparison. Relevant isotype controls, and the 
secondary antibody (anti-hIgGDyLight647) used to detect binding of unlabeled clones, served as 
negative controls. Binding was quantified by flow cytometry. Negative controls were used for gating. 
Independent repetitions of this experiment were performed. 
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5.4 Discussion 
Based on data from this and previous chapters, it has been established that 
clone SA1 binds to the Ig-like segment of ROR1, whereas clone F binds to its 
Fz domain. However, the specific epitopes of both antibodies still needed to 
be identified. 
In collaboration with Mimotopes Ltd, the first approach was to generate a 
library of biotinylated and overlapping peptides covering the extracellular 
portion of ROR1. One of the main advantages of this method is that it allows 
high throughput and quantitative analysis for identification of linear epitopes. 
Moreover, the presence of a linker between the biotin end and the actual 
peptide minimises steric hindrance to binding (Ltd). These features proved 
particularly useful for clone SA1, as data obtained from this approach 
narrowed down the search of SA1’s epitope to three peptides within the Ig-like 
domain. 
In contrast, when clone F was evaluated using the same platform, no binding 
was detected. Consistent results after independent repetitions of this 
experiment led to the hypothesis that clone F did not have a continuous but a 
conformational epitope. Intrigued by this possibility, soluble ROR1 protein was 
run under reducing (R) and non-reducing (NR) conditions on a Western blot 
(SDS-PAGEs). The presence of SDS in the polyacrylamide gels implied that 
although run under non-reducing conditions, soluble ROR1 protein was not in 
its native form. The absence of a reducing agent (such as β-Mercaptoethanol), 
however, meant that no disulphide bridges were disrupted. This explains the 
appearance of a higher molecular weight for ROR1 in the NR gels, since these 
conditions conveyed some 3D structure to the protein, although still minimal 
compared to native gels.  
Consistent with this, the 3D structure still present in soluble ROR1 allowed the 
binding of clone F to its conformational epitope. In contrast, when ROR1 was 
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run under reducing conditions, F binding was not detected. These results were 
further confirmed when cell lysates expressing full-length ROR1 or its 
truncated domains were run in SDS-PAGEs using the same methodology. 
Together, Western blot analyses confirmed clone F detected a discontinuous 
epitope in the Fz domain of ROR1. 
I next investigated the specific amino acids required for ROR1 binding. Data 
obtained from different approaches was collated in order to identify the most 
likely binding regions within the Ig-like and the Fz domains. Using this rational 
approach, retroviral vectors bearing single aa mutations within selected 
regions were generated. Importantly, amino acid substitutions were carried out 
using non-conservative mutations, whereby substituting amino acids were 
chosen based on the dissimilarity between them and the wild-type aa in terms 
of structure and the chemical characteristics of their side chains (R groups) 
(Yampolsky and Stoltzfus, 2005). As a result, this approach allowed the exact 
identification of those aa that were essential for the binding of clones SA1 and 
F to ROR1. 
Currently, there are other research groups working on ROR1 antibody-based 
immunotherapies, and some of their binders have resulted in the development 
of: i) a therapeutic antibody (Cirmtuzumab) (Choi et al., 2015) or ii) antibody 
derivatives such as CARs (Deniger et al., 2015, Berger et al., 2015). Clinical 
trials are now on-going or about to start in order to assess whether these 
products are able to achieve a significant clinical benefit on cancer patients, 
particularly those affected by CLL. With this in mind, one of the aims of this 
study was to differentiate our own ROR1 antibodies from the binders 
developed elsewhere. 
Clone D10, the prototype of clone UC-961 (Cirmtuzumab), and the scFv of 
clones 4a5 and R12 (used for CAR therapy) bind to the Ig-like domain of 
ROR1, as does clone SA1. Therefore, to verify that the epitope of SA1 was not 
shared with any other reported clone, competition assays were performed by 
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flow cytometry; where the combination of SA1 and F antibodies were used as 
negative control for overlapping epitopes. 
Consistent with previous findings, no reduced binding was observed when 
different pairings of reported antibodies and SA1 were used. This data 
indicated no epitope overlap, confirming the uniqueness of SA1 antibody. 
Another interesting observation was the shift produced when clones F and SA1 
were used together. Approximately 20% of the live events did not shift to the 
double positive quadrant. A likely explanation is the lower affinity of clone F 
towards ROR1, discussed in the previous chapter.   
Having established the uniqueness of both of our antibodies, I sought to 
determine the CDC activity of SA1. Based on pre-clinical in vitro studies of 
other monoclonal antibodies used in cancer therapy (Barth et al., 2015, Bowles 
et al., 2006, Cheney et al., 2014, Herter et al., 2013), purified SA1 was tested 
on CLL cells at 10ug/ml; and its cytotoxicity was compared to the one produced 
by another chimeric binder, Rituximab, a clinically approved anti-CD20 
antibody. Significant CDC activity elicited by both antibodies was observed, 
although the cytotoxicity of SA1 was not as high as Rtx’s. It is considered this 
might be due to the difference in expression between ROR1 and CD20, as 
high antigen density seems to contribute to potent cytotoxicity (Prang et al., 
2005, Velders et al., 1998).   
The next step was to humanise clones SA1 and F in order to increase their 
therapeutic potential. To this end, our collaborators, GenScript, used a CDR-
grafting approach. Certainly, this is a well-established humanisation method 
that has generated many of the therapeutic antibodies currently used in the 
clinic (Safdari et al., 2013). However, one of the major pitfalls of this strategy 
is the potential changes it can cause to CDR conformation, thereby causing 
loss of affinity (Safdari et al., 2013, Dall'Acqua et al., 2005). In line with this, a 
slight decrease of binding and subsequent CDC activity of our humanised 
antibodies compared to SA1 was observed. 
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Albeit reduced, it appears that both humanised clones HuA1 and HuA3 were 
still able to prompt significant CDC of CLL cells. However, as discussed in the 
Introduction section (Chapter 1), other mechanisms of action in terms of 
antibody cytotoxicity exist, such as those provoked by direct antibody binding 
in the absence (direct cell death) or presence of effector cells (ADCC). Assays 
evaluating these two mechanisms remain to be assessed. 
Up to date, these two mechanisms of killing using ROR1 MAbs have been 
reported before with mixed results. A study by (Yang et al., 2011) showed that 
no significant cytotoxicity was elicited by rabbit-raised ROR1 MAbs, 
suggesting that naked antibodies against ROR1 were not viable as therapeutic 
MAbs. The only publication where ROR1 binders were able to produce direct 
apoptosis on CLL cells was performed on FPLC-purified IgG and IgM murine 
antibodies (Daneshmanesh et al., 2012). However no follow up study on these 
antibodies has been reported. 
Moreover, except for a human tissue cross-reactivity study (Choi et al., 2015), 
the preclinical evaluation of Cirmtuzumab was not based on classicak in vitro 
or ex vivo data, but on in vivo models, amongst them: immunodeficient mice 
(for breast cancer (Cui et al., 2013)), Eµ-TCL1 transgenic mice (CLL (Widhopf 
et al., 2014)) and rodent and non-human primates for off-target or non-ROR1-
specific activity (Choi et al., 2015).  
Being aware of the potential that antibodies with dual specificity offer to the 
advancement of cancer immunotherapy, I developed bispecific antibodies that 
could combine simultaneous targeting of ROR1 and CD3 or ROR1 and PD-1. 
Since other members of our group were developing a similar concept in a BiTE 
format, I decided to design bispecific antibodies in full IgG. The main two 
advantages of this strategy are the extended half-life of the molecule and the 
extra cytotoxic potential this format offers due to Fc-Fc gamma receptor (FcR) 
interactions (Kim et al., 2016b); providing this molecule with a potential three-
fold cytotoxicity. 
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After successful cloning and expression of these new bispecific antibodies, 
their cytotoxicity was assessed by co-culture of ROR1+ and ROR1- solid 
cancer cell lines and PBMCs from healthy donors. Unfortunately, non-specific 
binding and cytotoxicity of a ROR1- breast cancer cell line (MCF-7) was 
detected. Independent experiments and cytokine data confirmed non-
specificity of SA1.  
It is hypothesised this might be due to a number of reasons. In some cases, 
although a single B-cell produces a monoclonal antibody with exquisite 
specificity, this antibody can crossreact with other antigens or exhibit dual 
specificity. This could be caused by similarity in shape or chemical composition 
of the epitope (Nelson et al., 2000). Also, the fact that the epitope of an 
antibody is a short linear peptide, does not mean it is not part of a particular 
conformation (Gershoni et al., 2007). Furthermore, SA1 antibody detects the 
apical region of the Ig-like portion of ROR1. Genomic analyses have shown 
that membrane proteins with Ig-like domains (immunoglobulin superfamily) are 
extremely abundant (Barclay, 2003). Moreover, this domain has evolved to be 
particularly good at being recognised as it is involved in many different kinds 
of protein interactions.  
Taken these data as a whole, studies using clone SA1 or its humanised 
versions were stopped. Research focused instead on the investigation of the 
therapeutic potential of a BiTE antibody based on humanised F and anti-CD3. 
Data from these studies will be explored in the next chapter. 
5.4.1 Conclusions 
- Peptide library ELISA indicated that clone SA1 detected a continuous 
epitope located in the apical region of the Ig-like domain of ROR1. 
- Single amino acid mutations in said domain, and flow cytometry-based 
competition assays confirmed that SA1 recognised a particular epitope 
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that is not shared with other anti-ROR1 antibodies reported in the 
literature.  
- In turn, I found that clone F did not possess a linear but a discontinuous 
epitope, as revealed by both peptide library ELISA, and Western Blot 
run under reducing and non-reducing conditions. 
- Single amino acids mutations allowed me to identify the amino acid 
within the Fz domain that is crucial for F binding to ROR1. 
- The latter confirmed that clone F is a unique antibody, able to detect a 
different domain in ROR1 compared to all the ROR1 antibodies (and/or 
their derivatives) currently used in the clinic.  
- CDC activity of clone SA1 assessed at 10ug/ml concentration revealed 
potent in vitro cytotoxicity of ROR1+ cell lines and primary cells from 
CLL patients but not PBMCs from healthy donors. However, it was not 
as strong as the one prompted by Rituximab (Rtx).  
- To increase the therapeutic potential of clones SA1 and F, their variable 
domains were humanised using the CDR-grafting method through 
collaboration with GenScript. 
- Humanised F was developed as antibody derivatives (CARs and BiTEs) 
by other members of the lab.    
- HEK293T cells were co-transfected with all 25 possible combinations of 
humanised VH and VL sequences derived from SA1. 
- Flow cytometry data allowed the identification of the best two possible 
combinations: HuA1 and HuA3 clones. 
- No considerable difference was found between them in terms of ROR1 
binding (41% and 43%, respectively). However, these values were 
lower than SA1’s (49.4%).  
- The CDC of HuA1 and HuA3 was compared to SA1, Rtx and GA-101 
(Obinutuzumab). Although still significant, cytotoxicity elicited by 
humanised clones on CLL cells was not as potent as the one prompted 
by SA1. 
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- To circumvent reduced CDC activity, bispecific antibodies in full IgG 
combining SA1 and anti-CD3 or SA1 and anti-PD-1 were designed.  
- When two ROR1+ and one ROR1- solid cancer cell lines were treated 
with these bispecific molecules, non-specific binding and cytotoxicity 
was revealed. 
- Independent experiments and quantification of IFN-γ and IL-2 cytokines 
confirmed non-specific killing of ROR1- cells. 
- As a whole, it was decided not to pursue further studies with clone SA1 
and focus instead on the investigation of the therapeutic potential of a 
clone F derivative developed alongside in our lab: F-aCD3 BiTE. 
 
5.4.2 Future work 
Although the in vitro studies reported in this chapter suggest that -except for 
clone SA1- our ROR1 antibodies might not elicit potent cytotoxicity, other 
methods such as direct cells death and ADCC assays need to be performed. 
Furthermore, it is considered that data from in vivo studies will ultimately reveal 
their cytotoxicity potential. As discussed above, the only example of a 
successful ROR1 antibody currently in clinical trials is Cirmtuzumab. It is 
believed the in vivo studies performed using this antibody were fundamental 
to its development as a therapeutic alternative, as no classical in vitro 
evaluations have been reported.  
Importantly, apart from the classical antibody mechanisms of action (direct cell 
death, CDC, ADCC and ADCP), recent studies have reported an additional 
vaccinal or autoimmunisation effect (Chapter 1); which was identified solely 
by in vivo evaluations. In brief, the vaccinal effect is prompted by the ability of 
antibodies to trigger an adaptive immune response that results in the activation 
of tumour-reactive CD4+ and CD8+ T-cells. This property is essential for the 
efficacy of antibody therapy as it promises anti-tumour long-term protection 
after cessation of MAbs treatment (Arce Vargas and Quezada, 2015). 
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Furthermore, in order to induce a T-cell dependent vaccinal effect, DiLillo et al. 
demonstrated that monoclonal antibodies need to engage FcγRIIA, the only 
activating FcR expressed on dendritic cells (DiLillo and Ravetch, 2015).  
Intriguingly, these Fc-FcR interactions can be further enhanced by 
glycoengineering of the Fc portion of monoclonal antibodies (Yu et al., 2017, 
Beers et al., 2016). I propose that a first step towards this would be the 
production of afucosylated antibodies. Certainly, afucosylation of the heavy 
chain constant has proved to enhance Fc-Fc gamma receptor interactions 
(Weiner, 2015). This can be achieved by production of monoclonal antibodies 
using alpha-1,6-fucosyltransferase (FUT8) deficient Chinese hamster ovarian 
(CHO/FUT8-/-) cells. A relevant example of this approach is Obinutuzumab, a 
humanised anti-CD20 antibody with superior ADCC activity.  
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Chapter 6 ROR1 therapy on PANC-1-derived tumourspheres 
6.1 Introduction 
Cytotoxicity data discussed in the previous chapter revealed that clone SA1 
bound non-specifically to MCF-7 cells, a ROR1- breast cancer cell line. Further 
confirmation of those results led me to focus instead on the study of a 
humanised ROR1 bispecific T-cell engager (BiTE). The latter was engineered 
to target both the Fz domain of ROR1 (through clone F scFv) and the CD3 
molecules on T-cell membranes (through an anti-CD3 scFv).   
Our group has already established the potent and specific killing that our 
ROR1 BiTE therapy has on a range of ROR1+ solid cancer cell lines both in 
vitro and in vivo, including pancreatic cancer cells (Gohil et al., 2017). To date, 
pancreatic cancer (PaCa) is one of the most aggressive malignancies, where 
metastasis and therapeutic resistance are hallmarks of the disease. The 
difficulties in curing PaCa are attributed to the presence of cancer stem-cell 
like cells (CSC) (Sergeant et al., 2009). Importantly, some reports indicate that 
ROR1 is also present on the cell surface of CSCs (Jung et al., 2016, Zhang et 
al., 2014). Thus, in this chapter, the ability of our ROR1 BiTE to target and 
eliminate ROR1+ pancreatic CSC was investigated.  
In the following sections, I will describe the generation of tumourspheres from 
a pancreatic cancer cell line by spheroid formation assay. Also, to corroborate 
the presence of an enriched CSC population within the generated 
tumourspheres, data from gene, protein and functional characterisation will be 
discussed. Finally, the efficacy of the ROR1 BiTE therapy on general cell 
viability and on specific ROR1+ compartments within the tumourspheres will 
be explored. Additionally, below it is provided a brief introduction on relevant 
research concepts involved in this study: i) BiTE therapy, ii) Pancreatic cancer, 
iii) CSC and iv) Spheroid formation assay. 
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6.1.1 BiTE Therapy 
BiTEs, a subclass of bispecific antibodies, are constructed by genetically 
linking the scFv portions of two different MAbs. In this format, one arm binds 
to the CD3ε subunit of the TCR complex expressed on T-cells, whilst the 
second targets a tumour-associated antigen (TAA) expressed on cancer cells.  
Both scFvs are connected by a short flexible glycine-serine linker which 
facilitates antigen-scFv interactions (Wolf et al., 2005). 
BiTEs induce the formation of 
immunological synapses by bringing T-cells 
closer to tumour cells (Fig. 6. 1). As a result, 
cytotoxicity is elicited by the release of 
perforin and granzymes from granules in the 
cytotoxic T-cell, which in turn induces 
apoptosis and lysis of the malignant cell 
(Suryadevara et al., 2015). Notably, it has 
been shown that T-cells exposed to 
Blinatumomab, the first-in-class clinically 
approved CD19-CD3 BiTE, remain 
activated and continue to produce and store 
perforin and granzymes in order to serially 
attack additional CD19+ cells (Nagorsen 
and Baeuerle, 2011, Hoffmann et al., 2005). 
On top of that, inflammatory cytokines are 
released, and T-cell proliferation is 
promoted (Newman and Benani, 2016).  
 
It is noteworthy that a major advantage of BiTEs over other T-cell 
immunotherapies such as CARs is that these bispecific antibodies are able to 
exploit the resident polyclonal T-cell population and do not rely on a particular 
Fig. 6. 1. Schematic representation 
of immunological synapse between 
a T-cell and a ROR1+ cancer cell 
mediated by ROR1 BiTE binding. 
Modified from Suryadevara CM et al., 
2015. 
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subset. Data from several studies indicate that, in addition to CD8+ cytotoxic 
T-cells, CD4+ helper T-cells are also able to upregulate production of perforin 
and granzyme B upon BiTE-mediated binding to target cells (Brischwein et al., 
2006, Haas et al., 2009, Suryadevara et al., 2015). Furthermore, this type of 
therapy does not require ex vivo manipulation.  
Due to their small size (55-60kDa), BiTEs may have a better chance to 
penetrate deep into solid tumours and re-activate local tumour-infiltrating 
lymphocytes (TILs) or even co-opt TREGs (Suryadevara et al., 2015). Plus, the 
short half-life of these bispecific binders offers a reduced clinical risk in the 
scenario of adverse events caused by BiTE therapy.  
In terms of clinical benefit, a long-term survival analysis of patients with 
minimal residual disease after chemotherapy showed 61% haematologic 
relapse-free survival at a median of 33 months after Blinatumomab (Newman 
and Benani, 2016). Despite these encouraging results, better strategies for 
managing concomitant major adverse events such as cytokine release 
syndrome (CRS), seen in both BiTE therapy and CD19 CARs, are required. 
Furthermore, although infrequent, the loss of CD19 expression has been 
reported as a mechanism of resistance after acute lymphoblastic leukaemia 
(ALL) patients treated with Blinatumomab in a phase II trial relapsed with 
CD19-negative B-cell ALL disease (Portell et al., 2013, Topp et al., 2012). 
More recently, adaptive resistance to BiTEs was described when (Kohnke et 
al., 2015) reported for the first time increased PD-L1 positivity in a 32-year-old 
male patient with refractory B-precursor ALL resistant to Blinatumomab. Also, 
high frequency of Tregs (defined with a cutoff of 8.525%) in B-precursor ALL 
patients had a 100% failure rate to Blinatumomab (Duell et al., 2017). 
Nevertheless, researchers suggested that therapeutic removal of Tregs by the 
use of cyclophosphamide and fludarabine (as per CAR therapy) could convert 
Blinatumomab non-responders to responders. 
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All in all, BiTEs represent a major advancement in cancer immunotherapy, with 
the added possibility of stepwise dose escalation and rapid cessation of 
treatment should toxicity occur. Further improvement in the management of 
toxicities coupled with better targets, such as ROR1, and long-term survival 
benefits will enhance the great promise that BiTE technology offers for 
patients, particularly those suffering from cancers where survival rates are 
dismal, such as pancreatic cancer.  
6.1.2 Pancreatic cancer (PaCa) 
According to the American Cancer Society (Society, 2015), PaCa is currently 
the third most common cause of cancer-related death in the US and the 7th 
worldwide. It has an extremely poor prognosis, which has shown little 
improvement over the last 40 years (Muniraj et al., 2013). Even with currently 
available therapies, a median survival of less than 6 months and overall 5-year 
survival rates of 1-5% are obtained (Ercan et al., 2017). For a more detailed 
description of PaCa biology, TME and current therapies, please see section 
1.2.2 (Chapter 1). 
Early detection of the disease is impaired by absence of symptoms and lack 
of specific diagnostic markers (Costello et al., 2012). Hence, the majority of 
patients (80-90%) are diagnosed when local metastasis has already occurred. 
Standard therapy at this stage is gemcitabine-based chemotherapy. However, 
the long-term efficacy and prognosis of this approach varies and is widely 
unsatisfactory for most PaCa patients (Ciliberto et al., 2013, Nakai et al., 
2012). Of note, even patients diagnosed at early stages of the disease and 
therefore able to benefit from surgical resection -currently the only curative 
option- have poor prognosis and more than 80% of patients relapse within 2 
years after surgery (Zhou et al., 2013). 
Pancreatic ductal carcinoma (PDAC) is a major histological subtype and 
represents more than 90% of all PaCas (Society, 2015). The high mortality 
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seen in pancreatic cancer in general, and PDAC in particular, is often 
associated to the highly dense fibrotic tissue (constituting 90% of the tumour 
volume) as it acts as a physical barrier to effective drug delivery. In addition, 
PDAC shows minimal response to chemotherapy, often attributed to the 
presence of cancer stem cell-like cells (Ercan et al., 2017, Wolfgang et al., 
2013), as they have been associated to tumourigenesis, metastasis, 
chemotherapy resistance and poor clinical outcome (Qiu et al., 2015).   
6.1.3 Cancer stem cell-like cells (CSC) 
For several decades, the heterogeneity seen in malignant tumours has been 
a source of continuous debate amongst scientists. Thereof, two main models 
have been proposed: i) the clonal evolution hypothesis (stochastic model), and 
ii) the hierarchical hypothesis (CSC model) (Reya et al., 2001). 
The first model proposes that a distinct population of tumour cells acquires 
relevant somatic mutations and stochastically self-renew/differentiate, allowing 
selection of more aggressive subclones. This would ultimately result in 
metastasis and therapy resistance. The CSC hypothesis, in contrast, suggest 
that only a small subset of tumour cells (CSC) has the ability to self-renew and 
give rise to heterogeneous progenitor cells with limited proliferation and 
tumourigenic potential (Reya et al., 2001, Cabrera et al., 2015, Odoux et al., 
2008). 
More recently, however, data from several studies indicate that both models 
are not mutually exclusive (Cabrera et al., 2015, Gasch et al., 2017, Nakata et 
al., 2014), but rather it would appear as if a single cancer tumour may comprise 
several CSC subclones that have a common ancestor. These CSC subsets 
would have persisted over time and accumulated genetic and epigenetic 
changes necessary for cancer initiation and progression. Each CSC subclone 
would then generate different progenitor cells, which would also accumulate 
genetic changes. In time, some of them would acquire self-renewal capabilities 
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modulated by microenvironmental stimuli. Remarkably, this unified model 
highlights the existence of different CSC subpopulations, tumour cells 
plasticity and suggests bidirectional conversion between non-CSC to CSC 
states (Fig. 6. 2). 
 
 
 
According to a report produced by CSC specialists at a workshop convened 
by the American Association of Cancer Research (AACR) in 2006, the 
consensus definition of a cancer stem cell is a cell within a tumour that possess 
self-renewal capacity and the ability to generate heterogeneous lineages of 
cancer cells. Researchers emphasised that a frequent error in defining stem 
cells is to extrapolate expression of biomarkers from CSC studies obtained in 
one organ to different organs, as they can differ significantly from one another 
(Clarke et al., 2006). To avoid misleading results, Clarke et al. indicated that 
Fig. 6. 2. Schematic representation of unified model of clonal evolution and cancer stem cell-
like cells. (A) The originating CSC, exposed to oncogenic mutations, (B) gives rise to subclones 
with self-renewal capacity. (C) Over time, these CSC accumulate genetic and epigenetic changes. 
Each different CSC subclone will go through asymmetrical division, generating more CSC and 
progenitors. (D) Progenitors in turn will proliferate, and fully differentiated cancer cells will emerge. 
Shown also is a subset of these progenitors (green) depicting tumour cell plasticity and bidirectional 
conversion between non-CSC and CSC, modulated by microenvironmental stimuli. Modified from 
Cabrera MC et al., 2015. 
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CSCs need to be tested first for their potential to show both self-renewal and 
tumour propagation and then for biomarker expression. The gold standard 
assay for this is serial transplantation in animal models. The feasibility, cost 
and time that this assay requires, however, rise the necessity of developing 
alternative in vitro models, such as tumourspheres generated by 3D sphere 
formation assay (Qureshi-Baig et al., 2016). 
6.1.4 Sphere formation assay: Tumourspheres 
Isolation of CSC relies on a number of functional features, such as anoikis-
resistance (evidenced by anchorage-independent growth), self-renewal, 
pluripotency, asymmetric division and chemoresistance (Qureshi-Baig et al., 
2016). The spheroid formation assay utilises the anchorage-independent 
growth properties of cancer stem cells-like cells and it has shown to better 
preserve the characteristics of original tumours in terms of: gene expression 
profile, tumour heterogeneity and morphology, compared to adherent cultures 
(Lee et al., 2015, Weiswald et al., 2015, Lee et al., 2006).  
The exact extent to which tumourspheres favour CSC enrichment, however, 
has not been fully described. Furthermore, contrasting results on CSC 
enrichment have been found depending on the cancer subtype studied and 
whether spheroids were obtained from primary tumour cells or cell lines –
where not all cell lines derived from the same cancer subtype possessed the 
same sphere formation capability (Bowles and Weiner, 2005, Collura et al., 
2013). 
Nonetheless, using a sphere formation system, (Hansford et al., 2007) showed 
for the first time successful expansion of tumourspheres derived from 
aggressive neuroblastoma, able to form metastatic tumours in a murine 
xenograft model with as few as 10 passaged cells. Furthermore, several 
reports have used tumoursphere culture as a means to isolate, enrich, 
maintain and expand CSC subpopulations from various types of cancer (Lee 
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et al., 2006, Ponti et al., 2005), including pancreatic cancer cell lines (Dalla 
Pozza et al., 2015, Gaviraghi et al., 2011). In this chapter, 3D culture of 
tumourspheres will be used for the study of the therapeutic effect of ROR1 
BiTE on pancreatic CSCs. 
6.2 Aims 
1. To generate tumourspheres from a PDAC cancer cell line (PANC-1) by 
3D spheroid formation assay, using ultra-low attachment plates. 
2. To perform: i) gene, ii) protein and iii) functional characterisation of 
PANC-1-derived tumourspheres by qPCR, confocal microscopy and 
transwell migration assay, respectively. 
3. To assess the effect of ROR1 BiTE therapy on the cell viability of 
tumourspheres and specific elimination of ROR1+ cell subpopulations.   
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6.3 Results 
6.3.1 Aim 1: Generation of PANC-1-derived tumourspheres  
To evaluate the efficacy of ROR1 BiTE therapy on PaCa CSCs, I first needed 
to establish tumourspheres from PANC-1, a pancreatic ductal 
adenocarcinoma cell line. For this, ultra-low attachment plate-3D culture 
approach was used (See Materials & Methods section – Chapter 2).  
As reported by others (2016, Cao et al., 2011, Qureshi-Baig et al., 2016), 
stemness and pluripotency of cancer cells can be assessed in vitro by inducing 
anchorage-independent growth of tumourspheres in the absence of serum. In 
line with this, single-cell suspensions of adherent PANC-1 cells (Parental) 
were cultured in ultra-low attachment 6-well plates. With regards to the cell 
culture media used, two different types were tested: i) MEBM + MEGM 
SingleQuots supplements (as per (Zhang et al., 2014)) and ii) CSC + 
Supplement Mix (as per (Garikapati et al., 2017)).  
Tumourspheres were fed every 3-4 days and passaged every 7-9 days. Of 
note, most cells died within the first 5 days of culture, indicating that ultra-low 
attachment plates selected for anoikis-resistant cells, a feature of CSC. During 
the second week, some small spheroids were detected. Moreover, cell viability 
increased over consecutive passages, which resulted in more and bigger 
spheroids over time. 
In Fig. 6. 3, images of PANC-1 Parental cells and tumourspheres generated 
using the different types of media aforementioned are shown.  Although 
spheroids from both methods presented high cell viability after 7 passages; it 
became evident that cells grown with CSC media displayed a higher count of 
live cells and formed bigger tumourspheres than those cultured with MEBM. 
As a result, the subsequent experiments were performed using only 
tumourspheres generated with CSC media.  
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As mentioned in the Introduction section of this chapter, specialists on CSC 
indicated more than a decade ago that relying solely on a marker expression 
profile for isolation of CSC, has proved to be equivocal as marker expression 
can vary from organ to organ (Clarke et al., 2006). Instead, there seems to be 
a consensus that CSC should be defined by their potential to show key 
properties of cancer stem cell-like cells: anchorage-independent growth 
(anoikis resistance) and the ability to self-renew. Having tested the former, I 
sought to evaluate their self-renewal capacity by performing a tumoursphere 
formation assay by limiting dilution.  
Fig. 6. 3. Tumoursphere formation assay on PANC-1 cells. Single-cell suspensions of 
PANC-1 adherent cells (Parental) were cultured in ultra-low attachment 6-well plates, using 
either: i) MEBM+supplements or ii) CSC+supplements media. Shown are images of PANC-
1 parental cells and tumourspheres (P7) generated using the culture media mentioned 
above. Images were taken with a 4x microscope objective lens. Scale represents 400um. 
P7= Passage 7. 
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In brief, tumourspheres (“CSC”) -directly obtained from PANC-1 parental cells- 
were segregated and carefully trypsinised in order to produce a single-cell 
suspension. Single cells were seeded in ultra-low attachment 96-well plates at 
a density of 0.5cells/well. CSC were fed every 4-6 days and their growth 
assessed under the microscope. Spheroids were detected after approximately 
10-12 days. CSC which possessed the capacity to form spheroids from a 
single cell were called “CSC96” (Fig. 6. 4). 
 
Fig. 6. 4. Evaluation of tumoursphere formation by limiting dilution. Shown are images 
of PANC-1 Parental cells, from which “CSC” were generated. After a few passages, CSC were 
prepared as a single-cell suspension by enzymatic dissociation in order to be plated by limiting 
dilution (0.5 ceIls per well) on ultra-low attachment 96-well plates. After 10-12 days, spheroids 
were observed (“CSC” 96-well plate). Cells able to form tumourspheres from a single cell were 
called “CSC96”. Newly generated “CSC96” were then transferred to ultra-low attachment 6-
well plates for serial passage and expansion. Images were taken with a 4x microscope 
objective lens. Scale represents 400um. 
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Fig. 6. 4 shows the generation of anoikis-resistant tumourspheres with self-
renewal capacity (“CSC96”); a process that started with PANC-1 Parental cells 
and involved cell culture in serum-free media under anchorage-independent 
growth conditions. This was then followed by limiting dilution, and resulted in 
the production of CSC96 cells. Images of PANC-1 Parental cells, the spheroids 
they originated (“CSC”) and a picture of a tumoursphere in a 96-well plate 
generated from a single CSC are presented. These new spheroids (“CSC96”) 
were transferred to 6-well plates in order to be expanded for further 
investigation.   
It is noteworthy to mention that apart from “CSC” and “CSC96” cells, a third 
type of spheroids were generated: “CSC Conf”. The latter were obtained by 
serial passage of CSC spheroids using a higher concentration of cells/ml (i.e. 
Once CSC were passaged at a 104 cells/ml conc., all the remnant cells were 
cultured together, typically at a 5x104 cells/ml). Morphologically, “CSC Conf” 
were bigger than regular “CSC” but not “CSC96” (data not shown).  
6.3.2 Aim 2: Characterisation of PANC-1 tumourspheres 
As mentioned above, identification and subsequent isolation of CSC based 
only on a marker expression profile might lead to error. However, if performed 
on established anokis-resistant tumourspheres with self-renewal capacity, the 
stemness of these cells can be ascertained in a more reliable manner, 
especially if markers at both gene and protein levels are coupled with 
functional characterisation.  
In this section, gene and protein expression will be assessed by qPCR and 
confocal microscopy, respectively. Additionally, the migration ability of CSC96 
compared to PANC-1 Parental cells will be evaluated using a transwell system. 
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6.3.2.1 Gene expression by qPCR 
The mRNA of all three versions of PANC-1 tumourspheres (namely, CSC, 
CSC Conf and CSC96), along with PANC-1 Parental cells were isolated in 
order to obtain cDNA. The absence of contaminant genomic DNA was verified 
by PCR using purposely-designed GAPDH primers (See Chapter 3). Having 
tested the cDNA quality of all the samples, gene expression of different 
biomarkers was then evaluated. 
In Fig. 6. 5A, the expression of stemness markers such as CD133, SOX2 and 
Nestin is shown. qPCR data indicates significant upregulation of both CD133 
and SOX2 in all three types of tumourspheres compared to Parental cells. 
Nestin expression, however, was downregulated.  
In terms of typical CSC-related markers, I evaluated genes encoding for 
antigens, molecules and signalling pathways involved in self-renewal (Notch1, 
Bmi1), as well as high invasiveness and metastatic potential (ROR1, ALDH1, 
CD24, Vimentin and CXCR4).  
As expected, data shown in Fig. 6. 5B indicates significant upregulation of 
Notch1, Bmi1, two isoforms of ALDH1, CD24 and CXCR4. Although slightly 
elevated, one isoform of ALDH1 (ALDH1-B1) and Vimentin gene expression 
on tumourspheres was not significantly different from the one observed on 
Parental cells. Surprisingly, however, ROR1 levels were significantly reduced. 
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To further investigate the latter, several repetitions of this experiment were 
carried out and the resulting qPCR products were run in an agarose gel. In 
Fig. 6. 6A, typical results showing the significant difference in ROR1 gene 
expression between PANC-1 Parental and tumourspheres are presented.  
A. 
B. 
Fig. 6. 5. Biomarker gene expression by qPCR. cDNA from PANC-1 Parental cells and all three 
versions of tumourspheres were evaluated by qPCR. (A) Typical stemness and (B) CSC-related 
genes were investigated. Gene expression was normalized to B-actin and compared to PANC-1 
Parental. Experiments were performed in triplicates. Error bars represent SEM. Statistical test: 
Unpaired t-tests. *p≤0.05, **p≤0.01, ***p≤0.001, ns= not statistically significant.  
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Fig. 6. 6B shows those qPCR products run in an agarose gel after 40 cycles 
of amplification. These results suggest that although ROR1 is significantly 
downregulated in all versions of tumourspheres, its presence is still detectable 
on all samples.  
 
In an effort to explain this apparent incongruence between qPCR and agarose 
gel data, qPCR experiments using 25, 30, 35 and 40 cycles of amplification 
were performed. qPCR products were subsequently run in agarose gels (See 
Fig. 6. 7). 
At 25 cycles, no quantifiable amplification was detected although faint bands 
corresponding to Parental and iPS samples were observed. After 30 cycles, 
Fig. 6. 6. ROR1 gene expression on PANC-1 Parental and tumourspheres. (A) ROR1 
gene expression evaluated by qPCR. (B) qPCR products run in a 1.7% agarose gel and 
stained with GelStarTM. cDNA from iPS was used as positive control, whilst nucleotide-free 
water, RT negative and cDNA from embryoid bodies acted as negative control. Gene 
expression was normalized to B-actin and compared to PANC-1 Parental expression. 
Experiments were performed in triplicates. Error bars represent SEM. Statistical test: 
Unpaired t-test.  ***p≤0.001. RT= Retro-transcriptase control. Ladder: Hyperladder 100bp. 
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however, qPCR data showed ROR1 amplification on Parental cDNA only, 
whilst products run in agarose gel revealed a clear difference in band intensity 
between Parental and all CSC versions. As expected, after 35 and 40 cycles, 
ROR1 gene expression was able to be quantified on all samples and agarose 
gels showed bands with similar intensity throughout, as ROR1 amplification 
reached saturation levels. Taken together, these data suggest that the 
discrepancy between qPCR and agarose gel data is explained by the fact that 
qPCR measured the difference in Ct values (i.e. gene expression in real time), 
whereas agarose gels showed the total accumulated product after qPCR 
amplification. 
  
Fig. 6. 7. Investigation of ROR1 gene expression by qPCR. Several qPCRs were performed using 
25, 30, 35 and 40 cycles of amplification. qPCR data was analysed, whilst amplicons were run in a 1.7% 
agarose gel, followed by staining with GelStarTM. cDNA from iPS and nucleotide-free water were used 
as positive and negative control, respectively. Gene expression was normalized to B-actin and 
compared to PANC-1 Parental expression. Ct and Melting curve graphs are shown for illustrative 
purposes. Experiments were performed in triplicates. Error bars represent SEM. Statistical test: 
Unpaired t-test. **p≤0.01, ***p≤0.001.  
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Additionally, to verify that the qPCR products being tested corresponded to the 
ROR1 gene, amplicons were sent for sequencing and aligned with full-length 
ROR1 nucleotide sequence (Fig. 6. 8). These results confirmed that the qPCR 
products matched the cytoplasmic region of ROR1. In turn, this further 
validated the observation that, whilst ROR1 was downregulated on PANC-1-
derived tumourspheres, its expression was still detectable.    
 
 
Fig. 6. 8. Sequencing alignments of ROR1 qPCR products. Amplicons from qPCR reactions were 
sent for sequencing and the resulting data was aligned with full-length ROR1 mRNA sequence. 
Amplicons showed correct alignment to the cytoplasmic region of ROR1. Red arrows represent location 
and matching sequence of qPCR products within the ROR1 nucleotide sequence. 
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In light of these results, my studies focused on CSC96 tumourspheres only 
and sought to further confirm their identity by testing five additional genes: i) 
Lgr4, a member of the leucine-rich repeat-containing GPCR (G-coupled 
protein cell receptor) family, which has increasingly been suggested to play 
critical roles in maintaining stem cell functions (Hsu et al., 2014, Nakata et al., 
2014); ii) ABCA2, ABCC1 and ABCG2, members of the ATP-binding cassette 
(ABC) transporters, involved in drug efflux and chemo-resistance (Calcagno 
and Ambudkar, 2010, Li et al., 2015, Mack et al., 2008), and iii) ROR2 (Huang 
et al., 2015, Many and Brown, 2014). I hypothesised that, if expression of 
ROR1 was truly downregulated on CSC96, another member of the ROR family 
could be overtaking ROR1’s role in promoting increased invasiveness and 
metastasis potential.    
Fig. 6. 9 shows significant upregulation of Lgr4 and ROR2 gene expression 
on CSC96 compared to PANC-1 Parental cells. An unexpected finding was 
the significant reduction of ABCG2 gene expression on tumourspheres; albeit 
both ABCA2 and ABCC1 showed significant upregulation compared to PANC-
1 adherent cells. Together, these findings confirm the enriched presence of 
cancer stem cell-like cells within CSC96 tumourspheres. 
  
    Chapter 6 
229 
 
 
 
6.3.2.2 Protein expression by confocal microscopy 
As per (Zhang et al., 2014), the protein expression studies were performed on 
ROR1 and the following biomarkers: i) ALDH1, an enzyme suggested to be 
involved in the detoxification of intracellular aldehydes and/or several cytotoxic 
drugs (Martinez-Cruzado et al., 2016, Nakahata et al., 2015, Alison et al., 
2011); and ii) Vimentin, a protein associated with epithelial-mesenchymal 
transition (EMT) that provides traits required for invasion and metastasis (Cui 
et al., 2013, Mitra et al., 2015, Scheel and Weinberg, 2012). 
In Fig. 6. 10A, high expression of Vimentin on both Parental and CSC96 
tumourspheres was observed. Conversely, whilst ROR1 could be detected on 
all Parental cells, its expression was clearly reduced on the cell surface of the 
tumourspheres; which was consistent with gene expression data discussed 
above. 
Fig. 6. 9. Further investigation of CSC biomarkers gene expression by qPCR. The gene 
expression of Lgr4, ROR2, and ABC transporters A2, C1 and G2 on CSC96 was compared to 
PANC-1 Parental cDNA amplification. Gene expression was normalized to B-actin. Experiments 
were performed in triplicates. Error bars represent SEM. Statistical test: Unpaired t-test.  *p≤0.05, 
**p≤0.01, ***p≤0.001. 
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As expected, Fig. 6. 10B shows similar results to Fig. 6. 10A in terms of ROR1 
protein levels. For ALDH1, however, its expression was detectable on 
tumourspheres but not Parental cells. These findings were also in line with 
gene expression results. Notably, confocal microscopy allowed the 
identification of a mixture of cell populations that expressed each biomarker 
alone:  cells with single positivity (ROR1+, Vim+, ALDH1+), double positives 
(ROR1+Vim+, ROR1+ALDH1+) or double negatives (ROR1-Vim-, ROR1-
ALDH1-). 
As per qPCR data, co-expression of ROR2 and Vimentin or ALDH1 was also 
investigated (Fig. 6. 11). Consistent with previous findings, the protein levels 
of ROR2 were clearly upregulated on tumourspheres compared to Parental 
cells.  
An interesting observation was the heterogeneity of ROR1, ROR2, Vimentin 
and ALDH1 expression throughout the cells comprised within CSC96 
tumourspheres. Importantly, the presence of mixed populations within our 
tumourspheres is congruent with the notion that a single CSC from a primary 
tumour is able to generate a novel tumour replicating comparable levels of 
heterogeneity. Moreover, based on previous reports and both gene and protein 
expression, it is considered that in this particular model, ALDH1+ and 
ALDH1+ROR1+ cells may account for different CSC populations, whilst other 
cell subsets, such as cells with single ROR1 positivity or double-negative cells, 
could be the ones comprising the bulk of the tumour. Since Vimentin 
expression is not exclusive to CSCs, it was not possible to classify Vim+ cells 
as a CSC subpopulation. 
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6.3.2.3 Transwell migration assay 
Having assessed the gene and protein expression of distinctive CSC 
biomarkers on CSC96 tumourspheres, their functional properties were 
characterised through a transwell migration assay. 
Based on Jung et al. (Jung et al., 2016), PANC-1 Parental cells and 
tumourspheres prepared as single-cell suspensions were seeded in an 8um 
pore size transwell 96-well plate. The lower wells were filled with either: i) 
serum-free RPMI (R0), ii) serum-supplemented RPMI (R10) and iii) 
conditioned media (Cond). For the latter, PANC-1 Parental culture media was 
used. After 72h, cells contained in the lower chambers were documented using 
a microscope to be then counted for quantitative analysis. 
Fig. 6. 12 illustrates the clear difference between PANC-1 Parental cells and 
tumourspheres in terms of migration capacity when exposed to R0. 
Specifically, Fig. 6. 12A shows representative images of lower chambers from 
both monolayer and CSC96 cells exposed to different types of stimuli. The 
quantitative analysis represented in a histogram graph is displayed in Fig. 6. 
12B.  
A significantly higher tumoursphere cell count compared to Parental cells 
located in the lower chambers was observed when both cell types were 
exposed to R0, but not R10 or conditioned media. These findings are in line 
with the enhanced gene expression of Notch1, CD24, CXCR4 and ROR2 
observed on PANC-1-derived CSC96 but not adherent cells. It is hypothesised 
that the reduced migration of tumourspheres on R10 and conditioned media is 
likely due to extended exposure to serum (72h). The presence of the latter 
could have trigger differentiation of CSCs, reducing their migration ability to 
almost that of adherent cells. 
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6.3.3 Aim 3: Evaluation of ROR1 BiTE therapy on CSC96 
One of the ROR1 antibody-based therapies we have developed in our group 
is a humanised anti-ROR1 BiTE; which combines the unique binding of clone 
F to the Fz domain of ROR1, and an anti-CD3 scFv.  
We have previously shown the specific and potent cytotoxic effect that our 
ROR1 BiTE has on a range of ROR1+ solid cancer malignancies, both in vitro 
and in vivo (Gohil et al., 2017). Therefore, I set out to evaluate the efficacy of 
A. 
B. 
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Fig. 6. 12. Transwell migration assay.  Single-cell suspensions in serum-free media were 
prepared from PANC-1 Parental cells and tumourspheres in order to be seeded in the upper 
chamber of a transwell 96-well plate. The lower wells were filled with either: i) serum-free 
RPMI media (R0), ii) complete media (R10) or iii) Condition media (Cond). Shown are (A) 
images of cells contained in the lower chamber after 72h of incubation. (B) Cells were counted 
for analysis and compared for calculation of statistical differences. Images were taken with a 
4x microscope objective lens. Experiments were performed in triplicates. Error bars represent 
SD. Statistical test: Multiple t-tests. **p≤0.01. Unless indicated, other comparisons were not 
statistically significant. SD= Standard deviation. 
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this approach on PANC-1 derived cancer stem-cell like cells by two 
approaches: i) WST1 cell viability assay and ii) specific cytotoxicity evaluation 
of ROR1+ CSCs and ROR1+ bulk cells by immunocytochemistry and confocal 
microscopy. 
6.3.3.1 WST1 cell viability assay  
 
Single-cell suspensions from both PANC-1 Parental and CSC96 
tumourspheres were seeded in appropriate TC-treated and suspension 96-
well plates, respectively. On the following day, cells were treated with 1ug/ml 
ROR1 BiTE and co-cultured with PBMCs at a 1:1 (E:T) ratio. After 72h, cell 
viability was assessed by cell proliferation reagent WST1 (Fig. 6. 13). 
Fig. 6. 13A display representative images of both Parental and CSC96 co-
cultures 72h post-ROR1 BiTE treatment. As expected, no morphological 
changes were observed on those cells treated with either “PBMCs alone” or 
“ROR1 BiTE alone” controls. Conversely, PANC-1 Parental cells exposed to 
ROR1 BiTE therapy (BiTE+PBMCs) were obliterated, whilst T-cells on those 
wells proliferated and formed clusters, a trait associated with potent 
cytotoxicity. Although less evident, CSC96 exposed to ROR1 BiTE therapy 
presented a different morphology compared to those treated with controls. 
Specifically, they were less sparse and seemed to present a fewer number of 
cells. Thus, these observations needed to be verified through a cell viability 
assay. 
Results of cell viability quantified with WST1 reagent are presented in Fig. 6. 
13B. Significant reduction of live PANC-1 Parental cells and CSC96 
tumourspheres was detected when these targets were treated with ROR1 
BiTE therapy compared to negative controls. A surprising finding was the 
unexpectedly high absorbance seen on Parental cells, as previous analysis of 
these wells under the microscope showed almost complete elimination of the 
target population. It is presumed that this observation could be explained by 
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the presence of various clusters of proliferating T-cells. In contrast, since 
CSC96 tumourspheres expressed lower levels of ROR1, it is likely that the cell 
viability signal on those wells was generated by a combination of both targets 
and proliferating effectors. Importantly, these findings show significant 
reduction on cell viability levels of CSC96 tumourspheres after ROR1 BiTE 
therapy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. 
B. 
Fig. 6. 13. WST1 cell viability assay on PANC-1 Parental and CSC96 cells after ROR1 
BiTE therapy. (A) PANC-1 Parental cells and CSC96 tumourspheres were seeded in 
appropriate 96-well plates. On the next day, cells were treated with 1ug/ml ROR1 BiTE, 
followed by addition of effector cells (activated PBMCs) at a 1:1 ratio. After 72h, WST1 was 
added in order to measure cell viability (Abs). (B) Abs values were compared to both PBMCs 
and ROR1 BiTE controls for statistical calculations. PANC-1 Parental cells were used as 
positive control. Images were taken with a 4x microscope objective lens. Experiments were 
performed in triplicates. Error bars represent SD. Statistical test: Unpaired t-test. **p≤0.01, 
***p≤0.001. SD= Standard deviation. 
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6.3.3.2 Cytotoxicity evaluation of ROR1+ CSC and ROR1+ bulk cells 
In an effort to ascertain true elimination of ROR1+ cells amongst the mixed cell 
populations detected within the tumourspheres, a cytotoxicity assay followed 
by immunocytochemistry and confocal microscopy was performed.  
CSC96 tumourspheres were treated with ROR1 BiTE and co-cultured with 
PBMCs as described above. After 72h, the assay plate was inspected under 
the microscope and images from representative wells were taken (Fig. 6. 14).  
 
For illustrative purposes, images of targets and effectors alone as well as 
targets treated with ROR1 BiTE therapy or different controls are shown. 
Consistent with the findings observed in the cell viability experiments, ROR1 
Fig. 6. 14. Cytotoxicity assay on CSC96 cells after ROR1 BiTE therapy. CSC96 
tumourspheres were seeded in suspension 96-well plates. On the next day, cells were treated 
with 1ug/ml ROR1 BiTE, followed by addition of effector cells (activated PBMCs) at a 1:1 ratio. 
After 72h, images were taken with a 4x microscope objective lens. Shown are representative 
images of targets and effectors alone, and targets treated with ROR1 BiTE therapy or controls 
(PBMCs alone, CD19 or ROR1 BiTE alone, and CD19 BiTE therapy). Experiments were 
performed in triplicates.  
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BiTE-treated tumourspheres displayed in Fig. 6. 14 showed a much more 
contracted cell population compared to those cells treated with CD19 BiTE 
therapy and other controls.  
To determine whether our ROR1 BiTE approach was able to elicit specific 
cytotoxicity of ROR1+ cells present within CSC subpopulations and the bulk of 
the tumour, CD19 or ROR1 BiTE-treated cells were harvested and processed 
for immunocytochemistry. Cells were stained with ROR1 (green) and either 
Vimentin (red) or ALDH1-A1 (red). Immunostaining was analysed by confocal 
microscopy. CD19 and ROR BiTE-treated cells were then counted, classified 
according to their biomarker expression and compared for statistical analyses 
(Fig. 6. 15). 
Fig. 6. 15A shows the single or double expression of ROR1 and Vimentin on 
CSC96 tumourspheres after CD19 or ROR1 BiTE therapy. Similarly, single or 
double expression of ROR1 and ALDH1-A1 on those same tumourspheres is 
presented in Fig. 6. 15B. Remarkably, expression of ROR1 as a single 
biomarker or in combination with Vim or ALDH1 is drastically reduced on 
ROR1 BiTE treated-cells compared to those exposed to CD19 therapy.  
Furthermore, Fig. 6. 15C displays the quantification of CSC96 classified by 
their biomarker expression after CD19 or ROR1 BiTE therapy, namely: Vim+, 
ROR1+ and ALDH1+ (for single biomarker expression); Vim+ROR1+ and 
ALDH1+ROR1+ (for double-positive cells); and Vim-ROR1- and ALDH1-ROR1- 
(for double-negative cells). Categorised cells were presented as the 
percentage of total cells counted (at least 550 per condition). Importantly, as 
mentioned earlier and based on previous reports (Mitra et al., 2015, Martinez-
Cruzado et al., 2016, Nakahata et al., 2015, Zhang et al., 2014), ALDH1+ and 
ALDH1+ROR1+ cells were considered potential CSC subsets cells within the 
tumourspheres.  
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As expected and in line with previous findings reported here and elsewhere 
(Gohil et al., 2017), a reduction on the percentage of cells expressing ROR1 
as a single biomarker after ROR1 BiTE therapy compared to CD19 BiTE 
treatment was observed. Notably, this reduction became significant when 
double positive cells were analysed. This is of particular importance as these 
results would suggest that ROR1 BiTE therapy is not only able to deplete 
ROR1+ cells comprising the bulk of tumours but also ROR1+ cancer stem cell-
like cells derived from a pancreatic cancer cell line. Furthermore, a significant 
increase of Vim-ROR1- cells was detected after ROR1 BiTE therapy. This data 
is consistent with the observation that immunotherapies targeting ROR1 
decrease the expression of Vimentin, thereby suggesting an association 
between both biomarkers (Cui et al., 2013, Zhang et al., 2014). Although not 
significant, a similar reduction was observed on ALDH1+ cells. 
All in all, these data suggest that although ROR1 gene expression was 
downregulated on PANC-1-derived tumourspheres compared to Parental 
cells, the protein levels of ROR1 could still be detected. In keeping with this, it 
has been showed that therapy with our ROR1 BiTE was able to target both 
cancer cells and cancer stem cell-like cells positive for ROR1 expression. It is 
envisaged that immunotherapies, such as the ROR1 BiTE developed in our 
lab, able to target not only the bulk of tumours but also CSC offer real 
prospects of decreased risk of metastasis. Evaluation of this type of therapies 
in clinical trials used as single agents and in combination with other anti-cancer 
treatments, such as PD-1 blocking antibodies and/or small molecule inhibitors, 
will ultimately reveal the clinical benefit ROR1 immunotherapy can achieve.  
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Fig. 6. 15. Immunocytochemistry by confocal microscopy on CD19 or ROR1 BiTE-treated CSC96 
tumourspheres. 72h post BiTE therapy, cells were seeded in matrigel-coated coverslips, fixed and 
stained with a commercial antibody against ROR1 (green) and either (A) Vimentin (red) or (B) ALDH1-A1 
(red).  Nuclei was counterstained with DAPI (blue). (C) More than 500 cells per treatment and biomarker 
staining were counted. Cells were classified according to their single or double biomarker expression and 
conveyed as % of the total cell count. % of ROR1 BiTE-treated cells was compared to that of CD19 BiTE 
for statistical calculations. Images were taken with a 63x microscope objective lens. Scale represents 
10um. Number of spheres imaged: CD19 BiTE Vim, n=619; ROR1 BiTE Vim, n=692; CD19 BiTE ALDH1, 
n=594; ROR1 BiTE ALDH1, n=550. Error bars represent SD. Statistical test: Multiple t-tests. **p≤0.01, 
***p≤0.001. Unless indicated, other comparisons were not statistically significant. V= Vimentin, R= ROR1, 
A= ALDH1-A1. 
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6.4 Discussion 
Several studies have identified subpopulations of cells within malignant 
tumours able to drive tumour initiation, progression and recurrence, termed 
CSCs. To date, most types of chemo and radiotherapy eliminate the bulk of 
the tumour but fail to eliminate CSCs; which survive and mediate relapse and 
metastasis. The development of a reliable model for the study of CSCs is 
therefore essential for preclinical cancer research.  
A number of methods have been tried to isolate and study CSCs, of which the 
use of specific markers has been the most popular. The main pitfall of this 
strategy however is the contradictory results from different studies where cells 
negative for so-called stem cell markers were still able to form tumourspheres 
and give rise to aggressive tumours in vivo (Singh et al., 2015). Recently, 
several reports have demonstrated that CSCs from primary tumours and 
cancer cell lines can be enriched within tumourspheres when cultured in 
serum-free media and in a low adhesion environment (Dalla Pozza et al., 2015, 
Gaviraghi et al., 2011, Ponti et al., 2005, Fitzgerald and McCubrey, 2014). 
In this study, two different types of media (MEBM and CSC) were tested in 
order to generate tumourspheres derived from PANC-1 cells. After a few 
passages it became evident that spheroids grown with MEBM were fewer and 
smaller compared to those cultured with CSC. This could be explained by the 
presence of antibiotics in MEBM medium. A study by (Relier et al., 2016), 
showed that antibiotics had no impact on monolayer cultures but inhibited the 
sphere-forming ability of six cancer cell lines. Furthermore, their data suggests 
that the number of cells with self-renewal potential were significantly 
decreased.  
In contrast, the CSC medium did not contain antibiotics; and tumourspheres 
grown in this media were successfully cultured for more than 20 passages, 
exhibiting consistently good cell viability.  
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It is worth mentioning that a potential limitation of this approach was the use 
of a pancreatic cancer cell line (PANC-1) instead of primary tumours, as it has 
been suggested that efficient enrichment of CSCs by sphere formation assay 
is not universal and is highly cell line-dependent (Calvet et al., 2014). 
Fortunately, in the past few years, there has been some reports indicating 
successful isolation and expansion of CSCs from pancreatic cancer cell lines, 
particularly PANC-1 (Dalla Pozza et al., 2015, Gaviraghi et al., 2011). 
Furthermore, the use of cancer cell lines is supported by the recently accepted 
concept of CSC plasticity, whereby CSCs and non-CSCs co-exist in the 
tumour in a dynamic equilibrium, and both types are able to interconvert in 
response to microenvironmental stimuli (Cabrera et al., 2015, Chaffer et al., 
2011, Varga et al., 2014).  
Accordingly, tumourspheres showed anoikis-resistance, a key feature of 
CSCs. Anoikis is a form of regulated cell death induced when anchorage-
dependent cells detach from their extracellular matrix. It is effectively a 
physiological barrier to metastasis; therefore, resistance to anoikis is pivotal 
for the survival of CSCs entering the bloodstream, thereby facilitating 
secondary tumour formation in distant organs (Kim et al., 2016a). Additionally, 
PANC-1 tumourspheres were subjected to a limiting dilution assay in vitro in 
order to assess their self-renewal capability.  Cells able to form new 
tumourspheres from a single cell under anchorage-independent growth were 
named CSC96. Notably, the sphere formation assay coupled with serial 
passages seems to allow the enrichment of CSC subpopulations, particularly 
when CSC biomarkers are not well defined (Cao et al., 2011).  
In the context of pancreatic cancer, several biomarkers have been proposed 
for CSC identification, including: CD133, SOX2, CD24, CD44, CXCR4, 
EpCAM, ABCG2, ALDH1, Nestin, among others. Their use however remains 
controversial (Matsuda et al., 2012).  
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Gene expression comparing biomarker levels of both CSC96 and PANC-1 
Parental cells revealed significant upregulation of stemness genes CD133 and 
SOX2, but downregulation of Nestin on tumourspheres. Interestingly, co-
expression of both CD133 and SOX2 has been found on CSCs from various 
tumours, particularly of neurogenic origin (Hussein et al., 2011). Also, 
Hermann et al. (Hermann et al., 2007) reported that the CD133+CXCR4+ CSC 
subpopulation in pancreatic tumours was essential for metastasis. In keeping 
with this, CXCR4 was also overexpressed on CSC96 spheroids.  
Nestin expression has been described in neural stem/progenitor cells and in a 
variety of mesenchymal and epithelial tumours, including PDAC. Moreover, a 
correlation between Nestin expression and clinical course has been reported 
for breast and ovarian carcinomas, gastrointestinal tumours, melanoma, etc. 
No such relationship however was found for PDAC (Neradil and Veselska, 
2015). Therefore, although Nestin has been considered a tissue 
stem/progenitor and CSC marker in various tissues -according to Matsuda, Y 
et al. (Matsuda et al., 2012)- it is not yet clear whether Nestin+ cells in PDAC 
are also pancreatic CSCs. Additional studies are needed to clarify the 
relationship between Nestin and PaCa CSCs.   
Biomarkers involved in high invasiveness, metastasis and EMT processes 
were also evaluated. One of the most important CSC markers, whose 
upregulation has been detected on CSCs from virtually all cancer subtypes 
studied so far, is ALDH1. ALDH is a family of enzymes responsible for 
detoxifying the cells and it has been involved in chemotherapy resistance. It is 
been also involved in the expansion and differentiation of stem cells and CSCs 
(Martinez-Cruzado et al., 2016). Of the various isoforms, ALDH1-A1 is thought 
to play an important functional role in stem cells (Nakahata et al., 2015). Also, 
overexpression of SOX2 and ALDH1-A1 is associated with enhanced 
malignant potential of spheroids (Martinez-Cruzado et al., 2016). Crucially, 
both genes were significantly upregulated on CSC96 tumourspheres 
compared to adherent cells.   
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An unexpected result was the downregulation of ABCG2 detected on PANC-
1-derived tumourspheres. However, the upregulation observed on both 
ABCA2 and ABCC1 suggest that CSC96 spheroids could have the potential 
to be resistant to chemotherapy as these ABC transporters are known to 
mediate the efflux of antimitotic drugs (Fitzgerald and McCubrey, 2014, 
Calcagno and Ambudkar, 2010, Mack et al., 2008). The study of 
tumourspheres derived from a human pancreatic cancer tumour would 
potentially lead us to confirm if these findings are reproducible on CSC from 
primary cells or if it is rather a limitation of the current model. 
Since ROR1 overexpression has been detected on CSCs derived from ovarian 
cancer and glioblastoma (Jung et al., 2016, Zhang et al., 2014), I investigated 
whether this was the case on pancreatic CSCs. Surprisingly, a significant 
reduction of ROR1 was observed. This was consistent, however, with the 
established concept that the use of CSC biomarkers cannot be generalised 
and their expression needs to be evaluated in a tissue-dependent manner 
(Clarke et al., 2006). In line with this, a recent report on nasopharyngeal 
carcinoma (NPC) revealed that, although ROR1 was detectable on NPC-
derived spheroids, there was no significant upregulation of this gene compared 
to NPC cell lines (Guo et al., 2017).  
In light of ROR1 downregulation, I hypothesised that the other member of the 
ROR family, ROR2, could be overtaking the role that ROR1 has on CSCs 
derived from other malignancies. As expected, gene expression data 
confirmed the overexpression of ROR2 on CSC96 spheroids compared to 
Parental cells. Importantly, the crosstalk between these two genes has been 
previously reported on melanoma, where ROR1 and ROR2 are inversely 
expressed and negatively regulate each other (O'Connell et al., 2013). 
Moreover, O’Connell MP et al. indicated that, exposure to hypoxia shifted 
ROR1+ melanoma cells to a more invasive ROR2+ phenotype. Similarly, 
according to Umebayashi, M. et al. (Umebayashi et al., 2014), hypoxia has 
also a strong effect on PaCa cell biology as it reduces its sensitivity to cell 
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death signals and promotes angiogenesis, proliferation and metastasis. 
Hence, hypoxia culture has been proposed as an alternative method of CSC 
isolation (Keith and Simon, 2007). Interestingly, high ROR2 expression has 
been correlated with poor prognosis in PDAC by Huang, J. et al. (Huang et al., 
2015). Researchers investigated ROR2 expression in both stromal and cancer 
cells and its role as a prognostic marker of survival in PDAC patients. However, 
PDAC CSCs were not specifically addressed. Together, these findings 
suggest that, as in melanoma, ROR2 expression might be associated with a 
more aggressive phenotype in PDAC. Whether this ROR1 to ROR2 shift is 
dependent on hypoxic conditions that drive non-CSCs to CSCs state remains 
to be addressed and elucidated.  
In this study, gene expression analyses were followed by protein expression 
evaluation. To this end, CSC96 spheroids were assessed by 
immunocytochemistry and confocal microscopy, whilst PANC-1 Parental cells 
were used as control. Based on another study that investigated ROR1 on 
ovarian cancer CSCs and reported an association between this marker and 
both Vimentin and ALDH1 (Zhang et al., 2014), my investigation focused on 
these proteins. As mentioned above, Vimentin is an EMT biomarker involved 
in metastasis, whilst ALDH1 is a widely accepted CSC marker. Results 
obtained by confocal microscopy showed that protein levels of ROR1, 
Vimentin and ALDH1 were consistent with gene expression data; whereby 
ROR1 expression was reduced on tumourspheres, expression of Vimentin on 
spheroids was not considerably different from Parental cells, and ALDH1 was 
clearly detected on CSC96 but not on PANC-1 adherent cells. Hence, unlike 
data from Zhang, S. et al. (Zhang et al., 2014), no clear association of these 
markers was observed.  
Considering that prior studies found that ROR1 could mediate proliferation, 
migration/invasion and tumourigenicity of cancer cells, downregulation of 
ROR1 on the pancreatic tumourspheres was puzzling. Recently, (Henry et al., 
2016), reported that silencing of both ROR1 and ROR2 was required in order 
    Chapter 6 
246 
 
to inhibit cell migration and invasion in chemoresistant ovarian cancer. Based 
on this and other studies (Henry et al., 2017, Huang et al., 2015, O'Connell et 
al., 2013, Rebagay et al., 2012), I decided to assess the protein expression of 
ROR2 on CSC96 spheroids. Notably, confocal microscopy data confirmed that 
whilst ROR1 protein levels were reduced, ROR2 was overexpressed on 
CSC96 compared to Parental cells. Although further investigation of the 
dynamics between these two molecules in PaCa CSCs are needed; this is, to 
my knowledge, the first time that ROR1 and ROR2 are simultaneously studied 
in the context of pancreatic CSCs. Furthermore, this observation could be of 
significance as it supports recent studies that indicate Wnt5a signalling –the 
sole ligand of both ROR1 and ROR2– is key for the regulation of normal and 
cancer stem cell self-renewal, proliferation, migration and invasion (Zhou et 
al., 2017b). 
Another interesting observation was the presence of mixed cell subpopulations 
within CSC96 spheroids. Unlike PANC-1 Parental samples –where cells 
showed uniform expression of Vimentin and ROR1 and virtually none for  
ALDH1– CSC96 tumourspheres displayed different cell subsets expressing 
none, one or two biomarkers. It is considered that this heterogeneity further 
supports the validity of this in vitro model as the existence of different cell 
subpopulations were potentially caused by the enriched presence of 
pancreatic CSCs. 
In terms of functional characterisation, CSC96 spheroids showed a 
significantly higher ability to migrate than PANC-1 adherent cells when 
exposed to R0 (serum-free media). A slight increase in the number of migrating 
cells, however, was observed when Parental cells were exposed to R10 or 
conditioned media compared to R0. This is likely explained by the stimulus that 
the presence of serum exerted on starved cells. In contrast, less migration of 
CSC96 tumourspheres was detected when cultured in R10 or conditioned 
media compared to R0. It is believed that the continued exposure to serum for 
72h could have been enough to trigger a differentiation process on CSC96 
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spheroids, which could possibly explain the decrease in migration levels when 
compared to tumourspheres culture in R0. This observation would be in 
keeping with tumour cell plasticity and the bidirectional conversion that is 
possible between non-CSC and CSC, discussed earlier. 
A limitation of the migration assay however was the absence of a chemokine 
as a positive control. The inclusion of a stimulant such as CXCL12 would have 
been relevant in order to produce conclusive results; particularly in the current 
scenario where upregulation of CXCR4 at a gene expression level was 
identified. Also, the functional evaluation of CSCs would greatly benefit from 
the inclusion of invasion and chemoresistance assays.  
BiTEs represent a novel immunotherapy that bridges T-cells to tumour cells, 
thereby inducing target cell-dependent polyclonal T-cell activation, leading to 
the elimination of bound cancer cells (Klinger et al., 2016). We have already 
demonstrated the specific cytotoxicity that our own ROR1 BiTE elicits on a 
range of ROR1+ solid malignancies, including PaCa (Gohil et al., 2017). In this 
study, co-culture data have shown that ROR1 BiTE therapy significantly 
reduces cell viability of PaCa tumourspheres compared to controls. This was 
quantified by WST1 reagent as per Dalla Pozza et al., 2015; this approach 
however could be supplemented with other evaluations such as the colony 
formation assay.  
When ROR1 BiTE-treated tumourspheres from a coculture assay were 
assessed by immunocytochemistry, confocal microscopy data indicated 
significant elimination of ROR1+ subsets, including ALDH1+ROR1+, a potential 
CSC compartment. It is worth mentioning however that the co-culture 
approach followed by immunocytochemistry was not taken from other reports 
in the literature and therefore further method validation would be needed in 
order to reach conclusive results.   
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Interestingly, whilst gene and protein expression data of Vimentin on CSC96 
suggested there was no significant difference with their adherent counterparts, 
targeting of ROR1 on CSC96 spheroids with our ROR1 BiTE showed 
significant reduction on the percentage of Vim+ cells compared to 
tumourspheres treated with CD19 BiTE. This is in keeping with previous 
reports (Cui et al., 2013, Zhang et al., 2014) which showed that ROR1 
targeting with a ROR1 MAb (Cirmtuzumab) led to the concomitant reduction 
of both ROR1 and Vim expression. Similarly, an association between ROR1 
and ALDH1 has been suggested by the same group (Zhang et al., 2014). 
Although downregulation on ALDH1 expression after ROR1 BiTE therapy was 
observed, this was not significant. Hence, further experiments are needed to 
confidently conclude this is the case. 
Collectively, these data suggest that establishment of PANC-1-derived 
tumourspheres exhibiting anchorage-independent growth and self-renewal 
properties was achieved. Moreover, gene and protein expression results as 
well as functional characterisation indicated significant enrichment of cancer 
stem cell-like cells within CSC96 spheroids compared to PANC-1 Parental 
cells. Notably, protein expression data also suggested high levels of 
heterogeneity within the tumourspheres. 
Although evaluation of ROR1 expression on tumourspheres at a gene and 
protein levels indicated significant reduction compared to Parental cells, 
presence of ROR1 protein was still detectable by confocal microscopy. 
Moreover, it has been shown that our ROR1 BiTE therapy is able to target both 
ROR1+ cells within the bulk of the tumour and a subset of ROR1+ cancer stem 
cell-like cells.  
Importantly, the 3D pancreatic cancer in vitro model has revealed upregulation 
of ROR2, consistent with other studies that report ROR2 as a poor prognosis 
marker in pancreatic ductal adenocarcinomas. It is proposed that both ROR1 
and ROR2 are excellent targets for the treatment of minimal residual disease, 
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which represents the final hurdle in the curative approach to many cancers 
(Rebagay et al., 2012).  
Lastly, I aimed to evaluate if our ROR1 BiTE was an effective therapeutic 
option able to provide both debulking of tumours and targeting of CSCs. With 
a spheroid in vitro model, it has been shown that targeting of ROR1+ cells 
present in different compartments of the tumour, including CSCs, was 
achieved. Additional pre-clinical and clinical work is required to conclusively 
demonstrate the therapeutic benefit that ROR1 BiTE alone and in combination 
might achieve for the management of ROR1+ malignancies. Furthermore, it is 
envisaged that a combined targeting of ROR molecules and checkpoint 
antibodies, such as anti-PD-1, would be of special interest as a recent study 
demonstrated that cancer cells that undergo EMT overexpress immune 
inhibitory molecules, among them PD-L1 and CTL4 (Lou et al., 2016). 
Moreover, recent findings in resistance mechanisms to BiTE therapy showed 
overexpression of PD-L1 and T-cell exhaustion (Kohnke et al., 2015, Krupka, 
2015). Therefore, combination studies of ROR1 BiTE and anti-PD-1 antibodies 
represent an exciting prospect yet to be investigated. 
6.4.1 Summary & Conclusions 
- Tumourspheres from a PDAC cancer cell line (PANC-1) were 
generated by 3D spheroid formation assay. 
- Comparison between MEBM and CSC media revealed that, after 
several passages, the latter consistently produced more and bigger 
spheroids compared to MEBM. 
- Both culture with ultra-low attachment plates and in vitro limiting dilution 
allowed the generation of “CSC96”; tumourspheres with self-renewal 
capability and able to grow under anchorage-independent growth 
conditions. 
- Gene expression analyses showed significant upregulation of stemness 
biomarkers such as CD133 and SOX2 on CSC96 spheroids compared 
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to PANC-1 Parental cells; Nestin expression, however, was 
downregulated. 
- Similarly, biomarkers associated with self-renewal such as Notch1 and 
Bmi1 were upregulated on tumourspheres.  
- Genes associated with high invasiveness and metastasis such as 
ALDH1-A1, ALDH1-L2, CD24 and CXCR4 were also overexpressed on 
CSC96 but not on adherent cells. 
- No significant changes on the gene expression of the B1 isoform of 
ALDH1 and Vimentin were detected. 
- Surprisingly, gene expression of ROR1 was found to be significantly 
reduced on tumourspheres. 
- Combined analysis of qPCR, agarose gel and sequencing data 
confirmed that, although downregulated, ROR1 gene was still 
expressed on CSC96. 
- Further gene expression studies showed that Lgr4, a CSC-related 
biomarker, was overexpressed on spheroids. This was also the case for 
drug efflux genes ABCA2 and ABCC1, but not ABCG2. 
- Remarkably, ROR2 gene expression was found to be overexpressed 
on tumourspheres compared to PANC-1 Parental cells. 
- Protein expression analysis confirmed the reduced presence of ROR1 
but upregulation of ALDH1 and ROR2 on tumourspheres. 
- Importantly, confocal microscopy showed the high heterogeneity within 
CSC96 spheroids, constituted of a mixture of cell subpopulations. Of 
these, it was hypothesised that both ALDH1+ and ALDH1+ROR1+ cells 
represented different CSC compartments. 
- Transwell migration assay data showed that CSC96 tumourspheres 
had a higher migration capability than PANC-1 adherent cells. 
- CSC96 spheroids treated with ROR1 BiTE and PBMCs displayed 
significantly reduced cell viability. 
- ROR1 BiTE therapy followed by immunocytochemistry and confocal 
microscopy showed specific elimination of ROR1+ cell subpopulations, 
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where the number of ALDH1+ROR1+ cells was significantly decreased 
compared to CD19 BiTE.  
- Interestingly, ROR1 targeting with our ROR1 BiTE seemed to be 
associated with the reduction of both Vimentin and ALDH1 protein 
expression, an observation consistent with other reports (Cui et al., 
2013, Zhang et al., 2014). 
 
6.4.2 Future work 
In terms of BiTE technology, a recent study has shown that current 
manufacturing challenges and short serum half-life of BiTEs could be 
circumvented by generating these bispecific antibodies in vivo. Systemic 
transfer of a nucleoside-modified mRNA-encoded BiTE resulted in sustained 
production of so-called RiboMAbs, with half-lives similar to those attained by 
conventional monoclonal antibodies (Stadler et al., 2017). Another promising 
option would be to further engineer BiTEs so they can become trifunctional 
antibodies, with the ability to bind FcγR in order to promote a potent vaccinal 
effect and attain a long-term immune response (Arce Vargas and Quezada, 
2015).   
In terms of the tumoursphere model, I propose to generate PaCa primary cells-
derived spheroids, characterise both models (cell line- and primary tumour-
derived) and test them in vivo. In parallel, based on the biomarkers proposed 
in the literature and those found to be upregulated on our own PANC-1-derived 
tumourspheres, it would be interesting to perform cell sorting on PaCa primary 
tumours and inject them in NOD/SCID mice, as per (Fitzgerald and McCubrey, 
2014). As mentioned earlier, the gold standard for CSC identification is to test 
for tumourigenicity in vivo. Comparison of these models would ascertain 
relevant differences and determine which CSC model would be the best for 
preclinical research.  
Also, it would be worth testing our range of ROR1 MAbs for cross-reactivity 
with ROR2, as it would provide us with an additional therapeutic tool. 
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Chapter 7 General discussion 
7.1 Discussion of results 
ROR1 is expressed in a wide range of solid and haematological malignancies 
with low expression in normal adult tissue. Similar to the physiological 
functions of ROR1 during embryogenesis; in cancer, ROR1 can have kinase 
activity-dependent or –independent function, which may come as a result of 
tissue specific expression of co-receptors or effector proteins (Borcherding et 
al., 2014).  
The discovery of ROR1 overexpression in CLL and other malignancies 
coupled with: i) different studies showing the induction of apoptosis by 
knocking down ROR1, ii) ROR1-mediated upregulation of EMT genes and iii) 
overexpression of this biomarker on CSCs, strongly support the notion that 
ROR1 it is not merely a bystander but rather plays an important role in cancer 
progression, metastasis and relapse.  
These unique features make ROR1 an ideal drug target for cancer 
immunotherapy. In line with this, the overriding aim of my research was to 
generate a ROR1-based immunotherapy using monoclonal antibody 
technologies. In this chapter, the findings of this thesis and their broader 
implications will be briefly summarised and discussed. Additionally, future 
directions for this work will be suggested.  
7.1.1 MAb-based ROR1 immunotherapy 
As mentioned earlier, ROR1 is an onco-foetal antigen, and as such might be 
recognised by the immune system. Accordingly, in 2008 Fukuda et al. (Fukuda 
et al., 2008) described for the first time a humoral immune response against 
ROR1 in CLL patients after vaccination with an adenovirus encoding CD154 
(Ad-CD154), a CD40 ligand which reverses the immune-suppressive 
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phenotype of CLL. Similarly, CLL patients treated with immune-modulating 
drug Lenalidomide presented anti-ROR1 antibodies in their sera 
(Lapalombella et al., 2010). More recently, spontaneous humoral and T-cell 
responses against ROR1 was reported in CLL patients (Hojjat-Farsangi et al., 
2015). Together, these results support the concept that ROR1 might behave 
as a neoantigen and may represent a valuable target for cancer 
immunotherapy. 
In this context, in Chapter 3, I reported the generation of 16 novel antibodies 
against ROR1. These binders were then engineered in order to produce rat-
human chimeric antibodies. Binding assays by flow cytometry revealed that 
only 12 MAbs were still able to target ROR1 in a human IgG1 isotype format. 
As one of the aims of this thesis was to develop therapeutic MAbs, the IgG1 
isotype was chosen for this purpose due to its extended half-life and ability to 
trigger potent effector mechanisms through Fc-FcγR interactions (Natsume et 
al., 2009).  
It is noteworthy to mention that the isotype of choice can have critical effects 
not only on antibody activity, but also on specificity, structure and affinity. 
Consistently, it is hypothesised that this change of isotype might have affected 
the binding of clones U, Psi, K2 and X, previously able to bind to ROR1 when 
they were in rat isotypes. A further illustration of isotype influence comes from 
a recent study of PD-1 therapy in vivo. Arlauckas et al. (Arlauckas et al., 2017) 
show that blocking anti-PD-1 antibodies in IgG4 –thought to have no major 
effect on CDC or ADCC/ADCP– were still able to attract macrophages, which 
in turn sequestered CD8+ T-cell bound PD-1 antibodies. These findings 
underline the importance of Fc-FcγR interactions and their role in immune-
modulation and immunotherapies.   
Notably, the generation of these novel antibody sequences also represented 
availability of new tools for developing MAb-derivatives such as CARs, ADCs, 
BiTEs, among others (Mackall, 2014). Since conventional antibodies mainly 
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rely on the immune system of the patient, which is often compromised 
(Ramsay et al., 2008), armed antibodies and derivatives have been recently 
exploited in order to increase cytotoxicity. In our research group, we were also 
intrigued by these therapeutic approaches. In order to decide which MAb-
based approach to choose, antibodies were characterised in terms of 
cytotoxicity, epitope mapping, KD determination and internalisation capability.  
Characterisation of all ROR1 chimeric MAbs is reported in Chapter 4, and with 
a particular focus on clones SA1 and F in Chapter 5. Binding assays using 
stable cell lines, expressing either full-length extracellular ROR1 or truncated 
domains, showed that out of 12 ROR1 MAbs, 10 detected the Ig-like domain 
of ROR1. In contrast, clone F was the only MAb able to bind to the Fz domain; 
whilst no antibodies were found to bind to the Kringle domain. This might be 
explained by the high sequence identity (99%) between rat and human for both 
Fz and Kg domains.  
In terms of KD determination, clones B5, Pi and SA1 exhibited the strongest 
affinities. Notably, clone SA1 also showed the slowest Koff rate which could 
potentially explain the good CDC activity exerted on CLL cells. As explained 
by Glennie et al. (Glennie et al., 2007), the slow off-rate would provide stable 
binding which would favour enhanced recruitment of C1q molecules.  
Data from different internalisation assays suggested that clone SA1 was also 
able to get internalised by primary CLL cells and ROR1+ suspension cell lines. 
This is not in disagreement with the cytotoxicity potential of this clone as a 
similar profile in terms of internalisation and cytotoxicity was reported for clone 
D10, the prototype of Cirmtuzumab (Cui et al., 2013, Widhopf et al., 2014).  
In light of these findings, I focused my studies on both clone SA1 and F. On 
the one hand, SA1 offered the possibility to be developed as a conventional, 
naked antibody due to its low KD value (1.81nM) and potent cytotoxicity. 
Additionally, due to its internalisation capabilities, it had the potential to be 
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further engineered in order to produce an ADC. On the other hand, clone F 
recognised a unique epitope in the Fz domain. Its membrane proximal epitope 
coupled with its KD value (5.46nM) –which was strong but not as potent as 
SA1’s– made clone F a suitable candidate for cancer therapy using antibody-
derivative technologies, such as CARs or BiTEs.  
7.1.2 ROR1 targeting in CLL: MAb therapy 
For CLL and other non-Hodgkin lymphomas, monoclonal antibodies have 
proven to be effective agents in the treatment of several cancers, particularly 
when used in combination with chemotherapy. They have been shown to 
improve response rates and prolonged overall survival (Hallek et al., 2010). To 
date, most MAbs currently used in the treatment of CLL are directed against 
CD20. This antigen, however, is expressed on normal B-cells and may lead to 
hypogammaglobulinemia. Other antigens such as CD19, CD37 and CD52 are 
also being investigated in the clinic (Robak, 2014), yet none of these antigens 
are unique to CLL cells. 
ROR1 is overexpressed on CLL cells but not healthy, critical tissue. Not 
surprisingly, a number of groups have recently developed MAbs targeting 
ROR1 (Baskar et al., 2008, Cui et al., 2013, Daneshmanesh et al., 2012, Yang 
et al., 2011). For therapeutic purposes, most of these antibodies have been 
generated against the extracellular portion of ROR1. Nonetheless, the results 
reported from these MAbs in CLL have been mixed, with Cirmtuzumab being 
the only ROR1 antibody currently under investigation in the clinic. Some 
groups have reported no CDC or ADCC activity with ROR1 MAbs (Baskar et 
al., 2012, Yang et al., 2011); probably because there is an estimate of only 103 
- 104 molecules of ROR1 on the surface of CLL cells (Baskar et al., 2008), 
which is 10-100 folds lower than conventional targets of MAb therapies (Yang 
et al., 2011). In contrast, researchers who developed MAbs directed against 
the Fz and Kg domains have reported cytotoxicity on CLL cells by direct 
apoptosis (Daneshmanesh et al., 2012). These results, however, were 
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attained by using IgG and IgM murine antibodies and none of these clones are 
currently in clinical trials.  
In this study, although clone SA1 was able to elicit significant CDC activity, the 
latter was reduced after humanisation of this clone (Chapter 5). Therefore, in 
an effort to bypass the lack of significant cytotoxicity, a bispecific antibody in 
full IgG targeting both ROR1 (chimeric SA1 clone) and CD3ε molecules on T-
cells was designed and engineered. Unfortunately, when tested on cytotoxicity 
assays, data revealed non-specific binding to ROR1 negative cell lines. In view 
of these results, no further studies were carried out with SA1 and instead 
focused on the development of clone F as a BiTE therapy.    
7.1.3 ROR1 targeting in PaCa tumourspheres: BiTE therapy  
Due to its unique epitope within the Fz domain of ROR1, our group developed 
clone F as a humanised BiTE and assessed its cytotoxicity potential on a range 
of solid cancer malignancies, including pancreatic cancer (PaCa) (Gohil et al., 
2017).  
PaCa is a lethal disease, often diagnosed when metastatic events have 
occurred. Despite therapy, the median survival rate is approximately 6 months 
(Society, 2015). The high mortality rate of PaCa is thought to be caused by its 
aggressive nature, local and advanced metastasis and intrinsic resistance to 
chemotherapeutics, including Gemcitabine (Ercan et al., 2017). Since cancer 
stem cell-like cells play a crucial role not only in tumour initiation but also in 
cancer progression, drug resistance and relapse (Adorno-Cruz et al., 2015), 
they represent excellent targets for effective novel therapeutic strategies. 
Expression of ROR1 on CSCs from ovarian cancer and glioblastoma was 
recently reported (Jung et al., 2016, Zhang et al., 2014). Thus, I next sought 
to investigate whether our ROR1 BiTE was able to target CSCs derived from 
a pancreatic cancer cell line (PANC-1) (Chapter 6). Of note, CSCs can be 
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identified by their self-renewal and tumour propagation potential. The gold 
standard assay for this is serial transplantation in animal models. The 
challenges that this assay presents in terms of feasibility, cost and time, 
however, rise the necessity of developing alternative in vitro models, such as 
tumourspheres generated by 3D sphere formation assay (Qureshi-Baig et al., 
2016). The spheroid formation assay utilises the anchorage-independent 
growth properties of cancer stem cells-like cells and it has shown to better 
preserve the characteristics of original tumours in terms of: gene expression 
profile, tumour heterogeneity and morphology, compared to adherent cultures 
(Lee et al., 2015, Weiswald et al., 2015, Lee et al., 2006). 
In this study, PANC-1 derived tumourspheres were generated in vitro. 
Characterisation data suggested relevant CSC biomarkers were upregulated 
at both gene and protein levels. Contrary to my expectations, however, ROR1 
was downregulated on PaCa spheroids compared to parental, adherent cells. 
Although surprising, this finding was consistent with the notion that CSC 
biomarkers described in a particular cancer type, cannot be extrapolated to 
other malignancies. In fact, these biomarkers need to be evaluated in a tissue-
dependent manner (Clarke et al., 2006).   
These data led me to evaluate the gene and protein expression of the other 
member of the ROR family, namely ROR2. As hypothesised, ROR2 was 
overexpressed on tumourspheres. Of note, both ROR1 and ROR2 share the 
same ligand, Wnt5a. These results are consistent with previous studies 
reporting that Wnt5a signalling plays a key role in the regulation of normal and 
cancer stem cell self-renewal, proliferation, migration and invasion (Zhou et 
al., 2017b). 
Although reduced, expression of ROR1 was still detectable on PaCa 
spheroids. Therefore, tumourspheres were treated with ROR1 BiTE therapy 
followed by immunocytochemistry analysis in order to ascertain whether this 
approach was able to specifically eliminate ROR1+ CSCs. Confocal 
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microscopy data revealed significant elimination of cells expressing both 
ROR1 and ALDH1. Moreover, in line with previous reports, a reduction on the 
expression of both Vimentin and ALDH1 after ROR1 targeting (Cui et al., 2013, 
Zhang et al., 2014) was observed. Further studies and method validation of 
both immunocytochemistry and confocal microscopy undertaken in this study 
are required in order to conclusively determine an association between ROR1 
and both Vimentin and ALDH1.  
Collectively, these data suggest that our ROR1 BiTE therapy is able to target 
both ROR1+ cells present in PaCa tumours as well as ROR1+ cells within CSC 
subsets. Additional preclinical studies using a tumoursphere model derived 
from PaCa primary cells as well as in vivo models of CSCs would help further 
validate the findings obtained in this study. Furthermore, it is anticipated that 
ROR1 BiTE therapy used in combination with checkpoint blockade antibodies 
would provide PaCa patients with a much-needed therapeutic option able to 
significantly enhance their clinical prospects, as the addition of an anti-PD-1 
antibody would potentially circumvent the BiTE therapy-driven T-cell 
exhaustion and increased expression of PD-L1 (Kohnke et al., 2015, Topp et 
al., 2017). More extensive preclinical and clinical studies will ultimately reveal 
the true therapeutic potential that ROR1 BiTEs alone or in combination will 
achieve.  
7.2 Summary of results/General conclusions  
As a whole, findings reported in this thesis confirmed the primary hypothesis. 
It was proposed that, due to its exquisite expression on malignant cells 
including CSCs but not adult, critical tissue, ROR1 is a druggable target for 
cancer immunotherapy.  
Although none of our ROR1 MAbs could be developed as a therapeutic 
antibody in full IgG, it was identified that clone F was able to bind to the Fz 
domain of ROR1. This made it a unique candidate for antibody-derivative 
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therapy, such as BiTEs or CARs. Moreover, it has been recently demonstrated 
that membrane proximal epitopes facilitate more potent cytotoxicity than 
membrane distal regions (Hudecek et al., 2013, Jensen and Riddell, 2014). 
Consequently, having developed a humanised F BiTE and established potent 
and specific cytotoxicity on a range of solid cancer cell lines, including 
pancreatic cancer (Gohil et al., 2017), I tested our ROR1 BiTE on ROR1+ PaCa 
CSCs.  
By using an in vitro model of PaCa tumourspheres, I have demonstrated that, 
contrary to previous assumptions, ROR1 expression was downregulated on 
PaCa tumourspheres compared to adherent cells; and instead, ROR2 
expression was found to be upregulated. Although ROR1 downregulation 
followed by ROR2 upregulation has been described in melanoma under 
hypoxic conditions (O'Connell et al., 2013); this is, to my knowledge, the first 
time both receptors are studied in the context of PaCa. Furthermore, it is 
proposed that overexpression of ROR2 might be overtaking the usual role of 
ROR1 on PaCa CSCs and might explain the increased migration capability of 
tumourspheres compared to parental cells.  
Despite ROR1 downregulation, protein expression assays revealed that its 
presence on the cell surface of spheroids was still detectable. By treating these 
tumourspheres with ROR1 BiTE therapy, followed by immunocytochemistry 
and confocal microscopy, specific targeting of ROR1+ cells, including cells 
expressing both ALDH1 (a CSC biomarker) and ROR1 has been shown. In 
light of this evidence, it is suggested that ROR1 therapy, particularly when 
used with BiTE technology, may prove a relevant and much needed addition 
to the currently available options for cancer treatment. The possibility of 
targeting and eliminating ROR1+ cells within the bulk of the tumour and CSC 
subpopulations warrants further preclinical and clinical evaluation. 
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7.3 Further work 
For optimal exploitation of our monoclonal antibodies against ROR1, I propose 
further evaluation of these reagents using different assay systems, such as 
ELISA, Western blot, immunohistochemistry, flow cytometry, etc. By 
performing a thorough characterisation of these MAbs and assessing in which 
system they work best, it would be possible to identify relevant tools for 
research and/or diagnostic applications. Additionally, due to the cross-talk 
between ROR1 and ROR2, it would be worth testing our range of ROR1 MAbs 
against ROR2. 
In order to truly assess the cytotoxicity potential of the ROR1 MAbs generated 
in this study, I suggest performing in vivo studies that would allow us to fully 
evaluate the distinct mechanisms of action exerted by these MAbs. 
Furthermore, antibody production using CHO/FUT8-/- cells would result in 
afucosylated antibodies, which have demonstrated strong ADCC activity and 
a potential vaccine effect. 
With regards to CSC models for preclinical research, a recent study from 
(Giustacchini et al., 2017), has shown that a single cell transcriptomics 
approach unravelled intratumoral heterogeneity and selective resistance of 
cancer stem cell subpopulations to molecularly targeted cancer therapies. It is 
envisaged that this strategy might become commonplace in order to better 
study and identify subpopulations of therapy-resistant CSCs –that are not 
apparent through cell-population analysis. Certainly, this approach offers an 
exciting opportunity to evaluate the therapeutic potential of our ROR1 BiTE at 
a preclinical level. 
Also, taking into consideration that it is unlikely that a single pathway is 
operative in all CSC subsets (Cabrera et al., 2015), a therapeutic approach 
targeting multiple pathways essential to CSCs and/or EMT plasticity would 
theoretically attain substantial clinical benefit. In this context, it is believed that 
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our ROR1 BiTE therapy represents a pivotal addition to the therapeutic arsenal 
against both CSC and EMT pathways. Furthermore, since it has been 
suggested that a more effective anti-tumour response might be achieved by 
including strategies that enhance T-cell priming, the use of checkpoint 
blockade antibodies could further boost T-cell proliferation and function (Arce 
Vargas and Quezada, 2015). 
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